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Therapeutic Strategies for Neurodegenerative Disorders 
1.1 INTRODUCTION 
 
1.1.1 Neurodegenerative Disorders 
Neurodegeneration is considered to be a specific pathological condition in which cells are 
damaged or cell loss occurs in the central nervous system (CNS). Dependent on the 
affected cell types, functions, and regions in the CNS, cell impairment or loss could result 
in distinct physiological, behavioral and cognitive dysfunctions. Neurodegenerative 
disorders include Alzheimer’s disease (AD), brain ischemia, as well as multiple sclerosis 
(MS) and Parkinson’s disease (PD). The causes of neurodegenerative disorders, however, 
remain still poorly understood. Currently, neurodegenerative disorders affect increasing 
populations, leading to serious cognitive deficits and even death, which demands effective 
and affordable diagnostic methods and therapeutic solutions.  Although neuroscientists 
and neurologists have focused on these diseases for decades, the prospects of treating 
neurodegeneration are still limited.     
Alzheimer’s disease (AD) is a major neurodegenerative disorder that was first described in 
1906 by the German physician Alois Alzheimer. AD is a progressive neurodegenerative 
disease and the most common cause of dementia related with ageing. The estimation is 
that AD affected about 26.6 million people by 2006, and the prevalence will quadruple by 
2050 (Brookmeyer et al., 2007). This prediction shows that AD will become a global 
epidemic that will greatly harm people’s quality of life. Oskar Fischer (1907) described the 
physiological histopathology of AD, including that loss of neurons, accumulation of 
extracellular amyloid-beta (Aβ) plaques, and intracellular neurofibrillary tangles. These 
histopathological features are mainly observed in hippocampus and cerebral cortex, which 
play a pivotal role in cognitive functions such as learning and memory. The clinical 
characteristics of AD patients include cognitive decline, personality changes and memory 
loss. Despite a great amount of studies on AD, the precise pathological processes 
underlying this disease remain elusive with various hallmarks including Aβ plaques, tangle 
formation, and neuronal cell death.  
1.1.2 Epidemiology and Genetics in Alzheimer’s Disease 
Epidemiological analyses of AD patients indicate that almost all AD cases are sporadic and 
only 1% of AD patients are of familial nature. However, both show the consistent 
pathology, which suggests a common underlying pathological mechanism of AD. To 
identify candidate genes that mediate the AD pathological features, families with 
autosomal dominant forms of AD have been screened for genes that carry mutations. So 
far, these screenings have revealed three genes to cause familiar AD (Guerreiro et al., 
2012), including the gene for amyloid precursor protein (APP) on chromosome 21, 
presenilin-1 (PS1) on chromosome 14, and presenilin-2 (PS2) on chromosome 1. 
Mutations in APP gene lead to the development of early onset of AD by increasing the 
proteolytic cleavage of APP, most of which are linked to the mutations in the PS1 and PS2 
genes (Guerreiro et al., 2012; St George-Hyslop and Petit, 2005). Moreover, 
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apolipoprotein E (ApoE) ε4 is one of the strongest  genetic risk factors for the 
development of AD, and this polymorphic gene is located on chromosome 19, coding for 
three common isoforms that distinguish at the positions 112 and 158 (Zannis et al., 1982). 
Even though the precise mechanisms of ApoE’s involvement in the pathogenesis of AD 
remains not completely clear, specific ApoE genotype increases the accumulation of Aβ 
and is believed to be a main genetic risk factor in both human AD patients and mouse 
models with AD (Castellano et al., 2011; Rebeck et al., 1993).  
 
1.2 MOLECULAR MECHANISMS UNDERLYING ALZHEIMER’S DISEASE  
 
1.2.1 Amyloid-beta Aggregation 
Cerebral Aβ peptides are generated by a series of proteolytic cleavages of the amyloid 
precursor proteins (APP) via β- or γ-secretases (Selkoe, 1989). APP is present in a number 
of tissues and organs and probably a trophic factor for neurons (Neve et al., 2000), but 
APP cleavage products are strictly modulated by neuronal activities (Kamenetz et al., 
2003). Aggregation of Aβ from physiological and amyloidogenic cleavage of APP are 
associated with the central physiopathological events of AD (Hardy and Selkoe, 2002; 
Zhang et al., 2012b). APP mutations that lead to excessive aggregations of soluble APP 
peptides are major contributors of amyloid plaques (Citron, 2010). Aβ1-40 and Aβ1-42 
plaques are the core components of soluble oligomeric Aβ fibrils to trigger Alzheimer’s 
disease (Balducci et al., 2010; Gandy et al., 2010; Walsh and Selkoe, 2007). Aβ1-42 is more 
prone to aggregation compared to Aβ1-40 (Selkoe, 1994). The ratio of Aβ1-40 to Aβ1-42, 
rather than the total amount of Aβ, is an important biomarker for AD development (Duff 
et al., 1996; Jan et al., 2008; Suzuki et al., 1994). A recent study has also suggested that 
pyroglutamylated Aβ could be the main APP cleavage product that causes AD because this 
molecule is not only more cytotoxic than Aβ 1-42 but also more potent in enhancing toxic 
Aβ (like Aβ3(pE)-42) residue formation (Nussbaum et al., 2012). Furthermore, Aβ1-16 has 
been demonstrated to be present at much higher concentration in AD patients therefore 
could serve as a novel marker for the pathogenesis of AD (Portelius et al., 2012). On the 
other hand, it is worth noting that although Aβ is thought to be a key factor in the 
pathogenesis of AD, a lower concentration of Aβ protects neurons against oxidative stress 
(Obrenovich et al., 2002) and only higher concentration of Aβ induces neurotoxicity and 
disorder of Ca2+ homeostasis (Selkoe, 2001).  
Additionally, Aβ-induced activation of NMDA receptors causes excitotoxicity and cellular 
constituent damage. The neurotoxic effects of glutamate are enhanced by introduction of 
APP cDNA (Ferreira et al., 2010; Tominaga-Yoshino et al., 2001). Studies have also 
suggested that Aβ induces astrocytic glutamate release, extrasynaptic NMDA receptor 
activation, and synaptic loss (Talantova et al., 2013). The genetic deletion of metabotropic 
glutamate receptor 5 has been shown to decrease Aβ plaques in a mouse model of AD 
(Hamilton et al., 2014). Thus, how accumulation of diverse sAPP fragments trigger 
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neuronal and synaptic dysfunction are urgent topics that need to be resolved in future 
studies. Evidence has suggested that activated TNF/TNFR1 signalling pathway increases 
Aβ1-42-mediated toxicity (Shen et al., 1997), while TNFR2 signalling pathway protects 
neurons against glutamate-induced excitotoxicity (Tominaga-Yoshino et al., 2001). In light 
of these findings, activating TNFR2 signalling or inhibiting TNFR1 signalling could be a 
potential approach to treat AD. 
1.2.2 Tau Protein 
Tau is a highly soluble microtubule-associated protein that is present in axons of healthy 
neurons and plays a primary role in microtubule (MT) dynamics and axonal transport 
processes (Li et al., 2011). Tau binds to and stabilizes microtubules and promotes 
microtubule polymerization (Cleveland et al., 1977). The insoluble tau protein, on the 
other hand, alters microtubule stability and fast axonal transport (Lee et al., 1994), and 
results in toxicity of neurofibrillary tangle through the insoluble aggregation of 
hyperphosphorylated tau proteins . The abnormal phosphorylated tau does not bind to 
microtubules but is present in high concentration of insoluble fibrillar inclusions. Tau is 
proposed to be a dominant element in AD, which composes of intracellular neurofibrillary 
tangles (Selkoe, 1991). Moreover, dendritic function of tau also increases Aβ toxicity in AD 
mouse models  (Chabrier et al., 2012). Because it is uncertain whether tau assembly is 
contributing to tau-mediated toxicity in neurodegenerative diseases, it is still of question 
whether tau accumulation inhibitors constitute a feasible therapeutic solution for AD. 
Some studies show that molecules stabilizing microtubules are considered to be a 
therapeutic approach to reduce tau function loss, such as axonal dysfunction and 
cognitive deficits (Zhang et al., 2012). Even though the molecular mechanisms that 
regulate tau phosphorylation are complex and currently incompletely understood, 
previous studies demonstrated that NMDA receptors can modulate tau phosphorylation 
(Burnouf et al., 2013; Ittner and Götz, 2011; Mondragón-Rodríguez et al., 2012). Thereby a 
potential therapeutic strategy is to reduce NMDA receptors activity to prevent tau protein 
toxicity. Furthermore, cognitive and synaptic defects mediated via expression of pro-
aggregate full-length tau are reversible after switching off expression of pro- and anti-
aggregate human tau (Jeugd et al., 2012). Although pathological tau may play a major role 
to induce AD, this will not be discussed here. Aβ peptide aggregation is thought to be the 
main upstream signalling event to stimulate tau hyperphosphorylation. The major topic of 
this thesis is the investigation of NMDA mediated neurotoxicity, Aβ neuropathology and 
relevant therapeutic strategies for AD and AD related diseases. 
1.2.3 Cholinergic System 
Pathological alteration of cholinergic neurons and the reduction of acetylcholine levels in 
the forebrain are among the earliest pathophysiological events of AD (Whitehouse et al., 
1982). Degeneration of acetylcholine-releasing neurons and cortical cholinergic 
denervation significantly contribute to the deterioration in cognitive function in AD 
patients (Coyle et al., 1983). The strong correlation between the damage of cholinergic 
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system and cognitive dysfunctions in AD underlies the so-called cholinergic hypothesis of 
AD (Bartus et al., 1982), one of the most prevailing theories for the cognitive dysfunction 
in AD patients. Among different cholinergic neuronal populations in the brain, damage of 
those localized in magnocellular nucleus basalis (NBM) and their cortical projections is 
correlated with the deficits of memory and learning functions in AD (Iraizoz et al., 1999). 
The significant loss of choline acetyltransferase (ChAT)-positive neurons in the 
magnocellular nucleus and their projections in the frontal cortex was observed in 
homozygous 3xTg-AD mice (Orta-Salazar et al., 2014), further indicating cholinergic system 
as a potential major player in AD. On the other hand, acetylcholine esterase (AChE) 
activity is increased around Aβ plaques (Talesa, 2001). One study has demonstrated that 
NMDA receptor function is impaired by membrane depolymerisation of Aβ in basal 
forebrain cholinergic neurons (Gu et al., 2014). The fact that the impairment of cholinergic 
system involves Aβ-mediated degeneration and Aβ aggravates excitotoxicity in cholinergic 
neurons implies a correlation between cholinergic system degeneration and amyloid β 
deposition in AD. Moreover, substantial age- and AD-related alterations in Ca2+-responsive 
proteins mostly contribute to selective vulnerability of basal forebrain cholinergic neurons 
(BFCN) to degeneration in AD (Riascos et al., 2014). Although the relationship either 
between cholinergic system and Aβ or between cholinergic system and Ca2+ homeostasis 
remains unclear, cholinergic dysfunction appears to influence APP metabolism and Aβ 
production and can be affected by Ca2+ imbalance.  
1.2.4 Excitotoxicity 
 
Glutamate is the major excitatory neurotransmitter in the brain. In neurodegenerative 
conditions like ischemia or AD, large quantities of glutamate are often released locally 
which finally trigger progressive neuronal death and cognitive dysfunction (Greenamyre et 
al., 1988; Rothman, 1986). This effect is likely a result of continuous activation of 
glutamate receptors, which leads to ion imbalance, subsequent neuronal cell apoptosis, 
and eventually the development of neurodegenerative disorders (Choi, 1992; Wroge et al., 
2012). Glutamate exerts its functions via two pharmacologically distinct receptor types: 
ligand gated ion channels (ionotropic receptors), which mediate the influx of cations into 
post-synaptic cells to induce membrane depolarization and can be divided into three 
classes: AMPA, N-methyl-D-aspartate (NMDA) and kainate receptors; and G-protein 
coupled receptors (metabotropic receptors), which respond to glutamate through 
regulation of second messengers, specifically intracellular Ca2+ signalling (Hollmann and 
Heinemann, 1994).  
Activation of ionotropic glutamate receptors leads to influx of sodium and calcium ions 
that need to be pumped out of the neuron in a process requiring energy (Sibson et al., 
1998), therefore increases energy consumption. Neurons are particularly vulnerable to 
glutamate after energy deprivation (Novelli et al., 1988). The ion imbalance caused by 
excessive Na+ and Ca2+ influx through glutamate receptors upon ligand binding also leads 
to cell physiological abnormalities. The drastic increase of glutamate in the synaptic cleft 
during brain damage could initiate two detrimental processes, which differ in time-
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dependency and ionic characteristics. The first process involves acute swelling of cell 
bodies and dendrites via the opening of membrane cation channels. The Na+ influx and 
passive influx of Cl- ions precede the cell volume expansion. The second one is a delayed 
response of neuronal degeneration. Evidence suggests that in vitro the neuronal death is 
related to the Ca2+ influx, which is mainly mediated by NMDA receptors since NMDA 
receptors exhibit the highest penetration to Ca2+ compared other glutamate receptors and 
thus play a crucial role in glutamate-induced neurodegenerative processes (Choi, 1992). 
Given the important role of NMDA receptors in glutamate induced neuronal death, such 
enrichment could be the reason why pyramidal neurons are susceptible to 
neurodegeneration and massive loss of pyramidal neurons has been observed in AD (Hynd 
et al., 2004). 
1.2.5 Calcium Homeostasis 
 
Deficits in synaptic function through activated NMDA receptors are linked to AD 
pathogenesis. A hypothetical mechanism of the excitotoxicity of excessive activation of 
glutamate receptors is to lead to changes of intracellular Ca2+ concentration that will 
eventually activate a cascade of enzymes that causes neuronal cell death or apoptosis 
(Lipton, 1999). Healthy neurons utilize strict mechanisms to maintain appropriate Ca2+ 
concentration to exert normal function. It has been suggested that Aβ-RAGE interaction 
disrupts not only neurons but also tight junctions of blood brain barrier via Ca2+ 
concentration changes in AD (Kook et al., 2012). Furthermore, the binding of Ca2+ with Aβ 
peptide can accelerate amyloid plaque formation (Becerril-Ortega et al., 2014), while Aβ 
can cause calcium mobilization and impair neuronal calcium homeostasis (Badolato et al., 
1995; Mark et al., 1995). Through its carboxy-terminal fragment, APP triggers significant 
changes in intracellular Ca2+ concentration and enhances glutamate-induced excitotoxicity 
(Kim et al., 2000). Neuronal Ca2+ signalling involves an intricate interplay between Ca2+ 
influx across the plasma membrane through voltage-gated Ca2+ channels, NMDA receptors, 
and transient receptor potential channels, and Ca2+ release from intracellular Ca2+-stores 
via inositol triphosphate receptor channels in the endoplasmic reticulum (ER) 
(Bezprozvanny and Mattson, 2008). Large quantities of Ca2+ influx in neurons disturbs Ca2+ 
homeostasis and affects the ER function in neurodegeneration (Salminen et al., 2009; 
Scheper and Hoozemans, 2009). Furthermore, the correlation between the calcium influx 
and neuronal toxicity is in line with current models of neurodegeneration in which calcium 
induced mitochondrial dysfuntion plays a key role in neuronal toxicity (Pivovarova and 
Andrews, 2010). Recent studies have demonstrated that hypothermia can decrease 
inflammation (Dietrich et al., 2004), prevent apoptosis (Liou et al., 2003), and reduce the 
extracellular levels of excitatory neurotransmitters (Ooboshi et al., 2000) in 
neurodegeneration. Hypothermia has been confirmed to reduce calcium influx mediated 
via activated NMDA receptors (Phillips et al., 2013). This research results provide a novel 
therapeutic strategy for neurodegenerative diseases like AD by maintaining Ca2+ 
homeostasis.  
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Marked changes to intracellular Ca2+ signal occur prior to cognitive decline and extensive 
neuronal death in AD (Szydlowska and Tymianski, 2010). Inhibiting the breakdown of Ca2+ 
homeostasis could be an effective therapeutic strategy of neurodegeneration. Abushik et 
al. revealed that intracellular Ca2+ transient induced by the neurotoxic effect of 
homocysteine in cultured cortical neurons was mediated by activity of NMDA and mGluR5 
receptors (Abushik et al., 2014). This indicates that the neurotoxicity of Ca2+ influx is 
probably determined by the crosstalk between NMDA receptors and mGluR5 receptors. 
Interestingly, Sattler et al. demonstrated that the source of Ca2+ entry, not the Ca2+ load, is 
the master determinant of the neurotoxicity of Ca2+ (Sattler et al., 1998). Such source 
specificity of Ca2+ neurotoxicity implies that this neurotoxicity is triggered by distinct signal 
transduction pathways rather than by a general overactivation of Ca2+-dependent 
downstream pathways. Researchers have also demonstrated that glutamate induced 
apoptosis involves intracellular Ca2+ transient, accumulation of intracellular oxidative 
stress, DNA damage depletion of GSH, as well as loss of mitochondrial membrane 
potential (Tirosh et al., 2000). 
1.2.6 Oxidative/Nitrosative Stress  
Oxidative/nitrosative stress has been postulated to be a critical factor associated with 
pathophysiological progression of AD, which, at least in part, contributes to destruction of 
neurons by Aβ. But underlying mechanisms are still poorly understood. Previous studies 
have shown that excessive neuronal protein oxidation products, protein carbonyl levels, 
are mainly observed in those regions of the brain where Aβ aggregation is present 
(Hensley et al., 1995). Furthermore, the primary site of production of reactive oxygen 
species (ROS) that generates oxidative stress is in the mitochondria. It has also been 
shown that glutamate-induced neuronal death in vitro was via elevation of intracellular 
ROS and mitochondrial dysfunction (Tirosh et al., 2000). Surprisingly, Nguyen et al. suggest 
that in neurodegeneration not only glutamate excitotoxicity and oxidative stress causes 
mitochondrial dysfunction, mitochondrial dysfunction conversely induces upregulation of 
activated NMDA receptors and oxidative stress (Nguyen et al., 2011). A vicious cycle, 
thereby, is in neurodegenerative diseases that comprise glutamate excitotoxicity, 
oxidative stress and mitochondrial dysfuntions. Due to high oxygen consumption, the 
brain tissue is particularly vulnerable to the product of reactive oxygen species that greatly 
increases oxidative stress.  
Endogenous nitric oxide (NO), which is a messenger involved in signal transduction, plays a 
critical role in diverse physiological progresses. In the CNS, NO can be synthesized by Ca2+-
dependent neuronal nitric oxide synthase (nNOS) in response to glutamate receptor 
activation (Garthwaite et al., 1988). A recent study showed that the neuronal nitrosative 
stress by NO is caused by activity of extrasynaptic NMDA receptors rather than synaptic 
NMDA receptors in AD (Molokanova et al., 2014). This indirectly indicates that the NO 
level might involve in physiopathology of neurodegenerative disorders, such as AD. A 
number of studies have demonstrated that increased NO levels plays a dominant role in 
neurotoxicity of neurodegenerative disorders (Dawson et al., 1991; Garthwaite et al., 1988; 
Nguyen et al., 2011). However, another research group show that the retinal neuronal 
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death induced by Aβ1-42 or glutamate is not involved in increase of NO production 
(Oliveira et al., 2011). Additionally, Xie et al. have also suggested that neurotoxicity of Aβ 
or lippolysaccharide-activated microglia is related not to NO generation but to 
peroxynitrite production generated by inducible NOS (iNOS) (Xie et al., 2002), and 
inhibitors of iNOS effectively protects neurons against toxicity associated with Aβ-
stimulated microglia (Combs et al., 2001). That underlying mechanisms of NO production 
in neurotoxicity, therefore, is still controversial. 
1.2.7 Neuroinflammation 
A substantial neuroinflammation characterized by activated microglia might play a central 
role in AD. Aβ plaques-activated microglia induce the release of pro-inflammatory 
cytokines including tumor necrosis factor alpha (TNF-α), interleukin(IL)-1β, IL-6, IL-8, 
chemokines, and reactive oxygen and nitrogen species, which are commonly thought of 
causing neuronal damage (Fernández et al., 2013; Zaheer et al., 2008;Combs et al., 
2001;Tan et al., 1999). While microglia also cause a rise in extracellular glutamate levels 
(Qin et al., 2006), it has been suggested that TNF-α can be produced in response to 
microglial activation and directly or indirectly potentiate glutmate-meidated excitotoxicity 
(Leonoudakis et al., 2008). Additionally, TNF-α can mediate such excitotoxicity by rapid 
triggering the surface expression of Ca2+ permeable-AMPA receptors and NMDA receptors 
(Leonoudakis et al., 2008). Thus, inflammation is also a major mediator in AD, especially 
microglial activation. 
 
1.3 NEUROPROTECTIVE SIGNALLING AND POTENTIAL THERAPEUTIC 
STRATEGIES AGAINST ALZHEIMER’S DISEASE 
 
1.3.1 Tumor Necrosis Factor Alpha Receptor Signalling Involvement in 
Neurodegenerative Disorders 
Cytokines are defined as small soluble proteins secreted by cells, which are involved in a 
variety of inflammatory and infectious conditions. They are not constitutively expressed 
but rather transiently induced by specific conditions. Tumor necrosis factor alpha (TNF-α), 
first discovered in the 1970s, is one of the major cytokines (Carswell et al., 1975). TNF-α is 
generated mainly by monocyte/macrophage lineage, but also by T lymphocytes, 
neutrophils, endothelial cells, and neurons. It exists in two forms, transmembrane TNF-α 
(tmTNF-α) and soluble TNF-α (sTNF-α). tmTNF-α is a 26-kDa type II cell-surface 
transmembrane protein, which can be cleaved by TNF alpha converting enzyme 
(TACE/ADAM17) to become a 17-kDa soluble form. Both are biologically active. Since 
clusters of TNF-α receptors are compulsory to initiate the downstream signalling pathways 
by forming homo-trimeric receptor molecules, TNF-α is also active as a soluble homo-
trimeric molecule of 51 kDa (Grell, 1995). TNF-α is a main coordinator to other cytokines 
(Probert et al., 1996), showing that reduced TNF-α results in the down-regulation of 
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expression of IL-6, IL-1 and chemokines. Multiple bioactivities of TNF-α are mainly 
mediated by its reactions to two distinct transmembrane receptors, TNF receptor 1 
(TNFR1, a 55-kDa protein) and TNF receptor 2 (TNFR2, a 75-kDa protein). TNFR1 is 
expressed in almost all tissues whereas TNFR2 is predominantly expressed at a low level in 
immune cells and endothelial cells (Loetscher et al., 1990; Schall et al., 1990; Smith et al., 
1990). tmTNF-α can bind to both TNFR1 and TNFR2 to promote their respective 
downstream signalling pathways while sTNF-α almost solely binds to TNFR1 (Grell et al., 
1995). TNFR1 activation can trigger fibroblast growth, endothelial cell adhesion, 
neuroinflammation, and cell death while TNFR2 promotes proliferation of thymocytes and 
peripheral T cells and inhibition of early hematopoiesis (MacEwan, 2002). Several reports 
have demonstrated that TNFR1 levels are increased in various CNS diseases (He et al., 
2007; Scalzo et al., 2009), and its activation triggers severe inflammation and thereby 
leads to cell death (Kaczmarek et al., 2013). 
Various studies have shown that TNF-α plays an important role in many CNS diseases 
(Ding et al., 2015; Lee et al., 2015; Meissner et al., 2015; Scalzo et al., 2009). 
Polymorphisms of TNF-α promoter are associated with AD (Di Bona et al., 2009; Ma et al., 
2004). It has also been shown that the levels of TNF-α and TNFR1 are both up-regulated in 
AD (Alvarez et al., 2007; Bruunsgaard et al., 1999), and overexpression of TNFR1 promotes 
Aβ-induced cell death (Li et al., 2004). Besides, TNFR1 has been illuminated to be involved 
in the abnormal Aβ processing and may participate in Aβ plaque formation, neuronal 
damage and cognitive deficits (He et al., 2007). These suggest that preventing TNF-
α/TNFR1 signalling pathways could be an efficient strategy in the treatment of AD. 
Recently, TNFR2 signalling has been concentrated increasingly. Marchetti et al. (2004) 
reported that TNFR2 signalling mediates neuroprotection via a PKB/Akt-mediated NF-κB 
pathway against ischemic reperfusion-induced retinal injury and TNFR1 exerts 
degeneration in this mouse lesion model. Furthermore, there is evidence that expression 
of TNFR2 is downregulated in AD patients (Cheng et al., 2010). Deletion of TNFR1 
significantly prevents amyloid-β (Aβ) plaque formation and remarkably attenuates 
learning and memory dysfunctions in AD transgenic mice (He et al., 2007). Additionally, 
TNF-α is demonstrated to exacerbate Aβ-induced toxicity in neurons through inhibiting 
TNFR2 signalling (Shen et al., 1997). 
 
1.3.2 Tumor Necrosis Factor Receptor-one Antagonists 
TNF-α signalling has long been demonstrated to mediated apoptosis and is a critical player 
in neurodegenerative disorders, such as AD, MS, ischemia/ischemic stroke, in which the 
levels of TNF-α are remarkably increased. This suggests that anti-TNF-α reagents could be 
effective as a therapy of neurodegenerative diseases. Anti-TNF-α reagents were tested in 
clinical trials of MS until Lenercept was reported to fail (1999). The failure of anti-TNF-α 
therapeutic might be due to the pleiotropic bioactivities of TNF-α, including pro- and anti-
inflammatory functions and neurodegeneration as well as regeneration, via its two 
receptors TNFR1 and TNFR2 (Madsen et al., 2016; Yang et al., 2011). TNFR1 has been 
demonstrated to result in pro-inflammation and worsening in neurodegeneration (Yang et 
9 
Therapeutic Strategies for Neurodegenerative Disorders 
al., 2011). Furthermore, TNFR1 genetic variant has also been reported to be one of 
reasons of failure of anti-TNF-α therapy in MS (Gregory et al., 2012). However, TNFR2 
signalling has been implicated to protect against neurodegeneration (Fontaine et al., 2002; 
Marchetti et al., 2004). Hence, the downstream signalling pathways of TNF-α should be 
separated depending on its distinct receptors. Selective manipulation of specific TNFRs 
that are involved in different downstream signalling pathways could therefore provide a 
beneficial therapeutic strategy. 
One way for specific manipulation of TNF-α downstream pathways is to use 
pharmacological agents that will only block TNFR1 signalling without altering the 
activation of TNFR2 signalling pathway. For instance, selective inhibitor of soluble TNF-α 
has been demonstrated to efficiently prevent acceleration of amyloid plaques in 
transgenic mice by inactivation of TNF-α/TNFR1 signalling pathway (McAlpine et al., 2009). 
Moreover, a specific human TNFR1 antagonistic antibody has been found to block TNF-α-
induced serious inflammation in vitro (Richter et al., 2013). Williams et al (2014) 
demonstrated that MS symptoms have been strongly prevented by a TNFR1-selective 
antagonist. Also, a novel TNFR1 antagonist effectively suppressed arterial inflammation 
and intimal hyperplasia in mice (Kitagaki et al., 2012). Aoki’s group (2007) designed a loop 
peptide mimic of TNFR1 that can inactivate TNFR1 signalling pathway and found that 
administration of this molecule strongly ameliorates collagen-induced arthritis. 
Additionally, inhibition of sTNF-α by XPro-1595 which mainly prevent TNFR1 signalling 
pathways protected EAE mice from clinical symptoms and improved axon preservation 
and remyelination (Brambilla et al., 2011; Taoufik et al., 2011). These studies show 
reagents that can block TNFR1 signalling pathway provide a promising treatment method 
for certain immune diseases not accompanied by drawbacks. It is of interest to test 
whether similar beneficial effects can be achieved on treating neurodegenerative diseases. 
1.3.3 Tumor Necrosis Factor Receptor-two Agonists 
A cell-protection effect of TNFR2 signalling was originally shown in a lung injury model 
(Ortiz et al., 1999), where knockout mice of both TNFRs developed lung injury induced by 
silica and bleomycin but an up-regulation of TNFR2 significantly prevents silica and 
bleomycin-induced lung damage in these double knock-out mice. Besides, TNFR2 null mice 
show sensitized response to cholesterol-bearing pullulan nanogel-induced resorption 
compared to wild type mice, suggesting a cell-protective role for TNFR2 (Nagano et al., 
2011). Fontaine et al. (2002) reported that TNFR2 activation can protect against ischemic 
reperfusion-induced retinal neuronal death through PKB/Akt-mediated NF-κB pathway, 
which is in contrast with the role of TNFR1 signalling in this injury model. Activation of 
TNFR2 signalling pathway therefore might be as a therapeutic approach against 
degeneration. Recently, the tests of potential therapeutic effects of TNFR2 pathway in 
neurodegenerative disorders have recently been reported. Fischer et al. (2011) 
demonstrated that increase of TNFR2 signalling by its agonist significantly prevents 
neuronal cell death induced by oxidative stress. Future studies will clarify whether TNFR2 
agonists could be developed to be effective drugs in treatment of neurodegenerative 
diseases, such as the early stage of AD that was markered by cholinergic denervation. This 
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successful therapeutic might be a novel approach to solve the AD problem at its early 
stage, and might provide a greater sense of hope for AD patients. 
1.3.4 Immunization and Immunotherapies 
AD is one of the most common dementia in aged population. Given that there is still no 
effective therapeutic solution for this disease, it presents an immense challenge to 
neuroscience research and clinical community to search for a more effective approach for 
treatment. A number of studies have investigated potential agents in the treatment of AD. 
For instance, the Wang’s group recently found that erythropoietin (EPO) is 
neuroprotective against AD-induced pathology and cognitive dysfunctions (Li et al., 2015). 
However, its neuroprotective mechanism remains unclear. Overall, it is difficult to judge 
whether these molecules applied for AD treatment would simultaneously cause adverse 
effects. As we know the main pathological hallmarks in AD are Aβ plaques and tau protein-
derived neurofibrillary tangles. Therefore, potential therapeutic strategies through 
inhibiting formation Aβ plaques and/or neurofibrillary tangles should be developed and 
investigated.  
Among different strategies, immunotherapy perhaps represents one of the best solutions 
because immunization is a chronic therapeutic approach and can be applied prior to the 
occurrence of symptoms. Because Aβ peptides form extracellular plaques and fibrillary 
tangles are formed within neuronal cells, increasing efforts have been paid to the 
investigation of Aβ antibodies. Major efforts are now set on passive immunization with 
preformed antibodies and active immunizations with epitope vaccines only using the B cell 
epitope for antibody specificity, avoiding the Aβ42 T cell epitope and therefore a potential 
T cell response (Carrillo et al., 2013; Lambracht-Washington and Rosenberg, 2013). The 
passive immunization has been applied for clinical trials, in which patients received Aβ1-42 
peptide immunization (Fox et al., 2005). Compared with passive immunotherapy, active 
immunization is much less costly and can be easily applied to large populations. More 
interestingly, a research group produced a DNA vaccine, p(Aβ3-10)-IL-4,encoding ten 
tandem repeats of Aβ3-10 fused with mouse interleukin-4 as adjuvant to immunize eight-
month-old APP/PS1 transgenic mice and found that immunization with this molecule 
significantly reduces Aβ peptide plaques in the hippocampus and the cortex and 
attenuates cognitive deficits (Xing et al., 2015). Vaccination against Aβ was considered to 
be the most promising therapeutic strategy until immunized patients showed that strong 
brain inflammatory response (Imbimbo, 2002; Münch and Robinson, 2002). Potential 
safety concerns of anti-Aβ vaccines render the investigation of alternative strategies to 
reduce Aβ burden in AD. Because soluble oligomeric forms of Aβ are considered to be the 
major mediators of cytotoxicity in AD, neuroscientists and neurologists increasingly focus 
on therapeutic strategies that can prevent Aβ to accumulate and/or form oligomers. A 
recent article showed that adjuvant immunotherapies in the presence of anti-Aβ 
antibodies can promote Aβ uptake capacity by the activation of peripheral monocytes 
(Hallé et al., 2015). Alternatively, our group (described in Chapter 6) also tested a novel 
vaccine, which was derived from Aβ and prevented the toxicity of Aβ1-42 oligomers 
(Mulder et al., 2016). 
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Aβ pathology leads to the downstream pathological accumulation of tau. Tau 
immunotherapy has also been tested in AD. Different studies have shown that active and 
passive immunization approaches were effective in reducing neurofibrillary tangles in the 
brain, delaying the onset of motor function decline of tau tangle pathology or slowing the 
progression of cognitive deficits (Asuni et al., 2007; Boutajangout et al., 2010; Davtyan et 
al., 2014). Interestingly, tau immunotherapy by using tau oligomer-specific monoclonal 
antibody reduced Aβ levels, suggesting a link between tau and Aβ oligomers (Castillo-
Carranza et al., 2015). These data suggest that immunotherapy could be a promising 
strategy for treatment of AD. 
 
Figure 1.1. Schematic overview of neuroprotective strategies for Alzheimer’s disease. Activated 
TNFR2 can lead to NF-κB activation to initiate transcriptions of cell survival factors and thereby to 
mediate neuroprotection. TNFR1 antagonists block TNFR1 apoptotic signalling pathway and share 
TNFR2-mediated neuroprotection. Moreover, anti-Aβ oligomers by immunization inhibit Aβ peptides 
to form soluble Aβ oligomers that are toxic and induce apoptosis in the brain. 
 
1.4 THE NUCLEUS BASALIS LESION    
The nucleus basalis meynert (NBM, known as nucleus basalis magnocellularis in the mouse) 
is an ‘open’ nucleus with no distinct boundaries and it forms several clusters within the 
basal forebrain. The NBM is a major source of cholinergic innervation of the cerebral 
cortex (Mesulam and Van Hoesen, 1976). The NBM in AD patients shows a substantial 
reduction of cholinergic neurons (Whitehouse et al., 1981). Also, NBM undergoes a 
profound degeneration manifested by a loss of cholinergic innervations in the cerebral 
cortex in the patients with AD and senile dementia of Alzheimer’s type and the NBM 
cholinergic neuronal loss occurs early in the course of the disease (Whitehouse et al., 
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1982). These findings suggest that a pivotal reduction of cholinergic neurons and their 
projections induced by the NBM lesion is a pathological hallmark in the early stage of AD. 
Furthermore, the NBM lesion-mediated cholinergic denervation rapidly and persistently 
induced amyloid precursor in the cerebral cortex (Wallace et al., 1993), indicating that loss 
of NBM cholinergic innervations may also participate in Aβ plaque formation. Importantly, 
cholinergic neuronal damage in the NBM and the NBM lesion-induced cholinergic 
denervation in the cortex result in cognitive dysfunctions that mimic cognitive deficits of 
AD, such as impaired learning performance and memory formation (Bartus et al., 1982; 
Iraizoz et al., 1999). These neuropathological studies suggest that the basal forebrain 
cholinergic system is affected in AD. Moreover, the NBM lesion model provides a valuable 
platform to investigate and evaluate the pharmacological capability of potential drugs 
(Harkany et al., 1995; Van der Zee et al., 1994). In addition, we can directly identify the 
lesion by the measurement of the cholinergic fibres in the forebrain cortex. In this thesis, 
we utilized this lesion model to test the effectiveness of pharmacological agents. 
 
1.5 OUTLINE OF THIS THESIS  
Neuronal and synaptic loss ultimately results in functional impairments and even death of 
patients in AD and related neurodegenerative diseases. A better understanding of the 
pathogenic mechanisms of AD is critical to develop effective therapeutic solutions to 
prevent or treat AD. This thesis elaborates the therapeutic strategies in prevention or 
treatment of AD with respect to TNF-α functions as well as passive immunization. Several 
studies showed TNF-α duality: it not only enables neuroprotective effects against 
glutamate-induced excitotoxicity but aggravates the pathological features in 
neurodegeneration. Although the molecular mechanisms underlying these effects of TNF-
α are largely unclear, it has been proposed that TNF-α binding to TNFR2 increases 
neuronal survival via the activation of PKB/Akt and NF-κB pathways. In contrast, TNFR1 
activation mediates degeneration in neurodegenerative diseases. Research in this thesis 
aims to not only gain information on the underlying molecular etiology of AD 
development but also identify novel targets for potential therapeutic intervention. TNF 
signalling is a rather complex process and we therefore mainly focused on TNF-α signalling 
mechanisms via its receptor 1 and receptor 2 in various neurodegenerative disorders 
(Chapter 2). Physiological functions of individual TNF-α receptor signalling are briefly 
described. This chapter provides a general description on TNF-α dual functions in 
neurodegenerative disorders and predicts differentially targeting TNF-α signalling 
pathways through its two distinct receptors, could lead to development of effectively 
therapeutic approaches.  
To assess the potential therapeutic effects of human TNFRs targets in vivo, such as TNFR1 
antagonists and TNFR2 agonists, which have been implicated neuroprotection, we 
designed and generated humanized TNFR1/2 knock-in mouse models as described in 
Chapter 3. 
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Epidemiological studies also suggest that targeting TNFRs could be useful for the 
prevention of AD (Fischer et al., 2011; McCann et al., 2014; Williams et al., 2014). Thereby 
one option could be to adjust TNF-α signalling in order to either slow or halt pathological 
processes associated with AD pathology. For this purpose, research was conducted to 
study the potential neuroprotective effects of human TNFR2 selective agonists, TNC-
scTNFR2 and EHD2-scTNFR2 and human TNFR1 specific antagonist, ATROSB in humanized 
TNFR knock-in mice. Their potential neuroprotective effects are investigated in an in vivo 
model for neurodegeneration in which nucleus basalis magnocellularis (NBM) was 
lesioned by NMDA in both huTNFR ki mouse lines (Chapter 4).  
In chapter 5 it is investigated whether the reagents, ATROSAB and EHD2-scTNFR2, can 
ameliorate behavioral deficits induced by NBM lesion in two mouse strains (hu/mTNFR1-
k/imice and hu/mTNFR2-k/i mice) by using tests for a spontaneous alternation, an 
elevated plus maze, and a passive avoidance task. These tests should give us an indication 
for the functional relationship with the NBM lesion.  
Aβ plaques and tau neurofilament tangles have been confirmed in human AD patients. 
Therefore preventing the aggregation of Aβ plaques and fibril tangles could be another 
effective therapeutic strategy. Chapter 6 therefore focuses on the investigation of the 
prevention of the accumulation of Aβ plaques. A vaccine based on the Aβ derived short 
synthetic peptides mimicking Aβ1-42 oligomer epitopes was used to immunize mice and 
tested in the NBM lesions induced by Aβ1-42 oligomers. 
Chapter 7 will discuss the major results of this thesis and will provide a short summary. 
Overall, this thesis discusses therapeutic strategies based on our current understanding of 
the AD pathogenesis.  
 
1.6 FUTURE PERSPECTIVES OF AD THERAPEUTICS 
A major challenge to study therapeutic strategies of AD is its complex neuropathological 
mechanisms, including Aβ accumulations, tau hyperphosphorylation, cholinergic system 
defecits, oxidative stress, neuroinflammation as well as calcium dyshomeostasis. 
Neuroscientists and neuorologists attempt to search effective therapeutic approaches 
according to complex neuropathological mechanisms of AD. So far, almost therapeutic  
strategies related to whether inhibiting amyloid aggregation or preventing tau 
hyperphosphorylation are failure to treat AD. For instance, the failure of γ- or β-secretase 
antagonists against AD might be linked to their poor permeability from blood-brain-barrier 
and the indiscriminate inhibition of other substrate processes and thereby lead to some 
severe adverse effects (Lee et al., 1998). Moreover, immunization with anti-Aβ  vaccines 
also failed in clinical trials. Thus, neuroscientists and neuorologists have to expend 
investigations and to search potential therapeutic approaches against AD from other 
directions. 
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Several studies have shown that cytokine expression is drastically altered in various 
neurodegenerative disorders (Bhaskar et al., 2014; Fillit et al., 1991). Since anti-TNF-α 
agents were widely used to treat inflammatory disease, neuroscientists have studied 
whether anti-TNF-α agents could be able to therapy neurodegenerative disorders, like AD. 
However, anti-TNF-α reagents induced some side-effects in patients with multiple 
sclerosis (Sicotte and Voskuhl, 2001). Studies have shown that up-regulated expression of 
TNF-α, TNFR1 and TRADD can be observed in AD, whereas TNFR2 and Fas-associated 
death domain-like interleukin-1-beta converting enzyme inhibition protein (FLIP) is down-
regulated in AD and progressive neuronal insult occurs (Fillit et al., 1991; Zhao et al., 2003). 
Moreover, deletion of TNFR1 in AD mouse models amyloid deposits and attenuated 
cognitive dysfunctions suggested that activation of TNFR2 is neuroprotective in AD (He et 
al., 2007). Together those observations suggest a connection between TNF-α and 
progression of AD: TNF-α duality including both neuron aggregation and neuron survival 
via the two distinct receptors in AD (Williams et al., 2014, Dong et al., 2016). Therefore, 
dependent on the opposite roles of TNF-α interacting with two distinct receptors, our 
group thought that selective targeting TNFRs, inhibiting TNFR1 signalling and activating 
TNFR2 signalling, could effectively prevent neurodegenerative disorders. We indeed found 
that both TNFR2 agonist and TNFR1 antagonist prevent the neocortical denervation and 
improve the related memory deficits (Dong et al., 2016), as described in this thesis. This 
therapeutic strategy could improve the therapeutic deficits of anti-TNF-α agents because 
selective inhibiting TNFR1 and/or activating TNFR2 changed the rate of TNFR1/TNFR2 
towards neuroprotective signalling and inhibiting TNFR1 rather than suppressed all TNF-α 
signalling. Developing TNFR1 antagonists and TNFR2 agonists might be a novel access to 
solve the AD problem. 
In future, several research directions might be concentrated to search therapeutic 
strategies against AD. Targets that can selectively activate TNFR2 signalling pathway 
and/or inhibit TNFR1 signalling pathway might be developed drugs to treat AD, such as 
TNFR1 inhibitors and TNFR2 agonists. Some protein accumulations and activations 
mediate TNFR1-downstream signalling, specifically TREDD and FADD recruitments and 
activation. Therefore, another therapeutic strategy for AD could be that prevention of 
TREDD activation or FADD activation depresses TNFR1 death signalling. An advantage of 
this strategy might be that just prevention of TREDD and FADD inhibits TNFR1-mediated 
death signalling but not interfere TNFR1-mediated other signalling pathways such as 
TNFR1-activated NF-κB signalling or TNFR2 neuroprotective effects. In future, some novel 
therapeutic strategies based on cytokine signalling pathways could be prevalent against 
neurodegenerative disorders.  
Additionally, accumulation of Aβ plaque peptides is responsible for the onset of AD. 
Although Aβ plaques are involved in the pathology of AD, Aβ plaques also seems to occur 
in non-diseased aging people (Dugger et al., 2014; Elobeid et al., 2016; Kovacs et al., 2013). 
As we know, it seems that Aβ oligomers are mainly responsible for toxic stress in the 
brains in AD patients. Although, inhibiting the accumulation of Aβ plaques will continue to 
be a main therapeutic strategy against AD in future. In particular, immunization against 
oligomeric Aβ appears to be promising strategy. However, immunization is a complicated 
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approach that involves vaccine optimization and the possibility of side-effects. 
Nevertheless it also seems an important and powerful strategy to prevent Alzheimer’s 
disease. 
Because AD is a complex pathological process related many etiologies, neuroscientists and 
neurologists thoroughly understand the precise mechanisms underlying AD, and then 
could rolve the problem on treating AD.   
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ABSTRACT 
Numerous studies have revealed the pleiotropic functions of tumor necrosis factor alpha 
(TNF-α), and have linked it with several neurodegenerative disorders. This review 
describes the signalling pathways induced by TNF-α via its two receptors (TNFR1 and 
TNFR2), and their functions in neurodegenerative processes as in Alzheimer’s disease (AD), 
Parkinson’s disease (PD), multiple sclerosis (MS) and ischemic stroke. It has become clear 
that TNF-α may exert divergent actions in neurodegenerative disorders, including 
neurodegenerative and neuroprotective effects, which appears to depend on its signalling 
via either TNFR1 or TNFR2. Specific targeting of these receptors is a promising therapeutic 
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2.1 INTRODUCTION 
Tumor necrosis factor-alpha (TNF-α) is a pro-inflammatory cytokine implicated in multiple 
inflammatory diseases, including cancer, rheumatoid arthritis, and in neurodegeneration 
as in Alzheimer’s disease (AD), stroke, multiple sclerosis (MS), Parkinson’s disease (PD) 
(Bruce et al., 1996; Franciotta et al., 1989; Lourenco et al., 2013; Moriwaki et al., 2015; 
Siebert et al., 2015). TNF-α is synthesized as a type II transmembrane protein of 26 kDa 
and forms a stable homo-trimeric molecule (mTNF-α) to exert its pleiotropic biological 
activities. It can be processed by proteolytic cleavage via TNF alpha converting enzyme 
(TACE/ADAM17) to a 17 kDa monomeric protein, that is biologically active as a soluble 
homo-trimeric molecule of 51 kDa (sTNF-α). TNF-α induces various cellular responses 
through its interaction with two distinct transmembrane receptors, the 55 kDa TNF 
receptor type I (TNFR1) and the 75 kDa TNF receptor type II (TNFR2). Under normal 
physiological conditions, TNFR1 is ubiquitously expressed in various cell types and tissues, 
whereas TNFR2 is predominantly expressed at low levels in immune cells and endothelial 
cells (Loetscher et al., 1990; Schall et al., 1990; Smith et al., 1990; Cabal-Hierro and Lazo, 
2012). TNFR1 activation can be induced by either sTNF-α or mTNF-α, and TNFR2 activation 
is predominantly initiated by mTNF-α (Grell et al., 1995). TNF-α is classically known to exert 
pro-apoptotic functions via TNFR1 (Fiers et al., 1995) and via TNFR2 in co-operation with 
TNFR1 (Weiss et al., 1997, 1998). On the contrary, more recent evidence clearly indicates 
that TNF-α induces cell survival and cellular proliferation via its TNFR2 (Van Herreweghe et 
al., 2010; Okamoto et al., 2009). This led to new insights that TNF-α exerts opposing 
effects via its two receptors with respect to neurodegeneration and neuroprotection. The 
potent pro-inflammatory functions of TNF-α in the brain play an important role in the 
etiology of neurodegenerative disorders such as ischemia/ischemic stroke, MS as well as 
AD (Fontaine et al., 2002; Van Herreweghe et al., 2010; Rossi et al., 2014; Williams et al., 
2014). Therefore, a thorough understanding of TNF-α signalling pathways in 
neurodegenerative disorders can promote the development of effective agents in the 
treatment of these conditions.  
This review will discuss TNF-α-mediated functions in the healthy and unhealthy central 
nervous system (CNS), focusing on TNF-α mediated signalling pathways via its receptors, 
TNFR1 and TNFR2. Finally, we will examine these signalling pathways as potential 
therapeutic strategies for neurodegenerative disorders, focusing on AD, PD, ischemic 
stroke and MS. 
 
2.2 TNF-ALPHA RECEPTOR SIGNALLING PATHWAYS 
 
2.2.1 TNF-α Receptor One Signalling 
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The two distinct transmembrane receptors of TNF-α are characterized by a conserved 
domain of N-terminal repeating cysteine-rich motif in extracellular regions that specifically 
interact with diverse TNF-related ligands (Locksley et al., 2001). The conserved domain is 
necessary and sufficient for the preassembly of TNFR complexes that bind TNF-α trimers 
and mediate downstream signalling (Chan et al., 2000a). However, the intracellular 
domains of the two receptors lack homologous sequences (Lewis et al., 1991), suggesting 
that distinct signalling pathways emanate from the two receptors. TNFR1 is distinguished 
from TNFR2 by its intracellular death domains (DDs) (Tartaglia et al., 1993). The 
extracellular domain of TNFR1 contains well-ordered cysteine rich amino-terminal, known 
as the preligand binding assembly domain (PLAD). PLAD favours pre-assembly of TNFR1 
into trimeric complexes and functions as preventative measure for receptor auto-
activation and is essential for ligand binding (Chan et al., 2000b). TNFR1 can be activated 
by both sTNF-α and mTNF-α (Grell et al., 1995). TNFR1-induced apoptosis involves 
formations of two sequential signal complexes (complex I and complex II) that are 
separated both temporally and spatially, but is limited by the successful activation of 
complex I (Micheau and Tschopp, 2003a). After TNF-α binding, the activated TNFR1 acts 
via its intracellular DDs to recruit the core adaptor TNFR-associated death domain (TRADD) 
(Chen and Goeddel, 2002; Chen et al., 2008; Hsu et al., 1995). Furthermore, receptor-
interacting protein 1 (RIP1) is recruited rapidly and modified with non-degradative poly-
ubiquitin chains (Meylan et al., 2004; O’Donnell et al., 2007). TRADD subsequently recruits 
other proteins such as TNFR-associated factor 2 (TRAF2) (Wang et al., 1998a), inhibitor of 
apoptosis protein 1 (cIAP1) and inhibitor of apoptosis protein 2 (cIAP2) (Varfolomeev et al., 
2008a), forming the initial signalling complex I. This signalling complex with RIP1 
ubiquitination initiates the later activation of the catalytic IκB kinase (IKK) complex (Ea et 
al., 2006). The activated IKK complex, which consists of an IKKα subunit and an IKKβ 
subunit, functions as an essential regulatory subunit of IKK complex (IKKγ/NEMO), which 
subsequently phosphorylates the inhibitor of kappa-B (IκB) complex (Karin and Ben-Neriah, 
2000). The IκB complex is then degraded via the ubiquitin-proteasome. Consequently, NF-
κB composed of p50/p52 and RelA (p65)/RelB subunits is released and translocated into 
the nucleus to initiate transcription of anti-apoptotic genes; cIAP-1, cIAP-2, TRAF1, TFAF2 as 
well ascellular FLICE-like inhibitory protein (cFLIP), to inhibit caspase 8 release from complex 
II(Ea et al., 2006; Micheau et al., 2001a; Wang et al., 1998a) (Figure 2.1). The caspase-8 
inhibitor cFLIP(L) which is harbored in complex II simultaneously inhibits the release of 
pre-caspase 8 (Micheau and Tschopp, 2003a; Micheau et al., 2001a). 
When complex I signalling fails to activate the NF-κB pathway in some instances, the 
activated TNFR1 will recruit the complex II to trigger apoptotic processing (Figure 2.1). 
After ligand binding to TNFR1, silencer of DDs is dissociated from the intracellular domains 
of TNFR1, and recruits the adaptor proteins such as TRADD, RIP1, TRAF2 and Fas-
associated death domain (FADD) and pre-caspase 8 to form complex II (Jiang et al., 1999). 
In the activated complex, FADD triggers pre-caspase 8 activation, resulting in the release 
of p18/p12 fragments that can trigger downstream caspase cascades to participate in 
apoptotic processes (Micheau and Tschopp, 2003a). This pro-apoptotic signalling 
mechanism involves FADD and caspase 8 as the key factors to trigger apoptosis (Juo et al., 
1998; Yeh et al., 1998). Upon recruitment of FADD and caspase-8, initiation of apoptosis 
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via caspase-8 is mainly determined by levels of the anti-apoptotic protein; cFLIP(L) 
(Micheau et al., 2001b). NF-κB activation triggered by complex I signalling determines the 
availability of cFLIP(L) protein at the moment complex II is formed (Micheau et al., 2001b). 
Therefore, adequate production of cFLIP(L) via NF-κB upon complex I signalling, prevents 
subsequent caspase-8 mediated apoptosis of the complex II signalling pathway (Micheau 
and Tschopp, 2003b). 
 
Figure 2.1. Multiple forms of TNFR1 signalling activation are mediated through intracellular 
protein complex assembly. The trimeric TNF-α engagement of TNFR1 leads to cellular apoptosis or 
cell survival via the distinct complex signalling pathways. 
TNFR1 signalling can also trigger caspase-independent programmed necrosis (necroptosis) 
in Jurkat cells and in ischemic brain injury (Degterev et al., 2005; Holler et al., 2000; 
Vercammen et al., 1998). It was shown in mouse embryonic TNFR1−/− fibroblast cells that 
necrotic cell death is primarily dependent on TNFR1-mediated pathways (Lin et al., 2004). 
In this process, RIPs, FADD and TRAF2 elements are still the critical components to form 
complex IIb (Lin et al., 2004) (Figure 2.1). RIP1 is required for the formation of complex IIb 
(Degterev et al., 2008). Additionally, RIP3 assembly is essential for RIP1 recruitment to this 
complex and identified as a crucial kinase to phosphorylate RIP1, which in turn 
phosphorylates RIP3 to form the RIP1-RIP3 pre-necrotic complex (Cho et al., 2009). This 
activated complex phosphorylates the downstream mixed lineage kinase domain-like 
protein (MLKL) which subsequently triggers necrosis (Sun et al., 2012). MLKL is therefore a 
critical factor in RIP3-mediated downstream necroptotic pathways. Dephosphorylation of 
RIP3 via protein phosphatase 1B (Ppm1b) restricts necroptosis (Chen et al., 2015). In 
addition to caspase suppression, cFLIP proteins can potentially inhibit TNF-induced 
necroptosis (Chan et al., 2003). Necroptosis is a newly discovered pathway of cell death 
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with essential functions in tissue homeostasis and development, and particularly studied 
in cancers and skin diseases. However, research on this pathway remains rather limited in 
CNS conditions. In primary hippocampal neurons necroptosis was induced via RIP3 upon 
an ischemic insult (Vieira et al., 2014). Moreover, it was recently shown in vivo in mice 
that intracerebroventricular injection with TNF-α caused RIP3-mediated necroptosis of 
hippocampal neurons (Liu et al., 2014). Besides neurons, necroptosis can also occur in 
activated (by stimulation with different inflammatory stimuli, including TNF-α) primary 
microglia, upon inhibition of caspase-8 (Fricker et al., 2013). Interestingly, in mixed 
cultures (where also primary neurons and astrocytes were present), necroptosis of 
activated microglia protected neurons from cell death (Fricker et al., 2013). Yuan’s group 
(2015) reported that necroptosis in cortical neurons mainly depends on the RIP1-RIP3-
MLKL signalling pathway induced via TNF-α/TNFR1 in MS. Przedborski’s group (2014), yet, 
showed that necroptosis-driven death of motor neurons triggered by amyotrophic lateral 
sclerosis (ALS) involves the RIP1-MLKL signalling pathway independent of TNF signalling. 
As such, it seems that RIP1-MLKL mediated neuronal necroptosis may be induced in 
different ways, both are dependent or independent of TNF-α. 
2.2.2 TNF-α Receptor Two Signalling 
Compared to TNFR1-mediated pathways, TNFR2-mediated signalling is still less well 
understood. TNFR2 is typically expressed at a low level in cells of the immune system, and 
is activated primarily by mTNF-α (Grell et al., 1995). Unlike TNFR1, TNFR2 does not include 
a death domain (DD). Trimerization of TNFR2 is induced upon binding of mTNF-α, leading 
to the recruitment of TRAF2 to the intracellular TRAF binding motif, which subsequently 
causes the recruitments of TRAF1, cIAP1 and cIAP2 (Figure 2.2). TRAF2 is a key mediator in 
this signalling pathway that triggers the subsequent signalling cascades leading to 
activation of NF-κB (Cabal-Hierro et al., 2014). The activation TRAF2-cIAP1/2 complex is 
recruited to NF-κB-inducing kinase (NIK) by TRAF3 resulting in proteosomal degradation of 
NIK (Sun and Ley, 2008). TNFR2 activation by mTNF-α maintains NIK stabilization via 
induction of TRAF3 degradation and thereby activates IκBα, leading to phosphorylation 
and activation of IKKα. Phosphorylated IKKα consequently activates the NF-κB precursor 
protein p100 (Rauert et al., 2010). This noncanonical NF-κB activation is independent of 
IKKβ and IKKγ (Sun and Ley, 2008). Moreover, it has been reported that human TNFR2 
contains a second intracellular binding region for TRAF2 and that this intracellular region 
can recruit TRAF2, which leads to the activation of NF-κB, dependent on activation of NIK 
and IκBα. Deletion of this binding region impairs the ability of TNFR2 to activate NF-κB 
(Rodríguez et al., 2011). 
TNFR2-mediated activation of NF-κB can also occur via the phosphoinositide 3-kinases 
(PI3K) - protein kinase B/serine-threonine kinase (PBK/Akt) signalling pathway (Marchetti 
et al., 2004) (Figure 2.2). The phosphorylated IκB is degraded via the ubiquitin-proteasome 
and NF-κB is translocated into nucleus to initiate transcription (Gustin et al., 2004). TNFR2-
mediated NF-κB activation is down regulated by phosphatase and tensin homolog deleted 
on chromosome ten (PTEN), which is a strong inhibitor of PI3K-PBK/Akt pathway. However, 
NF-κB activation via TNF-α leads to down regulation of PTEN (Eisel et al., 2006).  
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In addition to NF-κB activation, signalling via TNFR2 can elicit various non-apoptotic 
responses including c-Jun N-terminal kinase (JNK) or p38 mitogen-activated protein 
kinases (MAPK) that depends on the recruitment of TRAF2 to the different intracellular 
binding sites of TNFR2 (Matsuzawa et al., 2008; Ruspi et al., 2014). In these signalling 
pathways, TNFR2 binds TRAF2 to its intracellular region, and subsequently recruits TRAF1, 
TRAF3, cIAP1 and cIAP2 (Rothe et al., 1995; Varfolomeev et al., 2008b). According to 
spatial and temporal separation, this complex binds to a MAPK kinase kinase (MAP3K) 
protein called MEKK1 and enhances the activity of this kinase and phosphorylation of JNK-
activating kinase (JNKK1) (Baud et al., 1999), and thereby stimulates JNK activation to 
promote downstream signalling pathways which mediate cell survival. It should be noted 
however that while acute activation of JNK via TRAF2 has been related with cell survival, 
prolonged activation may also lead to apoptosis (Chen and Tan, 2000; Dhanasekaran and 
Reddy, 2008; Tabas and Ron, 2011). TNF-α mediated JNK activation depends, at least in part, 
on MEKK1 (Baud et al., 1999; Matsuzawa et al., 2008). As opposed to TRAF1 and TRAF3, 
TRAF2 positively regulates JNK activation (Cabal-Hierro et al., 2014). It has been suggested 
that TNFR2 harbours two sequences that are adaptors specific for JNK signalling (Ji et al., 
2012). TNFR2-TRAFs/cIAPs can mediate activation of p38 MAPK signalling pathway. TRAF2 
is a major player to promote activation of p38 MAPK signalling pathway (Cannons et al., 
2000). In this pathway, the TRAFs/cIAPs complex recruits RIP and subsequently activates 
MKK3 to initiate p38 MAPK activation (Aggarwal, 2003; Baud and Karin, 2001; Chen and 
Goeddel, 2002). 
 
Figure 2.2. Multiple forms of TNFR2 signalling activation are mediated through intracellular 
protein complex assembly. The transmembrane trimeric TNF-α engagement of TNFR2 leads to 
cellular survival via the distinct complex signalling pathways. PKB/Akt signalling is described in 
(Marchetti et al., 2004; Naudé et al., 2011). 
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TRAF2, TRAF1 and cIAP play a pivotal role not only in TNFR1 signalling pathways but also in 
TNFR2 pathways. This implicates that there could be a crosstalk between the two 
receptors (Naudé et al., 2011). It has been demonstrated that the depletion of TRAF2 
induced by TNFR2 activation specifically accelerates the TNFR1-dependent caspase 8 
activation (Fotin-Mleczek et al., 2002; Li et al., 2002; Wang et al., 1998b). TNFR2 signalling 
in a certain circumstance may therefore enhance TNFR1-mediated apoptosis by caspase 8 
activation.Crosstalk between TNFR1 and TNFR2 is complicated and dependent on the 
physiologic environment and signalling kinetics between the two receptors. We have 
previously described TNFR crosstalk in (Naudé et al., 2011). 
 
2.3 TNF AND ITS RECEPTORS—INVOLVEMENT IN NEURODEGENERATIVE 
DISORDERS  
2.3.1 Alzheimer’s Disease 
AD is a progressive neurodegenerative disorder, and the most common cause of dementia 
(Qiu et al., 2009). Besides the well-known pathological hallmarks of AD-including the 
formation of toxic aggregates of amyloid beta (Aβ) and hyperphosphorylated tau proteins-
neuroinflammation was more recently described to play a fundamental role in the 
pathophysiological processes of AD, in which TNF-α in particular could be an important 
mediator (McAlpine and Tansey, 2008). Evidence for the involvement of TNF-α in AD 
emanates from various research disciplines. On a genetic level, multiple polymorphisms in 
the TNF-α gene may be associated with the risk to develop AD (Di Bona et al., 2009). For 
example, the TNF-α G308A promoter polymorphism, which may cause higher TNF-α 
expression levels, has been found to increase the risk of AD in certain populations (Kang et 
al., 2014; Lee et al., 2015; Wang, 2015). At the protein level, plasma and serum TNF-α 
protein levels are elevated in AD (Alvarez et al., 2007; Bruunsgaard et al., 1999; Fillit et al., 
1991). Moreover, TNF-α levels in AD brain tissue were found to be increased, originating 
from microglia surrounding Aβ plaques (Benzing et al., 1999; McGeer and McGeer, 2003; 
Zhao et al., 2003). Besides promoting ongoing pro-inflammatory processes in the AD brain, 
increased TNF-α levels can also affect the accumulation of Aβ. For example, it has been 
suggested that higher levels of pro-inflammatory cytokines may interfere with 
phagocytosis of fibrillar Aβ via mechanisms that need further clarification (Koenigsknecht-
Talboo and Landreth, 2005). Yet, in monocyte derived macrophages it was shown that 
cytokines, including TNF-α, could directly decrease the expression of mediators involved in 
degradation of aggregated proteins, like insulin degrading enzyme, thereby interfering 
with breakdown of fibrillary Aβ (Yamamoto et al., 2008). Moreover, TNF-α may increase 
Aβ production by enhancing beta-secretase (BACE1) expression (via NF-κB dependent 
pathways) and activity, and stimulating gamma-secretase activity via JNK-dependent 
MAPK signalling (He et al., 2007; Liao et al., 2004). 
34 
Therapeutic Strategies for Neurodegenerative Disorders 
The extents of signalling through TNFR1 and TNFR2 are an important aspect to consider 
when interpreting the role of increased TNF-α in AD. TNFR1 protein levels in human post-
mortem AD brain tissue are significantly increased as compared to non-demented age-
matched controls, while TNFR2 protein levels are decreased (Cheng et al., 2010a; Zhao et 
al., 2003). Moreover, it appeared that TNF-α in the AD brain has an increased binding 
affinity to TNFR1, but a decreased affinity for TNFR2 (Cheng et al., 2010b). Interestingly, 
Zhao et al. (2003) also reported significantly increased levels of TRADD and caspase-3 in 
AD brains. Data from these studies suggest a shift towards TNFR1-mediated signalling in 
AD. On a genetic level, a polymorphism in exon 6 of the TNFR2 gene is associated with 
late-onset AD (Perry et al., 2001). The functional consequences of this polymorphism in 
TNFR2 however remain, to our knowledge, unclear.  
Studies using AD mouse models also have aimed to further the understanding of the role 
of TNF-α receptors in AD pathology. Montgomery et al. found that deletion of both TNFR1 
and TNFR2 in triple-transgenic AD mice (3xTg-AD) significantly exacerbated AD pathology 
(Montgomery et al., 2011). This suggests that total blockage of TNF-α signalling is not 
beneficial in this condition, and that both TNFRs should be appreciated separately. 
Interestingly, Montgomery et al. supported this idea, by showing that silencing of TNFR2 
aggravates TNFR1-mediated Aβ and tau pathology in aged 3xTg-AD mice (Montgomery et 
al., 2013). Moreover, knock down of either TNFR2 or both TNF-α receptors caused enhanced 
neuroinflammation. Likewise, the group of Shen recently reported that genetic deletion of 
TNFR2 enhances AD pathology in the APP23 mouse model for AD, while TNFR2 
overexpression can reverse these findings (Jiang et al., 2014). The same group also 
showed that genetic deletion of TNFR1 resulted in inhibition of Aβ production in APP23 
mice, and prevented learning and memory deficits (He et al., 2007). McAlpine et al. (2009a) 
showed that inactivation of TNFR1 signalling diminished Aβ pathology in 3xTg-AD mice, 
and that administration of inhibitors of sTNF-α (which predominantly activates TNFR1) had 
similar beneficial effects in 3xTg-AD mice. Moreover, intracerebroventricular injection of 
oligomeric Aβ resulted in cognitive decline in wildtype mice, but did not affect cognition in 
TNFR1 knockout mice (Lourenco et al., 2013). Finally, in an in vitro study with the SH-SY5Y 
neuroblastoma cell line, silencing of TNFR2 aggravated the neurotoxic effect of Aβ (Shen 
et al., 1997). These findings overall seem to support the hypothesis that increased TNFR1 
signalling and/or decreased TNFR2 signalling may play an important role in AD pathology. 
2.3.2 Parkinson’s Disease 
Neuroinflammation-besides the aggregation of alpha-synuclein (α-synuclein) proteins – 
also plays an important role in PD, by directly or indirectly contributing to the 
degeneration and death of dopaminergic neurons in the substantia nigra. The role of TNF-
α and its receptors in PD were also previously reviewed by McCoy and Tansey (McCoy and 
Tansey, 2008). TNF-α levels are significantly increased in the brain and CSF of PD patients, 
and increased TNFR1 levels were found in the substantia nigra of PD patients (Mogi et al., 
2000). Evidence for the involvement of TNF-α and its receptors in mechanisms of PD 
progression is described in studies with different PD animal models and in vitro models. 
For example, some models aim to mimic the α-synucleinopathy that is observed in PD, by 
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overexpressing wildtype or mutant α-synuclein. In vitro, BV2 cells (a murine microglial cell 
line) showed elevated TNF-α secretion upon α-synuclein overexpression 
(Rojanathammanee et al., 2011), and primary murine microglia presented a significant 
increase in TNF-α expression after exposure to mutant α-synuclein (Su et al., 2009). In vivo, 
overexpression of α-synuclein via recombinant adeno-associated virus (AAV-synuclein) 
injection into the substantia nigra was also found to increase TNF-α expression (Chung et 
al., 2009; Theodore et al., 2008). Another PD model makes use of 6-hydroxydopamine (6-
OHDA); a toxic dopamine analogue which leads to dopaminergic neuron death upon 
administration. In vitro, it was shown that selective activation of TNFR2 (by TNC-scTNFR2, 
a TNFR2-specific agonist) rescued cultured neurons from 6-OHDA-induced cell death 
(Fischer et al., 2011). In vivo, peripheral and intranigral injection in rats with specific 
inhibitors of sTNF-α (XPro-1595 and XENP345, respectively) showed to reduce 6-OHDA-
induced death of dopamine neurons (Barnum et al., 2014a; Harms et al., 2011; McCoy et 
al., 2006, 2008). Considering that sTNF-α preferably binds and activates TNFR1 rather than 
TNFR2, and that TNFR1 is highly expressed by dopamine neurons, it was suggested that 
the neuroprotective effects of these sTNF-α blockers may have resulted mostly from 
attenuated signalling via TNFR1 (McCoy et al., 2006; Probert, 2015). These findings 
indicate that TNF-α and its receptors exert similar functions in PD as previously described 
for AD; TNF-α functioning is shifted towards increased TNFR1 signalling and certain 
neuroprotective effects induced via TNFR2 signalling are decreased. It should be noted 
however that studies using mice with TNFR1 and/or TNFR2 deletions have led to 
contradictory findings about their roles in PD pathology, which may be due to differences in 
the PD models used, as reviewed in (McCoy and Tansey, 2008). For example, it was shown 
that mice lacking both TNFR1 and TNFR2 in the 1-methyl-4-phenyl-1,2,3,4-
tetrahydropyridine (MPTP, a dopaminergic neurotoxin) model for PD were completely 
protected against the dopaminergic neurotoxicity of MPTP, while mice lacking either 
TNFR1 or TNFR2 were not protected (Sriram et al., 2002). 
2.3.3 Ischemic Stroke 
Ischemic stroke can arise when a blood vessel supplying blood to the brain is obstructed. 
Sudden loss of blood flow to a brain region causes damage and cell death in the (nutrients 
and oxygen-) deprived area. Upon ischemic stroke, different brain cell types in proximity 
of the ischemic lesion site (including neurons, microglia and astrocytes) increase their 
production of TNF-α. This has been shown in human brain tissue as well as in experimental 
animal models of stroke (Dziewulska and Mossakowski, 2003; Liu et al., 1994; Sairanen et 
al., 2001; Tuttolomondo et al., 2008). As reviewed by Pan and Kastin, TNF-α was shown to 
have both detrimental and beneficial effects in stroke (Pan and Kastin, 2007). Several 
studies reported that inhibition of TNF-α (e.g., by etanercept, a human TNFR2-IgG Fc 
fusion protein) reduces infarct size and neuroinflammation (Arango-Dávila et al., 2014; 
Sumbria et al., 2012; Tobinick et al., 2012; Wu et al., 2015), while on the other hand 
complete knockout of both TNFRs increases the sensitivity for stroke and aggravates 
neuronal damage (Bruce et al., 1996). Moreover, in stroke in vitro and animal models, 
pretreatment with TNF-α (which models ischemic preconditioning), mediates 
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neuroprotective effects after ischemia (Ding et al., 2006; Nawashiro et al., 1997). In 
accordance with the above-discussed disorders, complete abolition of TNF-α signalling, as 
well as exaggerated TNF-α signalling are detrimental in ischemic stroke. This may likely 
depend on the contribution of TNF-α/TNFR1 and TNF-α/TNFR2 signalling. In addition to TNF-
α, its receptors are also up-regulated in stroke. These findings imply a neuroprotective 
role for TNFR1, while TNFR2 signalling may have detrimental effects by aggravating 
neuroinflammatory processes. However, conflicting data is also present. For example, our 
group previously showed that absence of TNFR1 in mice strongly reduced 
neurodegeneration after retinal ischemia-reperfusion, while lack of TNFR2 exacerbated 
neurodegeneration (Fontaine et al., 2002). This finding indicates that TNFR1 signalling may 
augment neuronal death and TNFR2 may promote neuroprotection. In accordance, an in 
vitro study with the SH-SY5Y neuroblastoma cell line showed that silencing of TNFR2 
aggravated cell injury upon hypoxic conditions (Shen et al., 1997). Moreover, in the 
immature brain, TNFR1-JNK signalling was responsible for neuroinflammation and 
neurovascular damage in lipopolysaccharide (LPS)-sensitized hypoxic-ischemia brain injury 
(Wang et al., 2014). The different models of ischemia that were used may in part explain 
these contradictory findings. Furthermore, the duration of the induced ischemia 
(acute/transient vs. chronic) might potentially affect the pathways, kinetics and outcomes 
of TNF-signalling. Also, the acuteness of ischemic lesions may explain differences between 
ischemic stroke and other neurodegenerative disorders like AD and PD, which gradually 
develop over a longer period of time. In disorders that develop slowly, the expression 
levels and distribution of TNFRs may gradually change during the pathological process (e.g. 
resulting in lower TNFR2 expression in AD brains). This might explain how acute insults 
could result in different effects of TNF-α, as compared to conditions in which lesions arise 
over a longer period of time. 
Table 2.1. Summary of the TNF-α family members that are subject of this review, and their roles in 
neurodegenerative conditions.  
TNF-α 
member 
Tissue Finding  Model Ref. 
TNF-α CNS  TNF-α protein levels are 




(Benzing et al., 1999; 
McGeer and McGeer, 
2003; Zhao et al., 2003) 
 Plasma, 
serum 
TNF-α protein levels are 




(Alvarez et al., 2007; 
Bruunsgaard et al., 1999; 
Fillit et al., 1991) 
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CNS TNFR1 protein levels are 
increased, TNFR2 protein 
levels are decreased. 
Human AD 
patients. 
(Cheng et al., 2010a; 
Zhao et al., 2003) 





(Montgomery et al., 
2011) 
  Silencing or deletion of 
TNFR2 aggravates AD 
pathology. TNFR2 
overexpression reverses 
these effects.  
3xTg-AD mouse 
model and APP23 
mouse model.  
(Montgomery et al., 
2013)(Jiang et al., 2014) 
In vitro, TNFR2 silencing 
promotes Aβ neurotoxic 
effects.  
SH-SY5Y cell line.  (Shen et al., 1997) 
  Deletion of TNFR1 
diminishes AD pathology.  
3xTg-AD mouse 
model and APP23 
mouse model. 
(He et al., 
2007)(McAlpine et al., 
2009a). 
  sTNF-α inhibitors diminish 
AD pathology.  
3xTg-AD mouse 
model. 








sTNFR1 levels are 
increased. 
sTNFR2 levels are 
unchanged or decreased. 
Human control 
and MCI patients. 
(Bai et al., 2013; Diniz et 
al., 2010; Faria et al., 
2014; Jiang et al., 2011; 
Sun et al., 2014) 
Higher sTNFR1 serum 
levels can predict 
conversion from MCI to 
AD. 
Human control 
and MCI patients. 
(Diniz et al., 2010) 
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sTNFR1 and sTNFR2 levels 
correlate with BACE1 
activity and Aβ40 levels, 
as well as with tau CSF 
levels. 
Human control 
and MCI patients. 
(Buchhave et al., 2010) 
TNF-α CNS and 
CSF 
TNF-α levels are increased 
in brain and CSF.  
Human control 
and PD patients. 
(Rojanathammanee et 
al., 2011;Chung et al., 
2009; Theodore et al., 
2008) 
TNFR1 CNS TNFR1 levels are 
increased in the 
substantia nigra.  
Human control 
and PD patients. 
(Mogi et al., 2000) 
  sTNF-α inhibitors reduce 
cell death of dopamine 
neurons. 
Rat 6-OHDA 
toxicity model.  
(Barnum et al., 2014a; 
Harms et al., 2011; 
McCoy et al., 2006, 
2008) 










CNS Deletion of both TNFRs 
protects from 
dopaminergic toxicity, 
while lack of either TNFRs 
alone is not protective.  
Mouse, MPTP 
toxicity model.  




Serum sTNFR1 levels are 
increased.  
Human control 
and PD patients. 
(Hirsch and Hunot, 2009; 
Mogi et al., 1994; Scalzo 
et al., 2009) 
Higher serum sTNFR1 
correlate with a later 
Human control 
and PD patients. 
(Scalzo et al., 2009) 
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onset of sporadic PD.  
Elevated plasma sTNFR1 
levels predict poorer 
executive functioning in 
PD.  
Human control 
and PD patients. 
(Rocha et al., 2014) 
TNF-α CNS TNF-α production is 
increased around the 
lesion site.  
Human brain 
tissue and animal 
models of stroke.  
(Dziewulska and 
Mossakowski, 2003; 
Sairanen et al., 2001; 
Tuttolomondo et al., 
2008) 
  Inhibition of TNF-α 




(Arango-Dávila et al., 
2014; Sumbria et al., 
2012; Tobinick et al., 
2012) 
TNFR1 CNS TNFR1 knockout mice 
have larger infarct sizes 
compared to wildtype and 
TNFR2 knockout mice.  
Stroke mouse 
model. 
(Gary et al., 
1998;Lambertsen et al., 
2009) 
TNFR1 is responsible for 
expression of 
neuroprotective factors 
upon ischemia.  
Stroke mouse 
model. 
(Taoufik et al., 2007, 
2008) 
Absence of TNFR1 reduces 
retinal Ischemia-





(Fontaine et al., 2002) 
TNFR1 signalling causes 
neuroinflammation and 
neurovascular damage in 
LPS-sensitized 
hypoxic-ischemia 
mouse model.  
(Wang et al., 2014) 
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the immature brain.  








(Fontaine et al., 2002) 
TNFR2 silencing increases 
cell injury upon hypoxic 
conditions.  
SH-SY5Y cell line.  (Shen et al., 1997) 
TNFR2 signalling can 













(Bruce et al., 1996) 
TNF-α CNS TNF-α levels are increased 
in MS lesions. 
Human MS brain 
tissue.  
(Hofman et al., 1989; 
Selmaj et al., 1991) 
  Constitutive TNF-α 
overexpression can cause 
a spontaneous 
inflammatory 




(Probert et al., 1995) 
  TNF-α knockout increases 
demyelination and 
inflammation.  
EAE mouse model.  (Constantinescu et al., 
2011; Liu et al., 1998) 
  TNF-α knockout delays 
both demyelination and 
Cuprizone mouse 
model. 
(Arnett et al., 2001) 
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remyelination.  
TNFR1 CNS TNFR1 knockout mice do 
not develop EAE or have a 
less severe disease 
course. 
EAE mouse model.  (Eugster et al., 1999; 
Kassiotis and Kollias, 
2001; Suvannavejh et al., 
2000; Williams et al., 
2014) 






(Akassoglou et al., 1998) 
  TNFR1 may contribute to 
inflammatory infiltration 
of the spinal cord. 
EAE mouse model. (Gimenez et al., 2006) 




EAE mouse model.  (Nomura et al., 2011; 
Williams et al., 2014) 
  sTNF-α inhibition protects 
against EAE symptoms.  
EAE mouse model.  (Brambilla et al., 2011; 
Taoufik et al., 2011) 
TNFR2 CNS TNFR2 knockout mice 
show aggravated 
demyelination and 
disease symptoms.  
EAE mouse model.  (Eugster et al., 1999; 
Kassiotis and Kollias, 
2001; Suvannavejh et al., 
2000; Williams et al., 
2014) 
  TNFR2 signalling mediates 
remyelination and 
oligodendrocyte precursor 
cell proliferation.  
Cuprizone mouse 
model.  
(Arnett et al., 2001) 
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  Selective stimulation of 
TNFR2 protects primary 
oligodendrocytes from 
oxidative stress.  
Primary 
oligodendrocyte 
cell culture.  
(Maier et al., 2013) 
 
2.3.4 Multiple Sclerosis  
MS is a chronic demyelinating disease of the CNS, resulting in disrupted nerve signalling 
and thereby a wide range of neurological symptoms. It has been suggested that the 
demyelination of axons is due to the death of myelin-forming oligodendrocytes, which in 
part may be caused by detrimental inflammatory and immune responses targeted to 
these cells (Cudrici et al., 2006). The involvement of TNF-α in MS has been explored in 
several studies (McCoy and Tansey, 2008). Increased TNF-α levels were found in MS 
lesions (Hofman et al., 1989; Selmaj et al., 1991). In a transgenic mouse model that 
overexpresses murine TNF-α specifically in the CNS, it was demonstrated that constitutive 
TNF-α expression leads to spontaneous development of a chronic inflammatory 
demyelinating disorder (Probert et al., 1995). In addition, peripherally increased TNF-α 
levels have been associated with synaptic instability in the brain, and as such may 
contribute to sensory and cognitive impairments as seen in MS (Yang et al., 2013). On the 
other hand, complete knockout of TNF-α in experimental autoimmune encephalomyelitis 
(EAE, an MS animal model) mice caused deleterious effects, including increased 
inflammation, demyelination and higher mortality as compared to control mice 
(Constantinescu et al., 2011; Liu et al., 1998). In the cuprizone model (a toxin causing 
reversible demyelination), complete knockout of TNF-α in mice resulted in delayed 
demyelination (suggesting that TNF-α promotes acute demyelination) as well as delayed 
remyelination (suggesting that in later stages, TNF-α promotes remyelination) (Arnett et 
al., 2001). The beneficial versus detrimental effects of TNF-α in MS may greatly depend on 
its signalling via either TNFR1 or TNFR2. Akassoglou et al. (1998) demonstrated a 
dominant role for TNFR1 signalling in TNF-mediated oligodendrocyte apoptosis and 
primary demyelination. In addition, TNFR1 was suggested to contribute to inflammatory 
infiltration of the EAE spinal cord (Gimenez et al., 2006). Interestingly, it was recently 
shown in different studies that administration of an antagonistic antibody that selectively 
targets TNFR1 ameliorated disease symptoms in the EAE mouse model (Nomura et al., 
2011; Williams et al., 2014). Also, inhibition of sTNF-α by XPro-1595 protected EAE mice 
from clinical symptoms and improved axon preservation and remyelination, indicating a 
detrimental effect of sTNF-α (which signals mostly via TNFR1) (Brambilla et al., 2011; 
Taoufik et al., 2011). Furthermore, studies showed that TNFR1 knockout mice do not 
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develop EAE, or have a less severe disease course. TNFR2 knockout mice on the other 
hand were seen to develop more extensive demyelination and aggravated EAE disease 
symptoms (Eugster et al., 1999; Kassiotis and Kollias, 2001; Suvannavejh et al., 2000; 
Williams et al., 2014). Similarly, in the cuprizone model, TNFR2 showed to be responsible 
for TNF-α mediated remyelination and proliferation of oligodendrocyte precursor cells 
(Arnett et al., 2001). A neuroprotective role of TNFR2 on oligodendrocyte progenitor cells 
was also directly shown in in vitro studies by Maier et al. (2013). In this study, primary 
oligodendrocytes from transgenic mice expressing human TNFR2 were shown to be 
protected from oxidative stress, after preconditioning the cells with a TNFR2 specific 
agonist. This protective effect might be elicited by TNFR2-mediated induction of anti-
apoptotic and cell survival genes (Maier et al., 2013). Taking together the above results, it 
may not be a surprise that general blockage of TNF-α signalling can have a net detrimental 
effect, by also inhibiting the neuroprotective signalling of TNF-α. This idea is supported by 
different studies, including reports in which administration of TNF-α antagonists was 
associated with the onset of MS (Pfueller et al., 2008; Sicotte and Voskuhl, 2001). In 
general, specifically blocking TNFR1 or stimulating TNFR2 signalling may provide a 
promising therapeutic possibility in MS. It should be noted however that TNFR1 might also 
have beneficial effects in MS. For example, it has been suggested that TNFR1 signalling is 
important for the onset of EAE, but also for limiting EAE progression at a later stage 
(Probert, 2015). Therefore, specific modulation of TNF-α receptor mediated signalling at 
specific stages of the disease may be a promising approach for effective outcomes in MS. 
2.3.5 Other Neurodegenerative Disorders 
Besides the four conditions described above, there are certainly many other disorders 
with neurodegenerative features in which a role for TNF-α has become clear. Although for 
this review it was chosen to focus on AD, PD, ischemic stroke and MS, investigation of 
TNF-α and its receptors in other neurodegenerative conditions may also greatly contribute 
to the understanding of TNF-α's effects, and the factors on which these effects depend. 
Examples of other disorders in which TNF-α has been implicated include traumatic brain 
injury (TBI) (Woodcock and Morganti-Kossmann, 2013), epilepsy (Li et al., 2011) and 
Huntington’s disease (HD) (Alto et al., 2014; Ellrichmann et al., 2013). Evidence exists that 
TNFR1 signalling may exacerbate cognitive dysfunction in a mouse model of TBI, while 
TNFR2 signalling may attenuate it (Longhi et al., 2008, 2013). Also in models of epileptic 
seizures, inhibition of TNFR1 signalling as well as activation of TNFR2 were suggested to 
protect against seizure-induced neuronal damage (Balosso et al., 2005; Li et al., 2011; 
Thompson et al., 2011). In in vitro and in vivo models of HD, blockage of sTNF-α by XPro-
1595 showed to reduce different pathological features of HD (Hsiao et al., 2014). Another 
group of diseases in which TNF-α signalling may play an important role is lysosomal 
storage disease (LSD). LSDs are rare, and result from mutations in lysosomal enzyme-
encoding genes, causing the enzyme's substrate to accumulate in the lysosomes. 
Depending on the enzyme that is affected, different substrates may pile up, leading to 
different LSDs. More than thirty LSDs are known, and include for example Fabry disease, 
Pompe disease, Gaucher disease and Niemann-Pick type C (NP-C) disease (Neufeld, 1991). 
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In the majority of LSDs neurodegeneration occurs, with neuroinflammatory processes 
being implicated as important contributors herein (German et al., 2002; Patel et al., 1999; 
Platt et al., 2012). In human NP-C patient brain tissue as well as in a mouse model of this 
disease, apoptotic neurons were detected. Interestingly, in affected brain regions in an 
NP-C mouse model, the expression of different components in TNF-mediated apoptotic 
signalling was found to be increased, including that of TNF-α itself, TNFR1 and caspase-8 
(Wu et al., 2005). Gaucher disease patients showed elevated serum TNF-α levels, and in 
the fetal brains of a Gaucher disease mouse model, TNF-α levels (as well as the levels of 
different other pro-inflammatory cytokines) were increased (Barak et al., 1999; Hong et al., 
2006). Also after birth, TNF-α and TNFR1 were found to be up-regulated in the brains of 
Gaucher disease mice with increasing age and disease severity (Vitner et al., 2012). All in 
all, there are many conditions with neurodegenerative components in which TNF-α 
signalling may significantly contribute to neuropathological processes, and more research 
focusing on TNF-α signalling via either TNFR1 or TNFR2 is warranted.  
 
2.4 TNFR1 AND TNFR2 MEDIATED SIGNALLING IN NEURODEGENERATION  
Despite the overlap between the signalling pathways of TNFR1 and TNFR2, their effects 
can differ greatly. For example, although both receptors may cause activation of 
transcription factor NF-κB (however with different activation kinetics (Marchetti et al., 
2004), different genes are transcribed, depending on which TNFR was activated. The 
involvement of possible TNFR1 and TNFR2 downstream signalling pathways in 
neurodegenerative disorders will be discussed based on studies using TNFR1- and/or 
TNFR2-specific knockout animals, or compounds targeting TNFRs specifically.  
2.4.1 TNFR1 - Possible Downstream Targets in Neurodegeneration 
Neutrophil gelatinase-associated lipocalin (NGAL, also known as lipocalin 2; the murine 
orthologue of NGAL) is a recently described downstream product of TNFR1-mediated 
signalling (Naudé et al., 2012). NGAL plays a role in the innate immune system, and is 
important in the defence against certain bacteria (Goetz et al., 2002). Mounting evidence 
recently provided insights into interesting functions of NGAL in the brain, particularly its 
role in neurodegenerative disorders. Robust increased NGAL protein levels were found in 
AD post mortem human brain tissue (Naudé et al., 2012), a mouse model for MS (Marques 
et al., 2012) and mouse model for cerebral ischemia (Wang et al., 2015). Increased NGAL 
protein levels are detrimental to neuronal health (Bi et al., 2013) and sensitize neurons 
and other brain cell types to cell death upon exposure to Aβ and oxidative stress (Lee et al., 
2012; Mesquita et al., 2014; Naudé et al., 2012). In addition, NGAL was shown to further 
promote pro-inflammatory reactions, and to stimulate classical inflammatory activation of 
microglia and astrocytes (Jang et al., 2013a, 2013b). NGAL plays an interesting role in TNF-α 
mediated signalling pathways. Our research group showed that NGAL is solely increased 
and secreted upon TNFR1 stimulation in murine primary neurons, astrocytes and microglia 
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cells. Increased NGAL in turn silences the TNFR2-mediated PI3K-PBK/Akt pathway in 
neurons, possibly by increasing PTEN levels (Naudé et al., 2012). Thus, NGAL may play an 
important role in shifting TNF-α signalling towards TNFR1-mediated pathways observed in 
different neurodegenerative conditions, as previously described in this review. 
Different studies demonstrated that TNFR1 can induce matrix metalloproteinase 9 (MMP-
9) expression (Lee et al., 2010; Lin et al., 2008; Tsai et al., 2014). In the A549 cell line (a 
human lung adenocarcinoma epithelial cell line) TNF-α can induce MMP-9 expression via a 
TNFR1/TRAF2/PKC alpha dependent pathway (Lee et al., 2010). MMP-9 has been 
associated with different physiological and pathophysiological processes. For example, 
MMP-9 was shown to be able to interact with Aβ, and can play a role in disruption of the 
blood-brain barrier (Lakhan et al., 2013; Mizoguchi et al., 2009; Takata et al., 2011; Yan et 
al., 2006). This latter effect seems to be associated with MMP-9’s actions in degradation of 
the extracellular matrix. Of note, it was shown that MMP-9 can form a complex with NGAL, 
and that NGAL may elongate the activity of MMP-9 (Yan et al., 2001). 
TNR1 could engage in processes concerning the clustering of the α-amino-3-hydroxy-5-
methyl-4-isoxazole propionic acid (AMPA) receptor (AMPAR). Deletion of TNFR1 was 
found to suppress excitatory synaptic transmission via the localization of AMPA receptors 
to the synapses of cortical neurons (He et al., 2012). It was therefore suggested that 
TNFR1 might be involved in AMPAR-mediated excitotoxicity. Furthermore, it was shown 
that TNFR1 signalling induces excitotoxicity by promoting glutamate release in mouse 
primary microglia and astrocyte cell culture (Bezzi et al., 2001; Olmos and Lladó, 2014; 
Takeuchi et al., 2006). More specific to AD, TNFR1 was found to be involved in processing 
of the amyloid precursor protein (APP) and Aβ plaque formation, by increasing BACE1 
promotor activity (He et al., 2007).  
2.4.2 TNFR2 – Possible Downstream Targets in Neurodegeneration 
Examples of TNFR2-specific signalling in neurodegeneration have also been described 
(Fontaine et al., 2002; Marchetti et al., 2004). Dolga et al. identified certain small 
conductance calcium-activated potassium K(Ca)2 channels as downstream products of 
TNFR2 signalling (Dolga et al., 2008a, 2011). These channels contribute to neuroprotection 
against neuronal overstimulation, by lowering the neuronal excitability. It is specifically 
the expression of K(Ca)2.2 that was shown to be downstream of TNF-α/TNFR2 signalling, 
via NF-κB activation. As such, it was suggested that in primary cortical neurons, TNF-α 
induces K(Ca)2.2 channel activation, resulting in neurons that are more resistant to 
excitotoxic cell death by preventing intracellular calcium levels to become pathologically 
high (Dolga et al., 2008a, 2011). In the past years it has been shown that K(Ca)2 channels 
may also be involved in mechanisms contributing in plasticity of the hippocampal CA1 
neurons and in learning and memory (Allen et al., 2011; Kuiper et al., 2012). 
Fischer et al. (2014) showed that TNFR2-mediated activation of the PI3K-PKB/Akt pathway 
in primary astrocytes induces the expression of different neuroprotective genes, including 
the gene that encodes leukemia inhibitory factor (LIF). LIF is a neurotrophic cytokine, 
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which in the brain is mainly produced by astrocytes. Elevated levels of LIF were shown to 
promote the maturation of oligodendrocytes (Fischer et al., 2014), and LIF was found to 
protect primary neurons against excitotoxicity (Moidunny et al., 2012). Moreover, in the 
EAE mouse model LIF was demonstrated to protect axons in the brain from acute 
inflammatory damage (Gresle et al., 2012). 
Other downstream products of TNFR2 signalling include CXCL12, which has also been 
implicated in the proliferation and differentiation of oligodendrocyte progenitor cells 
(Patel et al., 2012). Moreover, its levels were found down regulated in the Tg2576 AD 
mouse model, and reduced CXCL12 levels were shown to cause impairments in learning 
and memory (Parachikova and Cotman, 2007). Lastly, TNFR2 signalling in microglia has 
been related with induction of anti-inflammatory pathways, for example the upregulation 
of IL-10 (Veroni et al., 2010). 
All examples discussed in this chapter support the idea that TNFR1 may specifically induce 
factors that contribute to neurodegenerative processes, while TNFR2 specifically mediates 
factors involved in neuroprotective mechanisms (Figure 2.3). However, in agreement with 
the rest of this review, things are certainly far more complex. Therefore, different 
unknowns and contradictory findings underlining and adding to the complexity of TNF-
signalling will be addressed in the following chapter.  
 
Figure 2.3. Examples of specific downstream targets of TNFR1 and TNFR2 that may be involved in 
neurodegenerative disorders. Dotted lines indicate existing potential therapeutic approaches. Other 
general TNF-α blockers, not depicted in this figure, include adalimumab, certolizumab pegol and 
golimumab. Other new TNFR1-specific antagonists include DMS5540 and TROS (also see review by 
Fischer et al.(2015)). 
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2.5 COMPLEX MATTERS: TNFR1 SIGNALlING IS PRIMARILY DAMAGING AND 
TNFR2 BENEFICIAL?  
Although in this paper we generally highlighted an important neuroprotective role for 
TNFR2 and a neurodegenerative role for TNFR1 in different neurodegenerative disorders, 
findings that contradict this idea cannot be ignored. As described in the previous 
paragraphs, for several neurodegenerative disorders conflicting results have been found 
concerning beneficial/detrimental effects of TNFR1 and TNFR2 signalling. These 
contradictory findings emphasize the complexity of TNFR1/TNFR2 signalling, and confirm 
that our understanding of TNF-signalling is still work in progress.  
The outcome of TNF-α signalling will likely depend on many variables: the availability of 
both receptors, the available levels of sTNF-α and mTNF-α ligands, the availability of the 
components in their respective signalling cascades, and the level of crosstalk between the 
two pathways, all of which likely depend on the cell type, tissue and the condition. Indeed, 
different studies have suggested that TNF-α signalling may be strongly brain region-
specific, which may in part depend on, e.g., the relative density and activity of microglia in 
specific regions (Rodriguez et al., 2009; Sriram et al., 2006; Veroni et al., 2010). Also the 
timing of TNF-α signalling in different stages of neurodegeneration could affect the outcomes 
of TNF-α. For example, TNF-α mediates a neuroprotective effect when hippocampal 
organotypic slice cultures are treated with TNF-α before an ischemic insult (which may 
simulate ischemic preconditioning), but has neurotoxic effects when administered after 
the same ischemic insult (Wilde et al., 2000). Furthermore, TNFR2-mediated pathways have 
receivedless attention compared to TNFR1 and undefined signalling mechanisms possibly 
remain to be discovered. These and other factors greatly increase the complexity of TNF-
signalling, and a few will be further discussed below. 
2.5.1 Selective Harmful Downstream Targets of TNFR1 and Beneficial 
Downstream Targets of TNFR2?  
Although we described examples supporting the presence of potent detrimental 
downstream signalling pathways mediated specifically via TNFR1, while TNFR2 signalling 
may mostly activate genes with potential neuroprotective functions, matters are often not 
that clear-cut. For instance, it should be noted that there are certain examples available of 
neuroprotective pathways induced via TNFR1, and damaging outcomes of TNFR2 signalling. 
For example, a known downstream target of TNFR1 is nerve growth factor (NGF), which is 
important for survival and growth of neurons (Kuno et al., 2006), while TNFR2 may also 
promote expression of potentially detrimental factors, such as intercellular adhesion 
molecule-1 (ICAM-1), which has been associated with neuroinflammation and 
neurodegeneration (Lucas et al., 1997; Pola et al., 2003). Moreover, the specificity of 
certain downstream products to either TNFR1 or TNFR2 is sometimes unclear. For 
example, some studies have implied NGF to be solely induced via TNFR1 in fibroblasts, 
while it appeared in astrocytes that signalling via both receptors can cause NGF 
production (Hattori et al., 1996; Kuno et al., 2006). Such contradictory findings may 
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amongst others depend on variables like the cell type studied, the proximate cellular 
conditions, TNFR1-TNFR2 signalling kinetics and crosstalk between the receptors. In 
addition, although the above described processes were found to be specifically induced 
via either TNFR1 or TNFR2, there may very well be multiple other (TNF-α-independent) 
pathways that may influence TNF-α mediated pathways and their outcomes. For example, 
it may be good to keep in mind that lymphotoxin α (TNF-β) can also bind both TNFR1 and 
TNFR2. Comparable to TNF-α, lymphotoxin α also has been implicated in different 
processes in the brain, and in the pathogenesis of conditions including MS (Dopp et al., 
1997; Etemadi et al., 2013). 
2.5.2 Soluble TNF Receptors 
Adding to the complexity of TNF-α signalling, besides membrane TNF receptors (mTNFRs), 
soluble TNF receptors (sTNFRs) also exist, which influence TNF-α signalling mechanisms as 
well. sTNFRs (sTNFR1 and sTNFR2) can be formed via a process known as ectodomain 
shedding, in which the extracellular domains of membrane TNFRs are cleaved off by TACE 
(which thus shows to have more targets besides mTNF-α) and released into the 
extracellular space. Notably, in addition to ectodomain shedding, it has been described 
that TNFR1 can also end up in the extracellular space via exocytosis. This generates 
exome-like vesicles with full-length TNFR1 incorporated in the vesicle membrane (Hawari 
et al., 2004). The exact functions and mechanisms of actions of sTNFRs (as well as the full-
length TNFR1 within vesicles) however remain elusive. Shedding of mTNFRs is thought to 
regulate the actions of TNF-α, firstly by diminishing the number of mTNFRs on the cell 
membrane, and secondly by binding of sTNFRs to TNF-α, thereby preventing TNF-α to bind 
to and activate mTNFRs. Alternatively, it was suggested that sTNFRs bind to sTNF-α and 
subsequently stabilize and preserve the bio-active trimeric forms of TNF-α (Diez-Ruiz et al., 
1995). As such, sTNFRs levels might reflect the activity of TNF-α. Interestingly, intravenous 
injection of TNF-α in human volunteers suggested that TNF-α is a potent mediator of 
increased sTNFR1 and sTNFR2 release (Jansen et al., 1995).  
Different studies indicate that the levels of sTNFR1 as well as TACE activity are increased in 
plasma, serum and CSF from AD patients (Bai et al., 2013; Diniz et al., 2010; Faria et al., 
2014; Jiang et al., 2011; Sun et al., 2014). Moreover, Diniz et al. (2010) showed that higher 
serum sTNFR1 levels can predict conversion from mild cognitive impairment (MCI) to AD. 
Plasma and CSF sTNFR2 levels were found to be increased in AD by some groups (Bai et al., 
2013; Jiang et al., 2011), while other studies showed no differences in sTNFR2 levels (Diniz 
et al., 2010; Faria et al., 2014). Similar to AD, increased serum sTNFR1 levels were found in 
patients with PD (Hirsch and Hunot, 2009; Mogi et al., 1994; Scalzo et al., 2009). Also, a 
single nucleotide polymorphism in the gene encoding TNFR1, resulting in production of a 
soluble form of TNFR1 that is able to antagonize TNF-α, was found to be associated with 
MS (Gregory et al., 2012). Although in these cases the exact meaning of these increased 
serum sTNFR1 levels is not clear, it was found that higher serum sTNFR1 levels are 
associated with a later onset of sporadic PD (Scalzo et al., 2009). In addition to the 
potential functions and effects of sTNFRs described above, sTNFRs may also influence TNF-
α signalling via reverse signalling through mTNF-α. 
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Besides being a ligand for TNFR1 and TNFR2, mTNF-α can also act as a receptor itself. Thus, 
in addition to inducing a signalling cascade in TNFR1/TNFR2-expressing cells, mTNF-α can 
also elicit a signal transduction pathway back into the cell on which it is expressed (Eissner 
et al., 2004). This process is called reverse signalling, and can occur when mTNF-α is bound 
by a (s)TNFR or agonistic antibody (Eissner et al., 2004; Sipos et al., 2015). sTNFRs may 
have significant effects on cells by inducing reverse signalling. For example, it was 
reported that sTNFR1 can induce apoptosis of monocytes through reverse signalling via 
mTNF-α. It appeared that this sTNFR1-induced apoptosis is independent of death receptor 
pathways, but is mediated via autocrine transforming growth factor beta (TGF-β) through 
p38 MAPK (Waetzig et al., 2005). In addition, it was recently shown in cultured superior 
cervical ganglion (SCG) neurons that sTNFR1 promotes sympathetic axon growth and 
branching through reverse signalling via mTNF-α, and relies on downstream activation of 
ERK (Kisiswa et al., 2013). In addition to endogenous sTNFRs, different TNF-α inhibitors 
(like etanercept and infliximab) can induce reverse signalling through mTNF-α as well. As 
suggested in recent studies, effects of such compounds may significantly depend of 
reverse signalling, besides the effects arising from the prevention of mTNF-α and sTNF-α 
to bind their TNFRs (Kirchner et al., 2004; Meusch et al., 2009). 
Taken together, soluble TNFRs may play a substantial role in how TNF-α interacts and 
functions with its receptors, possibly especially in a systemic pro-inflammatory 
environment. This is an interesting and noteworthy research field that can provide 
important insights in TNF-α functioning. In theory, a potential therapeutic strategy to 
reduce excessive TNFR1 signalling may be by stimulating TNFR1 ectodomain shedding. 
Interestingly, some mediators (with aminopeptidase regulator of TNFR1 shedding (ARTS-1) 
appearing as a key regulator) have been identified that are essential for TNFR1 shedding, 
but do not affect TNFR2 shedding (Cui et al., 2002; Islam et al., 2006). While ARTS-1 also 
participates in shedding of other receptors besides TNFR1 (including IL-6R and IL-1R2 (Cui 
et al., 2003)), downstream effectors of ARTS-1 may prove to be TNFR1-specific, and could 
provide a therapeutic target.  
2.5.3 Interaction between TNFR2 and Interleukin-17 Receptor D 
Moreover, the signalling of membrane TNFRs may also hold more complexity than has 
become clear so far. For example, it was very recently demonstrated that TNFR2 (but not 
TNFR1) can form a heteromer with interleukin-17 receptor D (IL-17RD, also known as Sef), 
leading to activation of NF-κB signalling via TRAF2 recruitment (Yang et al., 2015). 
Depletion of IL-17RD was found to impair TNFR2-mediated activation of NF-κB. The 
complex between IL-17RD and TNFR2 was shown to be formed in HK-2 and 786-O cell 
lines (a human proximal tubular cell line derived from normal kidney, and a human renal 
cell adenocarcinoma cell line, respectively), and also in rat and mouse renal tissue. This 
indicates that the interaction between TNFR2 and IL-17RD may arise under physiological 
conditions (Yang et al., 2015). 
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All these complex issues and unknowns emphasize that gaps remain in the basic 
understanding of TNF-α signalling, which may challenge the identification of suitable TNF-
targeting therapeutics for different neurodegenerative disorders. 
 
2.6 TARGETING TNF ALPHA SIGNALLINGS: AN OPPORTUNITY FOR TREATMENT 
OF NEAURODEGENERATIVE DISORDERS? 
As concluded in this review, targeting TNF-α signalling towards its neuroprotective 
functioning could provide potent therapeutic strategies for patients with neurodegenerative 
disorders. It seems that therapeutics could aim at a certain step of TNF-α mediated 
signalling pathways via inhibiting detrimental pathways. 
2.6.1 Targeting TNF-α as Treatment for Neurodegenerative Disorders 
Because TNF-α is a key inductor in some inflammatory disease such as rheumatoid 
arthritis (RA), psoriatic arthritis (PsA), Crohn’s disease (CD) as well as some 
neurodegenerative disorders, directly inhibiting this cytokine could prevent or treat those 
conditions. A number of researchers have demonstrated that directly blocking the actions 
of TNF-α via anti-TNF-α antibodies and its antagonists indeed can ameliorate 
inflammatory and neurodegenerative disorders (Liu et al., 2015; McAlpine et al., 2009b; 
Mease, 2002). Additionally, inhibition of TNF-α not only prevents the course of MS but 
also promotes axon preservation and remyelination in EAE mouse model (Brambilla et al., 
2011). Due to its therapeutic capability, treatments aimed to inhibit the functions of TNF-α 
have been shown as effective treatment strategy of RA, PsA as well as CD in experimental 
trials and are currently being used worldwide in the clinical setting (Locksley et al., 2001; 
Maini and Taylor, 2000; Spinelli et al., 2014; 2015). So far, pharmaceutical anti-TNF-α 
agents that include thalidomide analogues which inhibit the production of TNF-α have 
been applied for the treatment of RA (Greig et al., 2004; Tweedie et al., 2007; Zhu et al., 
2003). Moreover, other pharmaceutical agents including etanercept, adalimumab and 
infliximab, that can bind both sTNF-α and mTNF-α thereby inhibiting their signalling, have 
been successfully applied for treatment for RA and PsA (Sfikakis, 2010). Studies into the 
effects of such pharmaceuticals in neurodegenerative disorders like AD, PD and MS 
however remain limited.  
Drugs targeting TNF-α for systemic inflammatory diseases still have adverse effects in a 
minority of patients (Hyrich et al., 2007). For instance, anti-TNF-α therapy for RA induces 
the risk of serious infections of the skin, soft tissues and joints (Atzeni et al., 2015). Anti-
TNF-α agents increase risk rates of malignancies in patients with inflammatory bowel 
disease (Beigel et al., 2014). It has been mentioned that two patients with rheumatoid 
arthritis treated with anti-TNF-α strategy developed neurological symptoms, including 
demyelination lesions (Richez et al., 2005). Furthermore, it was shown that new-borns 
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presented severe neutropenia after their mothers were treated with infliximab for 
ulcerative colitis during pregnancy (Guiddir et al., 2014). 
To reduce or diminish the drawbacks of anti-TNF-α agents in inflammatory diseases and 
neurodegenerative disorders, other therapeutic strategies should be investigated. 
Considering the various outcomes of TNF-α, targeting a specific point in its signalling 
pathways could be more effective and decrease the negative effects associated with anti-
TNF-α agents.  
2.6.2 Targeting TNFRs as Treatment for Neurodegenerative Disorders 
In essence, TNFR1 has often been demonstrated to deteriorate or aggravate 
neurodegeneration whereas TNFR2 mediates neuroprotection. Therapeutics that 
specifically modulate the signalling mechanisms of TNF-α, i.e., blocking TNFR1 actions 
and/or increasing TNFR2 signalling pathway could greatly reduce the side effects of 
current anti-TNF-α approaches. Sedger's group (Sedger et al., 2006) discovered that a 
leporipoxvirus TNF receptor homolog by its N-terminal preligand assembly domain (PLAD)-
homologous domain interacts with the intracellular domain of TNFR1 and showed that this 
interaction results in a heterocomplex that inhibits TNFR1 downstream signalling and 
significantly prevents TNFR1-induced apoptosis of lymphocytes. Selectively blocking the 
bioactivity of sTNF-α, thus preventing TNFR1-mediated signalling, attenuated the 
pathological symptoms in EAE mice (Brambilla et al., 2011; Taoufik et al., 2011). 
Furthermore, a soluble TNFR1-selective antagonistic mutant TNF (named R1antTNF) 
ameliorated the symptoms in EAE mice (Nomura et al., 2011; Shibata et al., 2008). 
Currently, an antagonistic TNFR1 specific antibody has been produced and demonstrated 
to treat MS clinical symptoms more efficiently in EAE mouse model (Williams et al., 2014). 
Another human TNFR1 specific antagonistic antibody that may prove to have therapeutic 
effects is ATROSAB (Richter et al., 2013; Zettlitz et al., 2010). 
As TNFR1 is mainly activated by sTNF-α, selectively inhibiting sTNF-α may prevent TNFR1-
mediated apoptosis and could be a therapeutic strategy in neurodegenerative disorders. 
In this regard, a blocker of sTNF-α, XPro-1595, significantly improved the cognitive deficits 
induced by spinal cord injury in mice compared to the drug etanercept (Novrup et al., 
2014). Furthermore, Tansey et al. (Barnum et al., 2014b) discovered that XPro-1595 
significantly reduced activation of microglial and astrocytes, and prevented loss of 
dopamine neurons in a rat model of PD. Shedding of TNFR1 mediated by iNOS-cGMP-TACE 
signalling has been suggested to significantly ameliorate the inflammation associated with 
sepsis (Deng et al., 2015). Increased sTNFR1 levels resulting from this TNFR1 shedding 
could compete to bind to sTNF-α and impair TNFR1-mediated downstream signalling 
pathways and potentially reduce its apoptotic signalling pathways. 
TNFR2-mediated signalling could be used as a therapeutic approach for 
neurodegenerative disorders. Lovastatin that is widely used to reduce cholesterol levels in 
patients has been confirmed to selectively increase TNFR2 expression (Nübel et al., 2005). 
Thereafter it was demonstrated that lovastatin protected primary cortical neurons against 
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glutamate-induced excitotoxicity (Dolga et al., 2008b). Moreover, in vivo evidence showed 
that lovastatin attenuated NMDA-induced nucleus basalis magnocelullaris (NBM) lesions 
and prevented cognitive deficits in mice (Dolga et al., 2009). This further supports the idea 
that TNFR2 activation could be a therapeutic approach for neurodegenerative disorders. 
Notably, Pfizenmaier's group (Fischer et al., 2011) constructed a soluble human TNFR2-
selective agonist (TNC-scTNFR2) and demonstrated that it successfully rescues human 
neurons from oxidative stress-induced cell death. TNC-scTNFR2 is synthesized by genetic 
fusion of the trimerization domain of tenascin C to a TNFR2-selective signal-chain TNF 
molecule, which specifically activates TNFR2 to promote PI3K-PKB/Akt-NF-κB signalling 
pathway and promotes neuroprotection.  
Selective targeting of TNFRs as a therapeutic strategy seems a promising avenue for the 
treatment of CNS conditions and some inflammatory diseases associated with TNF-α. Of 
note, it should be established whether simultaneous targeting of both receptors is 
necessary to achieve maximum therapeutic efficacy, as compared to 
inhibition/stimulation of either TNFR1 or TNFR2. Moreover, the ability of therapeutic 
compounds to cross the blood-brain barrier (BBB) is an obstacle that needs urgent attention. 
TNF-α blockers like etanercept and infliximab are too large to penetrate the BBB, and of certain 
new compounds it is yet to be examined whether they can pass the BBB. In the EAE mouse 
model, intraperitoneal injections with XPro-1595 and R1antTNF were effective in reducing 
pathology (Brambilla et al., 2011; Nomura et al., 2011; Taoufik et al., 2011). However, 
seeing the involvement of the peripheral immune system (and possibly the peripheral nervous 
system) in MS and EAE, it may be that targeting peripheral TNF-α is sufficient to reach 
therapeutic effects. Moreover, since the BBB is compromised in the EAE model, a possibility 
exists that these compounds may have entered the brain through an already leaky BBB. 
Nevertheless, a recent study on XPro-1595 in the 6-OHDA model for PD (in which the BBB is 
presumably not damaged enough to let XPro-1595 pass non-selectively) revealed that this 
compound could indeed reach the brain in therapeutically relevant concentrations (evidenced 
by inhibited glial activation and reduced dopamine neuron loss), after subcutaneous 
administration (Barnum et al., 2014b). Moreover, it may be that certain compounds, in 
certain conditions, do not necessarily have to pass the BBB to reach therapeutic effects. For 
example, in rat MCAO models for cerebral ischemia beneficial effects were reported upon 
intraperitoneal injection of etanercept (Arango-Dávila et al., 2014; Wu et al., 2015). Yet, it 
may be that etanercept could enter the brain via disruptions in the BBB, induced by the MCAO 
(Wu et al., 2015). Other important issues that will need to be addressed include the timing of 
treatment, and the potential side-effects that may arise from targeting TNF-α, TNFR1 and/or 
TNFR2. At least for ischemic stroke, start of treatment within a few hours after the ischemic 
insult may be crucial to limit damage as much as possible. However, as described in Chapter 
3.3 of this review, the timing of specific TNF-treatments may be particularly delicate in acute 
conditions such as ischemic stroke, where TNFR expression levels may be rather dynamic in the 
first hours/days after the stroke. It may be that apoptotic signalling is beneficial for a certain 
length of time right after the insult in order to clear damaged cells and protect surrounding 
cells. As such, administering e.g. TNFR1 antagonists may have to be very carefully timed; 
neither too early nor too late. For chronic disorders like AD, PD and MS it can be hypothesized 
that beginning treatment in early stages may in the end prove to be most effective, but that 
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also starting treatment in later stages may well slow down neurodegenerative processes. 
Furthermore, the potential side-effects TNF-targeting compounds have to be assessed. For 
example, the possibility that selective inhibition of TNFR1 or stimulation of TNFR2 signalling 
could negatively affect production of neurotrophic factors (such as NGF and BDNF) should be 
explored.  
 
2.7 CONCLUSIONS  
As discussed in this review, TNF-α is involved in many neurodegenerative disorders by 
exerting both neuroprotective and neurodegenerative functions. A balance between these 
opposite effects seems to depend on its actions via TNFR1 and TNFR2. A thorough 
understanding of TNF-α signalling pathways can contribute to the development of 
potential therapeutic strategies. Focusing on multiple molecular interactions, which can 
control signalling outcomes in TNF-α signalling pathways could be critical to develop 
preferable therapeutic strategies in the future.  
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ABSTRACT 
The role of tumor necrosis factor alpha (TNF-α) and its two receptors (TNFR1, TNFR2) has 
been implicated in the neuropathology of neurodegenerative diseases in animal models. 
Targeting TNF-α receptors could potentially be used to treat neurodegenerative diseases, 
such as MS, AD and stroke. The therapeutic potential of human TNFR-specific target 
agents for neurodegenerative disorders can only be properly studied in an in vivo model 
featuring human TNFRs. Mice carrying humanized TNFR represent an in vivo research 
model with human features. Here, we generated humanized TNFR1 and humanized TNFR2 
knock-in mouse models in which the extracellular domains of mouse TNFRs were 
substituted by human counterparts, respectively. In this chapter, we describe the 
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3.1 INTRODUCTION  
Tumor necrosis factor alpha (TNF-α) has been implicated to play a complex role in 
neurodegeneration, in particular Alzheimer’s disease (AD) and multiple sclerosis (MS) 
(Dong et al., 2015; Probert, 2015). TNF-α has been demonstrated to exert multiple 
biological activities due to the antithetic actions of its two receptors in cell lines and 
animal models: TNF-α binding to its receptor one (TNFR1) predominantly promotes 
inflammatory signalling pathways, which under certain circumstances leads to cell death 
(Fujita et al., 2016; Kälble et al., 2016), whereas TNFR2 signalling pathway mediates 
immune modulatory functions and promotes cell regeneration and survival (Chopra et al., 
2016; Pozniak et al., 2016). In TNFR1 or TNFR2 knock-out models, a number of studies 
have already examined the roles of TNFR1 signalling pathway and TNFR2 signalling 
pathway. For instance, deletion of TNFR1 significantly diminishes Aβ formation and 
prevents learning and memory deficits (He et al., 2007); And deletion of TNFR2 in 
C57BL/6J mice was shown to lead to a severe deterioration in retinal ischemia (Fontaine et 
al., 2002). These data indicates that targeting TNFRs by inhibiting TNFR1 and/or activating 
TNFR2 could ameliorate pathophysiological traits of neurodegenerative disorders. 
Recently, TNFR1 blockade has been demonstrated to have therapeutic functions in a 
stroke model of mice (Liguz-Lecznar et al., 2015) and in an EAE model of mice (Williams et 
al., 2014). Moreover, another study showed that a selective human TNFR2 agonist rescued 
human neurons from oxidative stress-induced neuronal cell death in vitro (Fischer et al., 
2011). These results suggest that TNFR1 blockade and TNFR2 agonists could be developed 
into potential treatment approaches against neurodegenerative disorders, including MS, 
AD and ischemic stroke. The therapeutic potential of targeting TNFRs agents for human 
neurodegenerative disorders can only be properly studied in an in vivo model featuring 
human TNFRs. 
Humanized mouse models are an important prerequisite to develop experimental animal 
models to mimic human pathological conditions and to test compound efficacy. 
Humanized mouse models means that a mouse gene has been replaced by a portion of or 
by the entire human gene, and thereby the human proteins/domains are then expressed 
while the mouse protein/domain is suppressed in all cells and tissues of mice. Humanized 
mouse models have been applied to investigate various human diseases and disease 
therapeutics, including infectious diseases (Abraham et al., 2016; Ernst, 2016; Sandal et al., 
2016), cancer (Hasegawa et al., 2016; Morton et al., 2016; Radin et al., 2016), injury-
inflammation diseases (Carpenter et al., 2015; Hidalgo et al., 2009), immunotherapy of 
diseases (Lemmermann and Reddehase, 2016; Smith et al., 2016) as well as 
neurodegenerative diseases (Sevigny et al., 2016). For instance, the Sandrock group 
(Sevigny et al., 2016) has found that a human monoclonal antibody that selectively targets 
aggregated Aβ reduces Aβ plaques in Alzheimer’s disease in a humanized mouse model. 
Therefore, humanized mice featuring human TNFRs are a useful research tool to 
investigate the features of human TNF/TNFRs signalling pathways in vivo and the 
therapeutic potential of human TNFR-specific targets. The establishment of humanized 
TNFRs mice by the use of knock-in technology has not been reported before.  
77 
Therapeutic Strategies for Neurodegenerative Disorders 
In the present work, we used conventional molecular biological techniques to generate 
humanized TNFR knock-in mouse lines in which the extracellular domains of mouse TNFRs 
were substituted by human counterparts by homologous recombination, respectively. We 
described the generation and identification and characterization of humanized TNFR1 and 
humanized TNFR2 knock-in mice.  
 
3.2 MATERIALS AND METHODS 
3.2.1 Setup of Humanized TNFR Knock-in Mice 
The humanized Tnfrsf1a and Tnfrsf1b knock-in mouse lines (hu/mTNFR1-k/i and 
hu/mTNFR2-k/i) were generated as contracted by Ozgene Pty Ltd (Bentley WA, Australia). 
For targeting TNFR1 the human sequence from chromosome 12 position 6330763 to 
6332522 was inserted in place of mouse chromosome 6 positions 125306866 
to 125310626. For TNFR2 the human sequence from chromosome 1 position 12188610 to 
12193082 was inserted in place of mouse chromosome 4 positions 144814170 
to 144819194. The targeting constructs were electroporated into C57BL/6J embryonic 
stem (ES) cell line, Bruce4. (Köntgen et al., 1993). Homologous recombinant ES cell clones 
were identified by Southern hybridization and injected into BALB/c-albino C57BL/6J 
blastocysts. Male chimeric mice were obtained and crossed to albino C57BL/6J females to 
establish heterozygous germline offspring on C57BL/6J background. The germline mice 
were crossed to a ubiquitous Cre mouse line to remove the loxP flanked selectable marker 
cassette. 
To initially distinguish between hetero- and homozygous mice, the genotype of 
hu/mTNFR-transgenic mice was tested using mouse TNFR specific forward primers 
(mTNFR1 OZ fwd& mTNFR2 OZ fwd, Table 3.1) in combination with mouse or human 
specific reverse primers (mTNFR1 OZ rev, huTNFR1 OZ rev, mTNFR2 OZ rev & huTNFR2 OZ 
rev, Table 3.1). The mouse/mouse TNFR1 specific primers for wildtype TNFR1 lead to a 
product of 1217 bp, whereas the mouse/human TNFR1 specific primers for the chimeric 
TNFR1 lead to a product of 702 bp. Similarly, the mouse/mouse TNFR2 specific primers 
for wildtype TNFR2 lead to a product of 1169 bp, whereas the mouse/human TNFR2 
specific primers for the chimeric TNFR2 lead to a product of 771 bp. After homozygous 
chimeric mice were bred for more than three generations, genotyping was carried out by 
PCR with primers specific for huTNFR1 (Table 3.2), leading to a 313 bp product for the 
human TNFR1 allele, and mTNFR1 (Table 3.2) inducing a 270 bp fragment for the wild 
type allele. Homozygous hu/mTNFR2-k/i animals were genotyped by PCR, using primers 
specific for huTNFR2 (Table 3.2) to produce a 300 bp fragment for human TNFR2 allele and 
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Table 3.1. Oligonucleotide sequences used for genotyping. 
Primer  Sequence  
mTNFR1 OZ fwd 5’-CTAAACATTCCTTGACCGGC-3’ 
mTNFR1 OZ rev 5’-TTCCCACACAAATCTTGACG-3’ 
huTNFR1 OZ rev 5’-ATGCTAGGGACAACAGCCAG-3’ 
mTNFR2 OZ fwd 5’-GGTCCAAACCTTCTAAGCCC-3’ 
mTNFR2 OZ rev 5’-ACATCAATATAGGCCAGCCG-3’ 
huTNFR2 OZ rev 5’-GCGTAGGGTGTAAATGCCAC-3’ 
Table 3.2.Oligonucleotide sequences used for PCR. 
gene forward reverse 
huTNFR1 5’-TGTCCCACCAAAACACACAC-3’ 5’-CTGGCTGTTGTCCCTAGCAT-3’ 
mTNFR1 5’-CGGCTTCTTTTGCTTGTTTC-3’ 5’-ACCTTTCCGACATGTCTTGC-3’ 
huTNFR2 5’-CTGGACTTTGTGGGGACAGT-3’ 5’-GACAGCTGGAAGCCAAAGAG-3’ 
mTNFR2 5’-AAGGACCAGAGGTCTCAGCA-3’ 5’-GCAGGAACAGAGGAGACGAG-3’ 
Male homozygous hu/mTNFR-k/i C57BL/6J mice (12 weeks, 24-30 g) were used for 
experiments. All animals were individually housed with a free access to food and tap 
water and kept in an air-conditioning room (21 ± 2°C) with a 12/12 h light-dark circle 
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(lights on 7:00 a.m.). Animal care and treatment were carried out in accordance with the 
local Ethical Committee guidelines on the use of experimental animals at the University of 
Groningen, the Netherlands (DEC6523) and University of Stuttgart, Germany (35-9815.81-
0350). 
3.2.2 Southern Blot Analysis 
Embryonic stem (ES) cell DNA was isolated, digested with restriction enzymes and 
analyzed on agarose gels. Specificity of digestion products was tested by Southern blotting: 
DNA was transferred to nylon membrane and hybridized with the 5’ or 3’ external probe. 
Membranes were washed and pattern of hybridization was visualized on an X-ray film by 
autoradiography. 
Genomic DNA from lung, heart, liver, brain, thymus, kidney and skin tissue of both 
homozygous hu/mTNFR1-k/i and hu/mTNFR2-k/i mice, respectively, was isolated, digested 
with BamHI and blotted on nylon membrane and probed with the endogenous probes 
































DNA from tail biopsies of C57Bl/6J wild type mice was used as a control. 
3.2.3 Primary Mouse Embryonic Fibroblasts 
Brain and dark red organs were removed from embryonic (E14–16) hu/mTNFR1-k/i or 
hu/mTNFR2-k/i mice. Remaining tissue was minced and digested using trypsin-EDTA 
(Gibco) and 1% DNase I (Sigma) for 30 min at 37°C. Digestion was stopped by addition of 
fetal calf serum (FCS) and homogenates were centrifuged (5 min, 200 g). Digested tissue 
was triturated in culture medium (DMEM, 10% FCS, L-Glutamine, 1% (v/v) 
penicillin/streptomycin (P/S)) and plated in cell culture dishes. After one to two days, cells 
were frozen or used for experiments. 
3.2.4 Immunoblot Whole Brain Samples 
The whole brain protein samples were prepared as described previously (Marchetti et al., 
2004). Protein concentration from brain tissues were quantified and adjusted to 1 mg/ml. 
Samples were incubated on ice for 20 min. 25 μl of 0.1% Nonidet P-40 was added for 2 
min, and the lysates were centrifuged at 8000 g for 10 min at 4°C. The lysates were boiled 
for 5 min in Laemmli's sample buffer (2% SDS, 5% DTT), and proteins was separated by 
SDS-polyacrylamide gel electrophoresis. After transfer to a PVDF membranes (Millipore, 
Billerica, MA, USA), membranes were blocked for 1 h with 1% I-blocker (Tropix, Bedford, 
MA, USA) in TBS containing 0.0625% Tween 20 and subsequently incubated overnight 
with primary antibody at 4°C (anti-human TNFR1 was purchased from Hycult Biotech, 
H398; anti-human TNFR2 was from Abcam, MR2-1). Afterwards, the membranes were 
washed with TBS containing 0.0625% Tween 20 and incubated with the appropriate HPR-
conjugated secondary antibody diluted to 1:5000 with TBS containing 0.0625% Tween 20 
for 1 h. Proteins were detected by using enhanced chemiluminescence (Piece 
Biotechnology, Rockford, IL, USA). Hypoxanthine guanine phosphoryltransferase (HPRT) 
served as internal standard protein.  
3.2.5 Statistics 
Data are presented as mean ± standard deviation (SD) or standard error of the mean (SEM) 
of n independent experiments. Normal distribution was analyzed by Shapiro-Wilk 
normally test. Statistical analyses were performed by Student’s t-test or one-way analysis 
of variance (ANOVA), followed by a post-hoc multiple comparison Tukey test. * p< 0.05 
(** p < 0.01; *** p < 0.001) was considered significant. 
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3.3 RESULTS 
 
3.3.1 Humanized TNFR Knock-in Mouse Models 
To investigate and evaluate the potential functions of reagents targeting tumor necrosis 
factor receptors (TNFR1 and TNFR2) for human disease studies, we established humanized 
TNFR1 or TNFR2 knock-in (hu/mTNFR-k/i) mouse models. In these mouse models, the 
extracellular domains of mice TNFRs are replaced by the counterparts of human TNFRs, 
respectively, as shown in figure 3.1.  
 
Figure 3.1. Humanized TNFRs knock-in mouse models. Schematic representation shows the 
structures of humanized TNFRs in chimeric mice. 
DNA sequence that encodes extracellular domains of human TNFR1 and TNFR2 (described 
in materials and methods) was recombined into a targeting vector, the Ozgene plasmid 
PacL A90264BA-E12. By incorporating the targeted gene into the vector by homologous 
recombination, human TNFR1 or TNFR2 gene was introduced into the mouse gene locus 
(Figure 3.2A and 3.3A). The gene targeting constructs were electroporated into C57BL/6J 
embryonic stem (ES) cell line, Bruce4 (Köntgen et al., 1993). Homologous recombinant ES 
cell clones were identified by Southern hybridization and injected into BALB/c-albino 
C57BL/6J blastocysts. Male chimeric mice were obtained and crossed to albino C57BL/6J 
females to establish heterozygous germline offspring on C57BL/6J background. The 
germline mice were crossed to a ubiquitous Cre mouse line to remove the loxP flanked 
selectable marker cassette. Thereafter, the genotypes of hu/mTNFR1 and hu/mTNFR2 
knock-in mice were determined by PCR. 
The mouse genomic locus of TNFR1 could be digested by EcoRV, BamHI, or NheI to 
generate 11.9 kb, 3.8 kb, or 11.1 kb fragments, respectively (Figure 3.2 A). On the other 
hand, the targeted locus could be digested by EcoRV, BamHI or NheI to generate 7.7 kb, 
7.7 kb or 7.5 kb fragments, respectively (Figure 3.2B). After the selectable cassette was 
removed, the gene locus of homozygous humanized TNFR1 mouse could be digested by 
BamHI to generate a 5.9 kb fragment (Figure 3.2C). Therefore, heterozygous and 
homozygous animals were distinguished via using Southern blot analysis using enzymes 
EcoRV, BamHI and NheI for digestion. 
The hu/mTNFR2-k/i mouse models have been shown in Figure 3.3. In wildtype mice 
(Figure 3.3A), TNFR2 genomic locus contained EcoRV, PshAI and BamHI restriction enzyme 
sites, and these sites could digest TNFR2 genomic locus to be a 32.4 kb, a 26.7 kb and a 5.9 
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kb sequence, respectively. The targeted gene locus included the PGK-Neo-cassette and 
could be digested by PshAI, BamHI and EcoRV restriction enzymes (Figure 3.3B). The 
recombination gene locus could be digested by PshAI to generate a 13.5 kb band and a 
14.5 kb band, and by BamHI to generate a 9.9 kb fragment. After the selectable cassette 
was removed, the genomic locus of chimeric mice could be digested by BamHI to generate 
a fragment of 8.2 kb (Figure 3.3C).  
 
 
Figure 3.2. Homozygous humanized hu/mTNFR1-k/i mouse models. Schematic representation of 
the homologous recombination in the TNFR1 gene locus. Shown is the wildtype genomic locus (A), 
the targeted locus including the PGK-Neo cassette (B) and the genomic locus of chimeric mice (Cre’d 
locus, C). Heterozygous and homozygous animals were distinguished using southern blot analysis 
using enzymes EcoRV, BamHI and NheI for digestion. Detected products are annotated in the graph. 
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3.3.2 Screening and Identification of Humanized TNFR Knock-in Mice by 
Southern Blot 
The targeted constructs of hu/mTNFR1 and hu/mTNFR2 were electroporated into 
C57BL/6J ES cell line, Bruce4 (Köntgen et al., 1993). Thereafter, nine homologous 
recombinant ES cells were identified by Southern hybridization (Figure 3.4). Genomic 
integration of hu/mTNFR1 was digested with EcoRV and probed with the 5’ probe showed 
expected products with wildtype (wt) 11.9 kb and targeted 7.7 kb (Figure 3.4 A, left). 
Probing with the 3’ probe and NheI digestion resulted in products of wt 11.1 kb and 
targeted 7.5 kb (Figure 3.4A, right). Genomic integration of hu/mTNFR2 was digested with 
PshAI and probed with the 5’ probe that resulted in 26.7 kb fragments and targeted 13.5 
kb fragments (Figure 3.4 B, left). Digestion with EcoRV and probing with the 3’ probe 
resulted in products of wt 32.4 kb and targeted 17.8 kb (Figure 3.4B, right). Thereafter, we 
obtained recombinant ES cell clones of hu/mTNFR1 and hu/mTNFR2 that could be injected 
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Figure 3.3. Homozygous humanized hu/mTNFR2-k/i mouse models. Schematic representation of 
the homologous recombination in the TNFR2 gene locus. Shown is the wildtype genomic locus (A), 
the targeted locus including the PGK-Neo cassette (B) and the genomic locus of chimeric mice (Cre’d 
locus, C). Heterozygous and homozygous animals were distinguished using southern blot analysis 
using enzymes PshAI and BamHI for digestion. Detected products are annotated in the graph. 
Male chimeric mice were obtained and crossed to albino C57BL/6 females to establish 
heterozygous germline offspring on C57BL/6 background. The germline mice were crossed 
to a ubiquitous Cre mouse line to remove the loxP flanked selectable marker cassetteas 
shown in Figure 3.2C and Figure 3.3C. After the neo cassette was removed, DNA fragments 
of 5.9 kb and 8.2 kb DNA should be shown in homozygous hu/mTNFR1-k/i mice and 
homozygous hu/mTNFR2- k/i mice, respectively. Here, we analyzed DNA fragments of 
hu/mTNFR1 and hu/mTNFR2 in lung, heart, liver, brain, thymus, kidney and skin tissues of 
homozygous chimeric mice by Southern blot (Figure 3.4 C and D). Our data showed a 5.9 
kb band in different tissues of hu/mTNFR2 k/i mice and a 3.8 kb band in wildtype mice 
(Figure 3.4 C); an 8.2 kb DNA band was shown in the different tissues of homozygous 
hu/mTNFR2-k/i mice, and a 5.9 kb DNA band was shown in wild type mice (Figure 3.4D). 
3.3.3 Identification of Generation of Chimeric Mice 
Upon removal of the neo cassette, the genotype of chimeric mice carrying hu/mTNFR1 or 
hu/mTNFR2 genes were tested by PCR with specific primers shown in Table 3.2. 
Homozygous and heterozygous hu/mTNFR1-k/i mice led to a 313 bp product for the 
human TNFR1 allele, and an approximate 270 bp fragment for the wildtype allele (Figure 
3.5A). Mice that only showed a band at 313 bp were homozygous for hu/mTNFR1. 
Heterozygous mice presented bands at both 313 bp and at 270 bp, and only a band at 270 
bp represented wildtype mice. Homozygous and heterozygous hu/mTNFR2-k/i mice 
produced a 380 bp fragment for human TNFR2 allele and a band at 300 bp for the 
wildtype allele (Figure 3.5B). Similar to the hu/mTNFR1-k/i mice, homozygous 
hu/mTNFR2-k/i mice only showed a band at 380 bp level; heterozygous mice presented 
bands at 380 bp and 300 bp, and only a 300-bp band represented wildtype mice. 
3.3.4 Hu/m TNFR1 and Hu/m TNFR2 Expression in Chimeric Mice 
The expression levels of hu/mTNFRs in primary mouse embryonic fibroblasts (MEFs) were 
also analyzed by flow cytometry (Figure 3.6 A and B, were performed by our collaborator, 
Roman Fischer, Germany). We found that hu/mTNFR1 and hu/mTNFR2 were stably 
expressed in chimeric mice and that the levels of hu/mTNFR1 and hu/mTNFR2 expression 
in chimeric mice were similar with levels of TNFR1 and TNFR2 expression in wildtype mice. 
Moreover, we isolated the brain tissue and tested hu/mTNFRs expression in hu/mTNFR1 
k/i, hu/mTNFR2 k/i and wildtype mice by Western blot (Figure 3.6 C and D). Furthermore, 
our collaborator (Roman Fischer) also tested the expression of hu/mTNFR1 and 
hu/mTNFR2 in chimeric homozygous mice using flow cytometry to analyze plenocytes and 
thymocytes (Supplementary figure 3.1). The comparison with wildtype mice showed that 
TNF receptors were expressed at similar levels. 
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Figure 3.4. Southern blot analysis of ES cells and mouse tissues. (A) Genomic integration of 
hu/mTNFRswas shown for nine embryonic stem cells. DNA was digested with EcoRV and probed 
with the 5’ probe, andresulted in 11.9-kb DNA size (wildtype, wt) and a 7.7 kb DNA size (targeting, 
left); Probing with the 3’ probe and NheI digestion resulted in products of wt 11.1 kb and targeted 
7.5 kb (right). (B) Genomic integration of hu/mTNFR2 was shown for nine embryonic stem cells. DNA 
digested with PshAI and the 5’ probe showed wt 26.7 kb and targeted 13.5 kb (left); digestion with 
EcoRV and probing with the 3’ probe resulted in products of wt 32.4 kb and 17.8 kb (targeted, right). 
DNA from lung, heart, liver, brain, thymus, kidney and skin tissue from homozygous hu/mTNFR1-k/i 
(C), hu/mTNFR2-k/i (D) mice were digested by BamHI, blotted on nylon membrane and probed with 
the endogenous probes enP. The DNA size marker phage Lambda DNA/StyI marker (Bioron, 
Ludwigshafen, Germany) was used to identify size of products. In all samples of homozygous 
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transgenic mice the neo cassette was removed as evident by the 5.9 kb (A, hu/mTNFR1-k/i) or 8.2 kb 
(B, hu/TNFR2-k/i) product. 
3.4 DISCUSSION 
Since tumor necrosis factor (TNF) and its two receptors (TNFR1 and TNFR2) have been 
reported to play a predominant role in the initiation and orchestration of immunity and 
inflammation and neurodegeneration (Aggarwal, 2003; Dong et al., 2015; Karatas et al., 
2016; Murayama et al., 2015), chemicals that target TNFRs could be developed into 
therapeutic drugs. It implies that establishment of humanized TNFRs mice is necessary for 
the investigations of human TNFR targets to treat certain diseases such as AD. Here, we 
generated two humanized mouse models in which the extracellular domains of mouse 
TNFRs were replaced by the human TNFRs counterparts, respectively. The design strategy 
on the two humanized TNFR mouse models was that mouse extracellular domains were 
replaced by human extracellular domains and mouse intracellular domains still maintain in 
the chimeric mice. Advantages of this design strategy are that in the two humanized 
mouse models the constructs of humanized TNFRs not only can be modulated by human 
TNFRs specific agonists or antagonists but also maintainthe downstream signalling 
pathways in the chimeric mice. 
 
Figure 3.5. The genotypes of hu/mTNFR1 and hu/mTNFR2 knock-in mice were determined by PCR. 
(A) The size of the humanized TNFR1 PCR product was 313 bp (lane 2), and that of mouse TNFR1 was 
approximately 270 bp (lane 1). (B) The size of humanized TNFR2 PCR product was shown a band at 
380 bp and mouse TNFR2 was shown at 300 bp. Lane M represents a 1 kb DNA ladder. 
On the other hand, one previous study had demonstrated that transgenic mice expressing 
3’-modified human TNF-α showed deregulated patterns of expression and developed 
chronic inflammatory polyarthritis (Butler et al., 1997; Keffer et al., 1991). Moreover, 
TG197hTNFR1 knock-in mouse model carrying fully human TNF-TNFR1 genes 
spontaneously develop arthritis due to the interaction of overexpressed human TNF with 
human TNFR1 (http://www.biomedcode.com/gr/en/content/human-tnf-tnfr1-driven-
arthritis) (Michopoulos et al., 2016). However, we just sought to determine therapeutic 
effects of human TNFR-specific reagents against neurodegeneration in certain humanized 
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TNF or TNFR transgenic mouse models with normal phenotypes. Humanized TNF-α 
transgenic mouse models that can spontaneously develop inflammation diseases were not 
reasonable models for investigations of TNFR-specific reagents against neurodegeneration. 
Therefore, we established two novel humanized TNFR knock-in (hu/mTNFR-k/i) mouse 
models expressing extracellular domains of human TNFR1 or human TNFR2 that could 
respond human TNFR-specific reagents, respectively. Notably, we found that the two 
humanized mouse models show normal physiological features but no signs of 
inflammatory diseases, such as arthritis. 
 
 
Figure 3.6. Expression of transgenic hu/mTNFR1-k/i and hu/mTNFR2-k/i in primary cells isolated 
from chimeric mice. Primary mouse embryonic fibroblasts (MEF) were isolated from wildtype (A, B), 
hu/mTNFR1-k/i (A) or hu/mTNFR2-k/i (B) C57BL/6 mice. Expression o f mouse TNFR1 (HP8002) and 
human TNFR1 (HP9002) (A) or mouse TNFR2 (HP8003) and human TNFR2 (HP9003) (B) was analyzed 
by flow cytometry (performedby Roman Fischer). Data are presented as normalized to unit area. (C, 
D) Brain tissueisolated from wildtype (C,D) hu/mTNFR1-k/i (C) or hu/mTNFR2-k/i (D) C57BL/6 mice. 
Tissue was lyzed and expression of huTNFR1 (wildtype, hu/mTNFR1-k/I,H398) or huTNFR2 (wildtype, 
hu/mTNFR2-k/I,MR2-1) was analyzed by western blot. 
In the present work, we found that the chimeric TNFRs genes are present in many tissues 
including lung, heart, liver, brain, thymus, kidney and skin by Southern blotanalysis (Figure 
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3.4 C and D). Chimeric TNFRs can expressstably in the brain tissue of chimeric mice by 
Western blot analysis (Figure 3.6 C and D), and the levels of chimeric TNFRs are similar 
with the levels of mouse TNFRs in wildtype mice (Figure 3.6 A and B, the flow cytometry 
analyses were performed by Roman Fischer, Germany). Additionally, we also found that 
chimeric TNFRs can be activated by mouse TNF-α as expected (Supplementary figure 3.2). 
Thus, the humanized TNFRs mouse models can be used for studies of human TNFRs 
signalling pathways in vivo, and investigations of therapeutic potential of specific drugs for 
inflammatory diseases and neurodegenerative disorders such as multiple sclerosis (MS), 
Parkinson’s disease (PD) and Alzheimer’s disease (AD). 
Humanized mouse models are critical tools for basic research, modeling of certain human-
specific diseases, efficacy testing of immunotherapy approaches, and safety assessment 
for some molecule therapeutics (Goettel et al., 2016; Grün et al., 2016; Lundbäck et al., 
2016; Masuda et al., 2016; Mukherjee et al., 2016; Radin et al., 2016). Humanized mice as 
a model had been used to study human hematopoietic stem cell transplantation (Denton 
et al., 2012). Humanized mice were also applied to study graft-versus-host disease during 
allogeneic bone marrow transplantation (BMT) (Zheng et al., 2013). Additionally, 
application of mice with human immune system was investigated for HIV drug discovery 
(Ibeh et al., 2016). We here generated two humanized mouse models featuring human 
TNFR1 and human TNFR2. Generation of the two humanized TNFR mouse models 
represents a major advance in current TNFRs research models compared to in vitro 
systems or non-human primate models. Dependent on the multiple roles of TNFRs in 
certain diseases, the two humanized mouse models featuring human TNFR1/2 can be 
applied to study the therapeutic potential of human TNFR-specific reagents. For instance, 
the roles of TNFRs have been reported in neurodegenerative disorders (Dong et al., 2015; 
Kollias and Kontoyiannis, 2002), such as AD and MS, thus human TNFR-specific reagents 
could be applied to treat these diseases in hu/mTNFR-k/i mice. 
In summary, the present work showed development and characterization of the 
humanized TNFR1 and humanized TNFR2 knock-in mouse models and provided evidence 
that the recombined TNFRs can be expressed stably in chimeric mice, indicating a more 
broadinvestigation of human TNF systems in vivo. We expect that using transgenic mouse 
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SUPPLEMENTARY MATERIALS AND RESULTS   
Isolation of Thymocytes and Splenocytes for Flow Cytometry 
Thymus and spleen of hu/mTNFR1-k/i or hu/mTNFR2-k/i mice were isolated and mashed 
through a 40 µm cell strainer (Falcon). Cells were centrifuged (300 g, 5 min) and washed 
once with PBA (PBS, 0.5% BSA, 0.02% NaN3). Then 0.5 x 10
6 cells were incubated with 
antibodies against mouse TNFR1 (HP8002) and human TNFR1 (HP9002) and mouse TNFR2 
(HP8003) and human TNFR2 (HP9003, Hycult Biotec, Uden, The Netherlands) for 45 min 
on ice. Cells were washed twice with PBA and incubated with fluorescence labeled 
secondary antibodies for 30 min on ice. Then cells were washed again twice with PBA and 
fluorescence was analyzed by flow cytometry (MACSQuant Analyzer 10, Miltenyi), 
Normalized data are presented as unit area vs fluorescence intensity. Antibodies against 
CD45R, CD68 and CD8 were from Miltenyi Biotech (Bergisch-Gladbach, Germany). 
Secondary antibodies coupled to Alexa-Fluor488 were from Life Technologies (Karlsruhe, 
Germany) and horseradish peroxidase (HRP)-labeled antibodies were purchased by 
Jackson ImmunoResearch Laboratories (Suffolk, UK). 
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Supplementary figure 3.1. Expression of transgenic hu/mTNFR1-k/i and hu/mTNFR2-k/i in 
chimeric homozygous mice. Splenocytes or thymocytes were isolated from C57BL/6J wildtype (A,B), 
hu/mTNFR1-k/i (A) or hu/mTNFR2-k/i (B) mice. Then mouse TNFR1 (HP8002) and human TNFR1 
(HP9002) (A) or mouse TNFR2 (HP8003) and human TNFR2 (HP9003) (B) expression was analyzed by 
flow cytometry using sub-gates for CD45R+ B cells, CD68+ macrophages (splenocytes) and CD8+ 
thymocytes. Gray histograms show the isotype controls, black lines indicate signals measured for 
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Supplementary figure 3.2. TNF-induced cytotoxicity in hu/mTNFR1-k/i mice. hu/mTNFR1-k/i mice 
were treated with mouse TNF (30 µg) or saline (i.v.). Animals were monitored over a period of 24 
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ABSTRACT 
Tumor necrosis factor alpha (TNF-α) that is a major pro-inflammatory cytokine has been 
implicated to contribute to physiopathology of onset in a number of neurodegenerative 
disorders. Despite the recognized role of TNF-α in inflammation and neurodegeneration, 
anti-TNF-α reagents failed to treat neurodegenerative disorders. Animal disease models 
had revealed the antithetic effects of the two TNF receptors (TNFR1 and TNFR2) in the 
central nervous system, whereby TNFR1 has been associated with inflammatory 
degeneration and TNFR2 with neuroprotection. This indicates that selective activation of 
TNFR2 or/and inhibition of TNFR1 might be of therapeutic benefit for neurodegenerative 
diseases. Here, we showed the therapeutic potential of selective activation of TNFR2 by 
human TNFR2-selective agonists, EHD2-scTNFR2 and TNC-scTNFR2, and selective inhibition 
of TNFR1 by a human TNFR1-specific antagonistic antibody, ATROSAB, respectively, in a 
mouse model of N-methyl-D-aspartate (NMDA) induced nucleus basalis magnocellularis 
(NBM) lesion. We found that co-administration of TNC-scTNFR2 or EHD2-scTNFR2 or 
ATROSAB into the NBM significantly protected cholinergic neurons and their neocortical 
projections. Also, the reagents significantly prevented microglial activation at the site of 
injection in the brain. Moreover, we also found that simultaneous blocking TNFR1 and 
TNFR2 signalling, however, abrogated the therapeutic effect of ATROSAB, uncovering an 
important role of TNFR2 in neuroprotection. Accordingly the therapeutic activity of 
ATROSAB is mediated by shifting the balance of the antithetic activity of endogenous TNF-
α towards TNFR2, which appears essential for neuroprotection. To conclude, our data 
indicate that selective targeting TNFRs could be effective therapeutic approaches for 
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4.1 INTRODUCTION 
Tumor necrosis factor alpha (TNF-α) is one of the major pro-inflammatory cytokines that 
plays an important role in the initiation of immunity and inflammation (Aggarwal, 2003; 
Fischer and Maier, 2015). Elevated levels of TNF-α have been associated with different 
autoimmune diseases; deregulation of TNF-α expression and signalling can lead to chronic 
inflammation and tissue damage (Dong et al., 2015; Fischer et al., 2015; Kollias, 2005; 
Probert, 2015). Therefore, several anti-TNF-α therapeutics are clinically approved and 
used to treat autoimmune disease, such as rheumatoid arthritis, psoriasis or inflammatory 
bowel disease. Additionally, up-regulated TNF-α expression has also been associated with 
in a variety of neurodegenerative diseases, such as Alzheimer’s disease (AD), Parkinson’s 
disease (PD), stroke and Multiple Sclerosis (MS) (McAlpine et al., 2009; Tan et al., 1999; 
Tarkowski et al., 2000; Yang et al., 2013). However, an anti-TNF-α therapeutic (Lenercept) 
failed in a Phase II randomized, multi-center, placebo-controlled study for the treatment 
of relapsing remitting MS because symptoms of Lenercept-treated patients were 
significantly increased compared to patients receiving placebo and neurologic deficits 
tended to be more severe in the Lenercept treatment group study (1999). Next to 
induction or aggravation of demyelinating diseases, all anti-TNF-α therapeutics may 
induce severe side-effects such as serious infections, including reactivation of tuberculosis, 
invasive fungal and other opportunistic infections.  
The failure of the Lenercept study and the severe side-effects of anti-TNF-α therapeutics 
might be explained by the pleiotropic functions of TNF-α, including both pro- and anti-
inflammatory functions and other immune regulatory as well as regenerative activities, 
through its two receptors (TNFR1 and TNFR2). Blocking all effects of TNF-α therefore 
might be counter-productive in neurodegenerative disorders. Because most of the pro-
inflammatory actions of TNF-α are mediated by TNFR1 (Fontaine et al., 2002; Maddahi et 
al., 2011; Yang et al., 2013; Zhao et al., 2003), a more effective therapeutic approach could 
be the selective blocking of TNFR1 signalling. Indeed, TNFR1 inhibition has been shown to 
significantly ameliorate experimental autoimmune encephalomyelitis (EAE) symptoms in a 
mouse model (Williams et al., 2014). This neuroprotective approach of TNFR1 inhibition 
could spare TNFR2 signalling, which has been implicated in various protective and 
regenerative responses, particularly in the central nervous system (CNS): TNFR2 signalling 
was shown to promote neuronal survival and oligodendrocyte regeneration in in vivo 
models of ischemic and neurotoxic insults (Arnett et al., 2001; Fontaine et al., 2002). 
Therefore, according to the antithetic effects of both TNF-α receptors, targeting TNFRs by 
inhibiting TNFR1 and/or activating TNFR2 signalling pathway might represent a potential 
therapeutic strategy against neurodegenerative disorders. 
In the present study, we investigated the therapeutic potential of novel human TNFR2 
selective agonists, TNC-scTNFR2 and EHD2-scTNFR2, and a novel human TNFR1 specific 
antagonist, ATROSAB, using a well-established model of in vivo brain damage, the nucleus 
basalis magnocellularis (NBM) lesion (Whitehouse et al., 1981;Coyle et al., 1983), in 
humanized TNFR knock-in mice (hu/mTNFR1-k/i and hu/mTNFR2-k/i) mice, respectively. 
We discovered that TNC-scTNFR2, EHD2-scTNFR2, and ATROSAB significantly prevent the 
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NBM lesion-induced cortical cholinergic denervation and massive size of microglial 
activation in both transgenic mouse lines. Also, we found that the neuroprotection of 
ATROSAB is mainly dependent on activation of TNFR2 signalling pathway.   
 
4.2 MATERIALS AND METHODS 
 
4.2.1 Materials  
Primers for gene expression studies were obtained from Biomers (Ulm, Germany) and for 
genotyping of humanized TNFR from Life Technologies. The TNFR2 specific antibody 80M2 
(Grell et al., 1995) and the TNFR1 selective antagonistic antibody ATROSAB (Zettlitz et al., 
2010) have been described. Antibodies against Akt and phospho-Akt (Ser473) were from 
Cell Signalling Technology (Boston, MA). The anti-TNF and anti-TNFR2 (MAB426) antibody 
was from R&D System (Wiesbaden, Germany). Secondary antibodies coupled to Alexa-
Fluror488 were from Life Technologies (Karlsruhe, Germany) and horseradish peroxidase 
(HRP)-labeled antibodies were purchased by Jackson ImmunoResearch Laboratories 
(Suffolk, UK). Primary antibodies used for immunohistochemistry were goat anti-ChAT IgG 
(Millipore, Billerica, MA, USA) and mouse anti-rat integrin αM (CD11b) monoclonal 
antibody (Chemicon International, Temecula, CA, USA). Secondary antibodies were rabbit 
anti-goat IgG (Sigma) and horse anti-mouse IgG (Vector, Brunschwig Chemie, Amsterdam, 
the Netherlands), respectively. Stainings were developed by use of the Vectastain Elite 
ABC Kit (Vector Laboratories) followed by incubation with 3,3’-diaminobenzidine 
(DAB,Sigma, St. Louis, MO, USA). Actinomycin D and 3-(4,5-Dimethyl-2-thiazolyl)-2,5-
diphenyl-2H-tetrazolium bromide (MTT) were from Sigma-Aldrich (Steinheim, Germany). 
All other chemicals were of analytical grade. 
4.2.2 Animals  
Male homozygous hu/mTNFR-k/i C57BL/6J mice (12 weeks, 24-30 g) were used for 
experiments. All animals were individually housed with a free access to ad libitum food 
and tap water and kept in an air-conditioning room (21 ± 2°C) with a 12/12 h light-dark 
circle (lights on 7:00 a.m.). Animal care and treatment were carried out in accordance with 
the local Ethical Committee guidelines on the use of experimental animals at the 
University of Groningen, the Netherlands (DEC6523) and University of Stuttgart, Germany 
(35-9815.81-0350). 
 
4.2.3 Nucleus Basalis Magnocellularis Injection and Treated Groups 
An injection into the NBM was performed as previously described by Luiten et al. (Luiten 
et al., 1995). Briefly, after anesthesia with isoflurane, mouse heads were mounted in a 
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Kopf stereotactic frame (Kopf Instruments model 900, Tujunga, CA, USA). A volume of 0.6 
µl solution was slowly infused in two steps of 0.3 µl into the NBM of the right hemisphere 
(coordinates: 0.6 mm posterior to bregma; 2.1 mm lateral to the sagittal suture; 4.6/4.4 
mm ventral to the dura; Paxinos and Franklin, 2001). After the injection (0.1 μl/min), the 
needle of a 1-μl Hamilton syringe was left in situ for 2 min to allow for an effective drug 
diffusion. The contralateral intact hemisphere served as internal control without 
interference. After 8 day upon the NBM injection, all mice were sacrificed. 
Hu/mTNFR2-k/i mice were divided into 6 groups: (1) phosphate-buffered saline (PBS, 0.01 
M, pH = 7.40); (2) PBS with 55 nmol NMDA (Sigma, USA); (3) PBS with 220 ng TNC-scTNFR2 
(Stuttgart, Germany); (4)NMDA with 220 ng TNC-scTNFR2; (5) PBS with 580 ng EHD2-
scTNFR2 (Stuttgart, Germany); (6) 55 nmol NMDA together with 580 ng EHD2-scTNFR2. 
Hu/mTNFR1-k/i mice were divided into 7 groups: (1) PBS; (2) PBS with 3 µg ATROSAB; (3) 
55 nmol NMDA; (4) 55 nmol NMDA together with 3 μg ATROSAB; (5) 55 nmol NMDA, 3 µg 
ATROSAB and 150 ng mouse TNFR2 antagonist (MAB426); (6) 55 nmol NMDA together 
with 150 ng MAB426 only; (7) 55 nmol NMDA and 2 µg anti-human epidermal growth 
factor receptor (huEGFR) IgG as an unspecific control antibody. 
4.2.4 Tissue Processing and Immunohistochemistry  
Under a deep anesthesia via an i.p. injection of pentobarbital sodium, mice were 
processed by a short pre-rinse with 0.5% heparin physiological saline and subsequently 
transcardially perfused by using a fixative solution of 4% paraformaldehyde in phosphate-
buffer (PB, 0.1 M, pH = 7.40). Brain tissues were removed, post-fixed 48 h with 
composition of 4% paraformaldehyde in PB, stored in PB at 4°C for 24 h, and 
cryoprotected by immersion in 30% sucrose at room temperature for 24 h. Afterwards, 
frozen coronal sections at a 20-µm thickness were cut on a cryostat microtome and 
collected in PBS (0.01 M, pH = 7.40) containing 0.1% sodium azide.   
Projected cholinergic fibres After rinsing several times in PBS, free-floating tissue sections 
were processed for choline-acetyltransferase (ChAT) immunohistochemistry by incubation 
in PBS with 0.3% H2O2 for 45 min, rinsed several times again, and pre-incubation in PBS 
containing 5% normal rabbit serum (NRS, Zymed, San Francisco, CA,USA) and 0.4% Triton 
X-100 at room temperature (RT) for 1 h. Subsequently, sections were incubated with goat 
anti-ChAT IgG (diluted 1:333, Millipore, Billerica, MA, USA) in PBS containing 1% NRS, 0.5% 
BSA and 0.4% Triton X-100 at 4°C for 3 days. After incubation of the primary antibody, 
sections were rinsed in PBS and incubated with rabbit anti-goat IgG (diluted 1:500, Sigma) 
in PBS containing 1% NRS, 0.2% Triton X-100 and 0.5% BSA at RT for 4 h and at 4°C 
overnight. Sections were rinsed in PBS and incubated in PBS with Vectastain Elite ABC Kit 
(both A solution and B solution were diluted to 1:500) at RT for 2 h. Finally, 3,3’-
diaminobenzidine (DAB, Sigma, St. Louis, MO, USA) reaction to peroxidase as chromogen 
was visualized. Visualization of DAB reaction was enhanced by Ammonium nickel sulphate 
(BDH Chemicals Ltd., UK).  
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Microglial activation Tissue sections were incubated in 0.3% H2O2 in PBS for 45 min, 
rinsed in PBS several times, pre-incubated in 5% normal horse serum (NHS) and 0.4% 
Triton X-100 PBS. Thereafter, sections were incubated with mouse anti-rat integrin αM 
monoclonal antibody (CD11b, diluted 1:1000, Chemicon International, Temecula, CA, USA) 
in PBS containing 1% NHS and 0.4% triton X-100 at 4°C for 3 days. Sections thereafter 
were incubated in Biotinylated horse anti-mouse IgG (Vector, Brunschwig Chemie, 
Amsterdam, the Netherlands) diluted 1:500 at 4°C overnight, followed by incubation of 
Vectastain Elite ABC Kit (diluted to 1:500) at RT for 2 h. Thereafter, peroxidase was 
visualized by DAB as chromogen. Visualization of the DAB reaction was enhanced by 
Ammonium nickel sulphate. 
4.2.5 Quantification of the NBM Lesions 
Quantitative analysis of cholinergic fibres ChAT-positive innervation density was 
measured in the somatosensory cortex by using a program of the LAS Image Analysis 
Software (Leica Quantimet, the Netherlands). Surface area density of cortical ChAT-
positive fibres was measured in the layer V of somatosensory cortex in eight coronal 
sections (coordinates: 0.6 mm posterior to bregma), which represent a strong reaction of 
cholinergic innervations from the lesioned NBM subdivision (Gaykema et al., 1990). After 
ground subtraction and gray-scale threshold determination, the surface area of ChAT-
positive fibres in the layer V of the parietal cortex was calculated by shown as a 
percentage by (the area coverage of ChAT-active cholinergic fibres)/(the total sampling 
area) x 100 in each coronal section. The correlated value of fibre reduction caused by the 
unilateral NBM lesion was calculated as the percentage difference between the surface 
area density of cortical fibres in the damaged side and that in contralateral side (Harkany 
et al., 2001).   
Measurement of microglial activation Quantification on the reactive volume of microglial 
activation has been previously described (Granic et al., 2010). Briefly, the size of the 
reactive region of CD11b-positive microglial activation was measured on the surface area 
of coronal sections in the lesion site by using a program of the Quantimet 600 system 
(Leica, the Netherlands). The reactive surface area of microglial activation was quantified 
in a series of CD11b-positive sections of each mouse brain. The total reactive volume of 
microglial activation in a brain was calculated as (x1+ x2 + …xn) x 100 μm
3, where ‘xn’ is the 
reactive surface area of each section (µm2) and 100 μm was the distance between two 
consecutive sections. 
4.2.6 Primary Cortical Neuron Culture  
Primary cortical neurons were prepared from embryonic brains (E14–16) of hu/mTNFR1-
k/i mice. The meninges were removed and the cortical neurons were separated by 
mechanical dissociation. Cells were plated in a density of 12 x 104 cells/well (96-well plates) 
and 2 x 106 cells/well (6-well plates) on poly-D-lysine pre-coated plates. Neurobasal 
medium (Gibco) with 2% (v/v) B27-supplement, 0.5 mM glutamine, 1% (v/v) 
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penicillin/streptomycin was used as culture medium. After 48 h neurons were treated 
with 10 µM cytosine arabinoside (Sigma) for another 66 h to inhibit non-neuronal cell 
growth. Subsequently, the medium was completely exchanged and after 7 days of in vitro 
culture, the neurons were used for experiments.  
4.2.7 MTT Assay 
Cells were incubated with MTT (0.5 mg/ml) for 2 h at 37°C. Then lysis buffer (10% SDS, 20 
nM HCl) was added, cells were lyzed overnight and optical density at 550 nm was 
determined. Each sample was analyzed in triplicates and data were analyzed using the 
software Microsoft Excel and GraphPad Prism 4. 
4.2.8 Western Blot 
Cells were lysed in homogenization buffer (10 mM HEPES pH 7.5, 1.5 mM MgCl2, 1.5 mM 
KCl, 1% NP-40, 0.2 mM PMSF, 20 mM β-glycerophosphate and 100 μM Na3VO4) at 4°C for 
30 min. Lysates were centrifuged (2 min at 9600 g) and protein concentration of 
supernatants were determined using the BCA method (Pierce, Bonn, Germany). 20 μg 
total proteins were denatured in Laemmli buffer and resolved by 12% SDS-PAGE (100 V; 
90 min). Then, proteins were transferred onto nitrocellulose membranes (semidry blot; 
1.5 mA/cm2 gel for 90 min) and non-specific protein binding was blocked with 5% 
skimmed milk powder solution in PBS with 0.1% Tween 20 for 30 min at RT and the 
membrane was incubated overnight at 4°C using specific antibodies. After incubation with 
HRP-conjugated secondary antibodies for 90 min at RT the signals were detected by 
enhanced chemiluminescence (Super Signal, Pierce, Rockford, IL).  
4.2.9 Statistics 
Data are presented as mean ± standard error of the mean (SEM) of n independent 
experiments. Statistical analyses were performed by Student’s t-test or ANOVA, followed 





4.3.1 TNC-scTNFR2 and EHD2-scTNFR2 Prevent the NBM Lesion-induced 
Cholinergic Denervation and Neuroinflammation in hu/mTNFR2-k/i Mice 
To assess the potential effects of both EHD2-scTNFR2 and TNC-scTNFR2 in an in vivo model 
of neurodegeneration, hu/mTNFR2 knock-in mice were used to establish the nucleus 
basalis lesion model in which NMDA was stereotactically injected into the nucleus basalis 
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magnocellularis (NBM). Our data showed that lesioning of the NBM resulted in a reduction 
of body weight (Figure 4.1), as compared to PBS-injected group. Application of TNC-
scTNFR2 or EHD2-scTNFR2 together with NMDA injected into the NBM showed a significant 
prevention for the loss of body weight (Figure 4.1, p < 0.01). 
 
Figure 4.1. Body weight changes after pharmacological treatment in hu/mTNFR2-k/i mice. (A) TNC-
scTNFR2 prevented the significant reduction of body weight induced by NMDA injection into the 
NBM after injection 1 day. (B) EHD2-scTNFR2 significantly prevented the reduction of body weight 
induced by NMDA injection into the NBM in hu/mTNFR2-k/i mice after injection 2 days or 4 days. n = 
7 mice/group, * p < 0.05, ** p < 0.01 were examined by one-way ANOVA with post-hoc comparisons 
of Tukey tests. Data are presented as means ± SEM. 
The sensitivity of cholinergic neurons in the NBM to NMDA excitotoxicity can be 
quantified by the reduction of their cortical projections (Harkany et al., 2000). We 
therefore assessed the cholinergic fibres in the parietal cortex of all tested group in 
hu/mTNFR2-k/i mice by histopathological analyses. We found that NMDA-injected into the 
NBM significantly induced a reduction of cholinergic innervations in the layer V of the 
parietal cortex (Figure 4.2 and 4.3, C and G, p < 0.0001). However, the application of TNC-
scTNFR2 or EHD2-scTNFR2 significantly prevented the cholinergic denervation in 
comparison to NMDA-injected group (Figure 4.2C and Figure 4.3C, p < 0.0001). Application 
of TNC-scTNFR2 alone did not alter cholinergic innervations. 
Furthermore, the neuroprotective effects of TNC-scTNFR2 or EHD2-scTNFR2 were reflected 
in the degree of microglial activation (Figure 4.2 and 4.3, E to H). An injection with NMDA 
caused a massive activation of microglia at the infused site in the NBM (Figure 4.2F), 
comparing to that in PBS group (p < 0.0001). Application of TNC-scTNFR2 or EHD2-scTNFR2 
together with NMDA showed a significant decline of size of microglial activation in 
comparison to NMDA-injected group (Figure 4.2 and 4.3, G and H, p < 0.0001). Application 
of TNC-scTNFR2 or EHD2-scTNFR2 alone did not affect the output of microglial activation.  
Taken together, these results show that TNC-scTNFR2 and EHD2-scTNFR2 remarkably 
prevents NMDA-induced NBM lesion in hu/mTNFR2-k/i mice. 
4.3.2 ATROSAB Prevents NMDA-induced NBM Lesion in hu/mTNFR1-k/i Mice 
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Roles of TNFR1 signalling have been directly or indirectly verified to aggravate 
neurodegeneration (Fontaine et al., 2002; Williams et al., 2014). Here, we tested the 
potential effects of human TNFR1 antagonist ATROSAB in vivo in the NBM-lesioned 
hu/mTNFR1-k/i mice. By stereotactic injection of NMDA lesions in the NBM were 
generated. We found that lesioning of the NBM resulted in a decrease of body weight 
(Figure 4.4, p < 0.01) in comparison to that in control groups. However, ATROSAB showed 
a strong protective effect against a reduction of body weight (one-way ANOVA, p < 0.05).  
 
Figure 4.2. TNC-scTNFR2 protects against NMDA-induced NBM lesion in hu/mTNFR2-k/i mice. (A-D) 
Representative images show ChAT-positive cholinergic innervations in the parietal cortex. NMDA 
injected into the NBM induced an extensive cholinergic fibre loss in the layer V of the parietal cortex 
(C), compared to the control groups (A and B). However, TNC-scTNFR2 treatment prevented fibre loss 
(D). Parallel bars (A-D) indicate the layer V of the parietal cortex in which quantitative 
measurements were performed. (I) Quantification of cholinergic fibre density in layer V of the 
parietal cortex. Fibre density was measured in 8 sections/mouse, n = 7 mice/group. All data in bar 
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charts represent means ± SEM. *** p < 0.0001, one-way ANOVA with post-hoc comparisons Tukey. 
(E-H) Representative images show CD11b-positive activated microglia in the NBM. NMDA injected 
into the NBM induced a massive volume of microglial activation (G), compared to those in both 
control groups (E, F). However, TNC-scTNFR2 treatment significantly reduced microglial activation 
induced by NMDA (H). (J) Quantification of total extent of activated microglia around the injections. 
Microglial activation was measured in a series of sections with microglial activation, n = 7 mice/ 
group. All data in bar charts represent means ± SEM. *** p < 0.0001, one-way ANOVA with post-hoc 
comparisons Tukey. 
 
Figure 4.3. EHD2-scTNFR2 prevents the NMDA-induced NBM lesion in hu/mTNFR2-k/i mice. (A-D) 
Representative images show ChAT-positive cholinergic innervations in the parietal cortex. NMDA 
injected into the NBM induced an extensive cholinergic fibre loss in the layer V of somatosensory 
cortex (C), compared to the control group (B). However, EHD2-scTNFR2 treatment prevented fibre 
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loss (D). Parallel bars (A-D) indicate the layer V of the somatosensory cortex in which quantitative 
measurements were performed. (I) Quantification of cholinergic fibre density in layer V of the 
parietal cortex. Fibre density was measured in eight sections/mouse, n = 7 mice/group. All data in 
bar charts represent means ± SEM. *** p < 0.0001, one-way ANOVA with post-hoc comparisons 
Tukey. (E-H) Representative images show CD11b-positive activated microglia in the NBM. NMDA 
injected into the NBM induced a massive volume of microglial activation (G), compared to those in 
both control groups (E, F). However, EHD2-scTNFR2 treatment significantly reduced microglial 
activation induced by NMDA (H). (J) Quantification of total extent of activated microglia around the 
injections. Microglial activation was measured in a series of sections with microglial activation, n = 7 
mice/ group. All data in bar charts represent means ± SEM. *** p < 0.0001, one-way ANOVA with 
post-hoc comparisons Tukey. 
By histopathological examination of brains from treated mice, we observed that ATROSAB 
administration protected against the reduction of cholinergic fibres in the parietal cortex 
and the massive volume of microglial activation at the site of the NBM induced by NMDA 
excitotoxicity (Figure 4.5 D and I, p < 0.0001). Injection of a control IgG (anti-huEGFR), 
however, did not significantly alter NMDA mediated neurodegeneration (Figure 4.5 E and 
J). Taken together, these data show a neuroprotective activity of ATROSAB in vivo that 
supports a previous in vitro study (Richter et al., 2013). 
 
Figure 4.4. Body weight changes after pharmacological treatment in hu/mTNFR1-k/i mice. 
ATROSAB did prevent the significant reduction of body weight induced by NMDA injection into the 
NBM, but it only showed a statistically significant prevention on Day 1. 
4.3.3 TNFR2 Signalling is Essential for ATROSAB Neuroprotection 
TNF-α/TNFRs signalling pathways are complicated in neurodegenerative processes: 
TNF/TNFR1 signalling pathway has been reported depravation, whereas TNF-α/TNFR2 
signalling pathway is neuroprotective via PKB/Akt activated NF-κB signalling pathway 
(Fontaine et al., 2002). Our previous studies have shown that activation of TNFR2 and 
inhibition of TNFR1 survived cholinergic neurons against NMDA-mediated NBM lesion 
(Figure 4.3, I and J). To clarify the importance of inhibition of TNFR1 and activation of 
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TNFR2 in vivo, we blocked TNFR2 signalling pathway by a mouse TNFR2 antagonist 
(MAB426) and meanwhile inhibited huTNFR1 signalling pathway by ATROSAB in this lesion 
model as shown by (Figure 4.6). We found that MAB426 completely abolished ATROSAB 
mediated protection on both cholinergic innervation and microglial activation (Figure 4.6 
D and I).  
PKB/Akt is considered to be a prominent and ubiquitous downstream target protein of 
PI3K (Cantley, 2002). Previously we have shown that the PI3K-PKB/Akt pathway mediates 
TNFR2-promoted protection from excitotoxic cell death (Dolga et al., 2008a; Fontaine et 
al., 2002; Marchetti et al., 2004). To further study the molecular pathways underlying the 
neuroprotective effects of ATROSAB, we isolated primary neurons from hu/mTNFR1-k/i 
mice and investigated TNF-induced phosphorylation of PKB/Akt (Ser473). As expected 
stimulation with a non-receptor selective mouse tmTNF-mimetic, (EHD2-sc-mTNF) 
induced phosphorylation of PKB/Akt. Interestingly, phosphorylation was enhanced in 
presence of the TNFR1 antagonist ATROSAB (Figure 4.7A), suggesting that PKB/Akt 
activation occurs via TNFR2 and concomitant TNFR1 signalling interferes with this pathway. 
In addition, TNF was shown to protect primary neurons from glutamate-induced cell death 
in a TNFR2-dependent manner (Marchetti et al., 2004). Similarly, we could show that the 
mouse TNFR2-specific TNF, EHD2-sc-mTNFR2, protects primary hu/mTNFR1-transgenic 
neurons from excitotoxic cell death (Figure 4.7B). In accordance with ATROSAB mediated 
increase of PKB/Akt phosphorylation, ATROSAB enhanced the neuroprotective effect of 




TNF-α has been reported to exert opposite effects via its two receptors, TNFR1 and TNFR2, 
particularly in the central nervous system(CNS) (Dong et al., 2015; Probert, 2015), 
suggesting that TNFR1 mediates deterioration and TNFR2 mediates protection. 
Investigations in a mouse model of retinal ischemia revealed that TNFR1-deficient animals 
were protected from ischemic lesions, whereas TNFR2-/- mice showed enhanced neuronal 
loss and a more severe pathology compared to wildtype animals (Fontaine et al., 2002). 
Similar, using the cuprizone-induced mouse model of demyelination, it was shown that 
TNFR2 is critical for oligodendrocyte regeneration, whereas TNF-α signalling via TNFR1 
promoted nerve demyelination (Arnett et al., 2001). TNF-α exacerbates Aβ-induced 
toxicity in neurons through inhibiting TNFR2 signalling (Shen et al., 1997). These studies 
demonstrate that TNF-α/TNFR2 signalling pathway is neuroprotective in a 
neurodegenerative instance, which is opposite to the role of TNFR1. The same principle 
applied to oligodendrocyte progenitor cells, TNFR2 was shown to protect against oxidative 
stress (Maier et al., 2013). Furthermore, Fischer et al. (2011) demonstrated the generation 
of a human TNFR2 selective agonist (TNC-scTNFR2) and described in vitro that TNC-scTNFR2 
rescues neuronal survival from oxidative stress-induced toxicity. We here showed in an in 
vivo model of NMDA induced cellular degeneration and loss of neuronal functions that 
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both TNFR2 selective agonists (TNC-scTNFR2 and EHD2-scTNFR2) and a TNFR1 selective 
antagonistic antibody (ATROSAB) exert clearly neuroprotective activity, which is in line 
with previous studies (Fischer et al., 2011; McCann et al., 2014). 
 
Figure 4.5. ATROSAB prevents NMDA-induced NBM lesion in hu/mTNFR1-k/i mice. (A-E) 
Representative images show ChAT-positive cholinergic innervations in the parietal cortex. NMDA 
injected into the NBM induced an extensive cholinergic fibre loss in the layer V of the parietal cortex 
(C), compared to the control group (A, B). However, ATROSAB treatment prevented fibre loss (D). A 
human anti-EGFR antibody (hEGFR) did not alter NMDA-induced NBM lesion. Parallel bars (A-E) 
indicate the layer V of the somatosensory cortex in which quantitative measurements were 
performed. (K) Quantification of cholinergic fibre density in layer V of the parietal cortex. Fibre 
density was measured in eight sections/mouse, n = 7 mice/group. All data in bar charts represent 
means ± SEM. *** p < 0.0001, one-way ANOVA with post-hoc comparisons Tukey. (F-J) 
Representative images show CD11b-positive activated microglia in the NBM. NMDA injected into the 
NBM induced a massive volume of microglial activation (H), compared to those in both control 
groups (F, G). However, ATROSAB administration significantly reduced microglial activation induced 
by NMDA (I). (J) A control IgG (anti-hEGFR) did not alter the NMDA-induced microglial activation. (L) 
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Quantification of total extent of activated microglia around the injections. Microglial activation was 
measured in a series of sections with microglial activation, n = 7 mice/ group. All data in bar charts 
represent means ± SEM. ** p < 0.01, *** p < 0.0001, one-way ANOVA with post-hoc comparisons 
Tukey. 
Studies on lovastatin actions further support TNFR2 involvement in neuroprotection. 
Lovastatin is a cholesterol-lowering drug with reported neuroprotective properties that 
can reduce the incidence of stroke and progression of Alzheimer's disease (Elkind et al., 
2008; Fonseca et al., 2009). Lovastatin increased the expression of TNFR2 in cortical 
neurons in vitro (Dolga et al., 2008b) and was neuroprotective in TNFR1-/-neurons, 
whereas lovastatin’s protection was lost in neurons from TNFR2-/- mice (Dolga et al., 
2008b). Furthermore, lovastatin-mediated neuroprotection led to an increase in PI3K 
dependent PKB/Akt phosphorylation, whereas inhibition of PKB/Akt activation entirely 
abolished lovastatin-mediated neuroprotection. This is in line with previous findings that 
TNFR2 mediated neuroprotection is dependent on the PI3K-PKB/Akt pathway (Marchetti 
et al., 2004) and suggests that Lovastatin induced neuroprotection is dependent on TNFR2 
signalling pathway. 
In the present study, we evaluated the therapeutic potential of TNFR2 agonists TNC-
scTNFR2 and EHD2-scTNFR2 and a TNFR1 antagonist ATROSAB in the mouse model of 
NMDA induced NBM lesion. Similar to lovastatin, both TNC-scTNFR2 and EHD2-scTNFR2 
protected cholinergic neurons and neocortical innervations against NMDA induced 
excitotoxic damage and remarkably reduced microglial activation at the site of the lesion. 
In addition, ATROSAB has also shown a dominant neuroprotection against the NBM 
damage. ATROSAB mediated neuroprotection from neurodegeneration was found to be 
linked to an enhancement of TNFR2 signalling leading to PKB/Akt activation. This is 
evident from abrogation of neuroprotection in vivo upon co-treatment with TNFR2 
blockers and from in vitro studies showing increased phosphorylation of PKB/Akt as well 
as enhanced resistance of primary cortical neurons towards excitotoxic insult by the 
TNFR2 selective TNF in the presence of TNFR1 blockade. The PKB/Akt pathway is known to 
be essential for several physiological processes, including cell differentiation, regeneration 
and cell survival (Skaletz-Rorowski et al., 2003). TNFR2 promotes PKB/Akt activation and  
translocation via phosphorylation at Ser473 in neuronal cells (Marchetti et al., 2004). Our 
data showed that in cortical neurons EHD2-sc-mTNFR2 was able to activate PKB/Akt 
(Ser473), and this activation was further increased significantly by ATROSAB. Together 
these data in vivo and in vitro suggest that TNFR2 -PKB/Akt signalling pathway is essential 
in ATROSAB-mediated neuroprotection.  
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Figure 4.6. ATROSAB prevents NMDA-induced NBM lesion in hu/mTNFR1-k/i mice mainly via 
indirect activation of TNFR2. (A-F) Representative images show ChAT-positive cholinergic 
innervations in the parietal cortex. NMDA injected into the NBM induced an extensive cholinergic 
fibre loss in the layer V of the parietal cortex (C), compared to the control groups (A and B). However, 
ATROSAB treatment attenuated fibre loss (D). ATROSAB mediated protection against fibre loss was 
prevented by TNFR2 antagonistic MAB426 (E). However, MAB426 alone did not significantly alter 
NMDA-induced NBM lesion (F). Parallel bars indicated the layer V of the somatosensory cortex in 
which quantitative measurements were performed. Scale bar is 100 µm in (F). (M) Quantification of 
cholinergic fibre density in layer V of the somatosensory cortex. Fibre density was measured in 8 
sections/mouse, n = 7 mice/group. All data in bar charts represent means ± SEM. * p < 0.05, ** p < 
0.01, *** p < 0.0001, one-way ANOVA with post-hoc comparisons Tukey. (G-L) Representative 
images show CD11b-positive activated microglial in magnocellular nucleus basalis. NMDA injected 
into the NBM induced a massive volume of microglial activation (I), compared to those in the groups 
(G and H). However, ATROSAB treatment significantly reduced microglial activation induced by 
NMDA (J). ATROSAB neuroprotection against microglial activation was prevented by TNFR2 
antagonistic MAB426 (K). MAB426 did not significantly alter NMDA-induced NBM lesion (L). Scale 
bar is represent 500 µm in (L). (N) Quantification of total extent of activated microglial infiltration 
around the injections. Microglial activation was measured in a series of sections with microglial 
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activation, n = 7 mice/ group. All data in bar charts represent means ± SEM. ** p < 0.01, *** p < 
0.0001, one-way ANOVA with post-hoc comparisons Tukey. 
Here, we provide compelling evidence NMDA induced acute neuronal lesions that 
abrogation of complete TNF signalling by blocking TNFR1 by ATROSAB is neuroprotective. 
We propose that the neuroprotective activity of ATROSAB is accomplished by a twofold 
action: As a consequence of the excitotoxic insult activated microglia promotes, via 
soluble TNF production, the expansion of the degenerative tissue response in an autocrine 
TNFR1 dependent way; inhibition of TNFR1 limits this process. At the level of neuronal 
cells, it was shown previously that proper TNFR2 activation induces protection from 
excitotoxicity in vitro (Dolga et al., 2008b; Marchetti et al., 2004); in the in vivo model 
analyzed here, in neurons in the vicinity of the acute insult and not immediately 
succumbing to excitotoxic death, a competition of TNFRs for limiting amounts of 
endogenously produced membrane form of TNF molecules occurs, which results in 
suboptimal activation of TNFR2 of this cell population under a non-treatment condition. 
Moreover, at the level of intracellular signalling, it is known that signal crosstalk between 
TNFR1 and TNFR2 exists in terms of competition for common signal transducers like TRAF2 
(Fotin-Mleczek et al., 2002; Weiss et al., 1997), with TNFR1 outperforming TNFR2 
pathways in the case of abundance of soluble TNF-α, which triggers exclusively TNFR1 
(Probert, 2015). In the presence of ATROSAB, neuronal response is shifted towards TNFR2 
because of blocked neuronal TNFR1, allowing the induction of a resistant state by 
endogenous mTNF-α. 
 
Figure 4.7. ATROSAB is neuroprotective via enhanced TNFR2 signalling. (A) Primary neurons, 
isolated from hu/mTNFR1-k/i mice, were stimulated with or without ATROSAB (100 µg/ml) for 30 
min followed by addition of Blot (n = 4, ± SEM). (B) Primary neurons, isolated from hu/mTNFR1-k/i 
mice, were stimulated wildtype EHD2-sc-mTNF (10 ng/ml). Then cells were incubated for 24 h, lyzed 
and phosphorylation of Akt was quantified by Western with or without ATROSAB (100 µg/ml) for 30 
min followed by addition of wildtype EHD2-sc-mTNF or mouse TNFR2-selective EHD2-sc-mTNFR2. 
After 24 h, glutamate (5 µM) was added and cells were incubated for an additional hour. Then 
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determined by MTT assay (n = 3). All data in bar charts represent means ± SEM. ** p < 0.01, one-way 
ANOVA with post-hoc comparisons Tukey. 
Glutamate, a major neurotransmitter, can interact with the ionotropic α-amino-3-
hydroxy-5-methyl-4-isoxazol-propionic acid (AMPA) and N-methyl-D-aspartate (NMDA) 
receptors. Exacerbated activation of these glutamate receptors, specifically the increase in 
intracellular calcium concentrations ([Ca2+]i) induces disturbances in the [Ca
2+]i 
homeostasis, which finally leads to progressive neuronal cell death and is a hallmark of 
acute and chronic neurological diseases  (Harkany et al., 2000; Mattson, 2004; Donnelly 
and Popovich, 2008). It seems that targeting NMDA receptors by inhibition might be 
protective against neurotoxicity. In contrast, a number of articles have shown that NMDA 
receptor antagonists such as dizocilpine (MK-801) lead to neuronal apoptosis by triggering 
caspase-3 activation (Inta et al., 2015),  and impair memory functions in mice and in rats 
(Smith et al., 2016; Tomazi et al., 2016). Thus, NMDA receptor antagonists as therapeutic 
strategy against excitotoxicity are not valid. However, TNF, a pro-inflammatory factor, 
induces cell apoptosis by prevention of calcium release (Yan et al., 2015). Interestingly, 
activation of potassium intermediate/small conductance calcium-activated channel KCa2 
prevented [Ca2+]I deregulation and reduced neuronal death following glutamate toxicity 
and cerebral ischemia (Dolga et al., 2011), proposing that KCa2 channels activation might 
be a potential treatment strategy to alleviate damage in the course of acute or chronic 
neurodegenerative disorders. It was previously demonstrated that a potential molecular 
mechanism of TNFR2 mediated protection against glutamate excitotoxicity was associated 
with an increased expression of KCa2.2 channel (Dolga et al., 2008a) outlining a potential 
molecular mechanism of TNFR2-mediated protection of neurons from death during 
exposure of a priori excitotoxic stimuli. Since TNFR2 signalling protects neurons from 
glutamate induced excitatory cell death in vitro, ligands promoting TNFR2 signalling might 
be superior to NMDA antagonist as they do not completely inhibit glutamate induced 
signal transmission, but buffer excitotoxicity likely by acquisition of a resistant state of 
affected cells. Because of the antithetic action of TNF via its two receptors, we reasoned 
that a selective activation of TNFR2 signalling could shift the balance of endogenous TNF 
activity towards an overall neuroprotective/regenerative response. Additionally, TNFR2 
selective agonists seem to be particularly suitable to treat inflammatory, demyelinating 
diseases, because next to the direct neuroprotective effects shown in this report, data 
from different laboratories outline that TNFR2 is also involved in immune suppression via 
expansion and stabilization of regulatory T cells (Chen et al., 2007, 2008, 2010a, 2010b, 
2013; Okubo et al., 2013) and induces remyelination (Arnett et al., 2001; Fischer et al., 
2014; Patel et al., 2012). Thus, TNFR2 agonists might promote therapeutic effects via 
multiple cellular targets.  
Importantly, initial studies with anti-TNF-α therapeutics showed that TNF blocking drugs 
cannot be used to treat neurodegenerative diseases, such as MS. In support of this, we 
here provide compelling evidence in an in vivo model of NMDA induced acute neuronal 
lesions that abrogation of complete TNF signalling by blocking both TNFRs is not 
protective, because mounting of a neuroprotective TNFR2 dependent response is 
prevented. However, pre-clinical studies in the EAE model (Brambilla et al., 2011; 
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Evangelidou et al., 2014; Taoufik et al., 2011) or a mouse model of spinal cord injury 
(Novrup et al., 2014) revealed that selective neutralization of sTNF/TNFR1 signalling is 
neuroprotective. Of note, in the EAE model, systemic application of TNFR1 blocking 
antibodies proved to be therapeutically effective (Williams et al., 2014). Accordingly, 
TNFR1 antagonists such as ATROSAB should be superior to conventional anti-TNF drugs in 
the treatment of neurodegenerative diseases, as they spare TNFR2 but still block 
detrimental signals transmitted via TNFR1.  
In summary, this translational study reveals that activation of TNFR2 through using TNC-
scTNFR2 and EHD2-scTNFR2 indeed protects against neurodegenerative physiopathology in 
vivo in hu/mTNFR-k/i mice. Furthermore, these drugs did not take any adverse effects for 
animals during the experimental processing. These suggest that TNC-scTNFR2 and EHD2-
scTNFR2 are worth to be considered to develop the therapeutic agents in AD. Apparently, 
we provide proof that these drugs could be further developed for the treatment for the 
clinical trials with AD. Our study has been focused on mice with acute pathological 
processes (the NBM lesion model). Before translation of this strategy into human patients 
with AD, further development of this approach is essential. For instance, firstly these 
pharmacological drugs should be assessed the potent against the cognitive deficits 
induced by the NBM lesion, and then evaluated their therapeutic potent against the 
chronic pathophysiology in AD transgenic mice. It is worthwhile in addition to test the 
capability of these compounds for crossing the blood brain barrier or to modify these 
compounds accordingly. Although we did not find any adverse effects of these drugs in 
our experimental trials, further information on potential side effects and 
pharmacokinetics are needed. 
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ABSTRACT 
The nucleus basalis Meynert (NBM) is a main source of cholinergic innervations to 
cognitive areas of the brain. Cholinergic denervation in the cerebral cortex induced by the 
NBM lesion causes memory dysfunctions that resemble cognitive deficits in AD patients. 
Previous studies have shown in vitro and in vivo that NMDA-mediated excitotoxicity can 
be prevented by TNF receptor 2 (TNFR2) signalling pathway whereas exacerbated by TNF 
receptor 1 (TNFR1) signalling pathway. This suggests that selective targeting TNFRs via 
activation of TNFR2 and/or inhibition of TNFR1 could be effective against 
neurodegeneration. In the present study, we established the NBM lesion model which was 
induced by NMDA excitotoxicity, tested cholinergic system-related cognitive functions and 
evaluated the therapeutic effects of a selective TNFR2 agonist EHD2-scTNFR2 and a specific 
TNFR1 antagonist ATROSAB. We found that the NBM lesion led to the cortical functional 
impairment by showing performance in a passive avoidance paradigm but did not affect 
hippocampus- or amygdala-related behavioral functions. Of note, the cortical functional 
impairment was reversed by EHD2-scTNFR2 and ATROSAB treatments. Therefore, selective 
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5.1 INTRODUCTION 
Alzheimer’s disease (AD), a progressive neurodegenerative disorder, is considered to be 
the most common cause of dementia. In addition to pathological features of extracellular 
amyloid β (Aβ) plaques and intracellular neurofibrillary tangles (NFTs) (Flament and 
Delacourte, 1989; Smith and Perry, 1997), depletion of acetylcholine (Ach) and cholinergic 
neurons and cholinergic innervations in basal forebrain has been considered as a reliable 
pathological hallmark of AD (Davies and Maloney, 1976; Norvin et al., 2015). Cholinergic 
innervations in the cerebral cortex are reduced significantly in early onset of AD patients 
(Whitehouse et al., 1982), which are mainly projected by cholinergic neurons in the 
nucleus basalis of Meynert (named nucleus basalis magnocellularis in mice, NBM) 
(Whitehouse et al., 1981). In AD patients cholinergic neurons in the NBM are also reduced, 
a loss ranging from 44% to 76% (Tagliavini and Pilleri, 1983). Coyle et al. (1983) reported 
that degeneration of acetylcholine-releasing neurons and neocortical cholinergic 
innervations play a dominant role in memory dysfunctions such as learning performance 
and memory formation deficits which mimics cognitive dysfunction in AD patients. Also, 
Iraizoz et al. (1999) showed that damage of cholinergic neurons localized in NBM and their 
cortical projections correlated with the deficits of memory and learning functions in AD. 
Consistent with this model, studies have shown that disrupted cholinergic projections to 
the cerebral cortex by NMDA-mediated NBM lesion indeed leads to memory deficits 
(Dolga et al., 2009). These data therefore suggest that the cortical cholinergic denervation 
induced by NBM lesion in animals is a well-established lesion model that can be used to 
investigate the potential of therapeutics by showing cholinergic innervations and cognitive 
functions. 
Tumor necrosis factor alpha (TNF-α), a major pro-inflammatory cytokine, has been 
implicated an involvement in the pathology of neurodegenerative diseases, such as AD 
and multiple sclerosis (MS) (McAlpine et al., 2009; Tan et al., 1999; Tarkowski et al., 2000; 
Yang et al., 2013). It has been reported that TNF-α through its receptor one (TNFR1) 
increases N-methyl-D-aspartate (NMDA)-mediated neuronal excitotoxicity but survives 
neurons via its receptor two (TNFR2) against excitotoxicity of NMDA (Fontaine et al., 2002), 
indicating that inhibition of TNFR1 or/and activation of TNFR2 might be as a novel and 
potential therapeutic strategy against neurodegeneration. Recently, a few studies have 
just started to report potential therapeutic effects via inhibition of TNFR1 or activation of 
TNFR2 pathway. For instance, a recombinant human TNFR1 selective antagonist prevents 
the symptoms of EAE mouse model (Williams et al., 2014); also, a humanized TNFR2 
specific agonist showed to rescue neurons against oxidative stress (Fischer et al., 2011).  
The objective of the present study was to investigate the functional roles in cognitive 
processing affected by the damage of cholinergic system, and to assess the therapeutic 
effects of both a human TNFR2 selective agonist EHD2-scTNFR2 and a human TNFR1 
specific antagonist ATROSAB in humanized TNFR knock-in (hu/mTNFR1-k/i and 
hu/mTNFR1-k/i) mice. We here focused on the NBM projected cholinergic innervations-
related cognitive functions because it appears to be significantly reflected in AD. Through 
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testing mouse cognitive functions that relate with the NBM cholinergic projections 
including the short-term memory, animal anxiety and long-term memory, in a 
spontaneous alternation task, an elevated plus maze and a passive avoidance paradigm, 
we found that NMDA-induced NBM lesion-mediated cholinergic denervation did not affect 
the short-term memory and animal anxiety while devastated the long-term memory; 
however, both EHD2-scTNFR2 and ATROSAB reversed the long-term memory impairments. 
 
5.2 MATERIALS AND METHODS 
 
5.2.1 Animals  
Male homozygous hu/mTNFR-k/i C57BL/6J mice (12 weeks, 24-30 g) were established by 
using genetic techniques. All animals were individually housed with a free access to ad 
libitum food and tap water and kept in an air-conditioned room (21 ± 2°C) with a 12/12 h 
light-dark circle (lights on 7:00 a.m.). Animal care and treatment were carried out in 
accordance with the local Ethical Committee guidelines on the use of experimental 
animals at the University of Groningen, the Netherlands (DEC6523) and University of 
Stuttgart, Germany (35-9815.81-0350). 
5.2.2 Nucleus Basalis Injection 
An injection into the nucleus basalis magnocellularis (NBM) was performed as previously 
described by Luiten et al. (1995). After anaesthesia with isoflurane, mouse heads were 
mounted in a Kopf stereotactic frame (Kopf Instruments model 900, Tujunga, CA, USA). A 
volume of 0.6-µl solution was slowly infused in two steps of 0.3 µl into the NBM of the 
right hemisphere (coordinates: 0.6 mm posterior to bregma; 2.1 mm lateral to the sagittal 
suture; 4.6/4.4 mm ventral to the dura.) (Paxinos and Franklin, 2001). The contralateral 
intact hemisphere served as internal control without interference. After each slow 
injection (0.1 μl/min), the needle of a 1-μl Hamilton syringe was left in situ for 2 min for 
effective drug diffusion. 
5.2.3 Behavioral Evaluation 
All hu/mTNFR-k/i mice were performed a unilateral injection at the right site of NBM. 
Hu/mTNFR1-k/i mice were divided into four groups: (1) phosphate-buffered saline (PBS, 
0.01 M, pH = 7.40); (2) 3 µg ATROSAB (descripted by Zettlitz et al., 2010); (3) 55 nmol 
NMDA (Sigma, USA); (4) 55 nmol NMDA together with 3 μg ATROSAB. Hu/mTNFR2-k/i 
mice were also divided into four groups: (1) PBS; (2) 580 ng His-EHD2-scTNFR2 descripted 
by (Grell et al., 1995); (3) 55 nmol NMDA; (4) 55 nmol NMDA together with 580 ng EHD2-
scTNFR2. After 5 days, memory performances were assessed as shown by the time outline 
(Figure 5.1). 
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Figure 5.1.  Schematic outline of the experimental setup. hu/mTNFR-k/i mice received a unilateral 
infusion into the NBM. Five days upon the injection, the cognitive performances of all mice were 
tested in a spontaneous alternation task, an elevated plus maze and a passive avoidance paradigm 
to evaluate their short-term memory, animal anxiety and long-term memory. 
5.2.4 Spontaneous Alternation Task 
Evaluation of spontaneous alternation behavior in a Y-maze to investigate spatial short-
term memory (working-memory) was performed as described previously (Dolga et al., 
2009). Briefly, the device consisted of three transparent Plexiglas and tubular arms (5 cm 
in diameter, 27.5 cm length) with an angle of 120°. Mice were placed in the maze center 
and allowed to freely explore for 8 min. The sequence of arm entries was recorded visually. 
A criterion was considered that a mouse complete entered one arm with all four paws. A 
successful spontaneous alternation was defined as entries into all three different arms by 
consecutive choices. The percentage of spontaneous alternation was calculated as the 
ratio of actual to the maximum possible number of alternations. The maximum possible 
number of alternations was defined as the total number of arm entries minus two.  
5.2.5 Elevated Plus Maze 
Anxiety-related behaviors performed in an elevated plus maze were as described 
previously (Harkany et al., 2000). The plus maze consisted of two open arms (5.5 cm width 
x 30 cm length) and two enclosed arms (5.5 cm width x 30 cm length x 15 cm high) and 
was elevated 50 cm above the ground. After 5 days upon the NBM injection, mice were 
placed the center of the maze (5.5 cm x 5.5 cm) and allowed to explore freely for 8 min. A 
criterion was considered that a mouse complete entered one arm with all four paws. The 
time spent on the open or closed arms, the number of arm entries and total entries were 
recorded. The correlation values of this apparatus were calculated as a percentage time 
spent on open arms, a percentage time spent on closed arms or a percentage of time 
spent on center area, a percentage of number of open arm entries (the time spent on 
open arms/ total time x 100%, the time spent on closed arms/ total time x 100%, the 
number of entering open arms/ total arm entries x 100%).  
5.2.6 Passive Avoidance Paradigm 
A one-trial learning, step-through passive avoidance test was performed in an apparatus 
(Venault et al., 1986). This device was divided into two compartments by a retractable 
door, an illuminated compartment with a plastic floor and a dark compartment with a grid 
floor. The illuminated compartment was lighted by a 12-watt light bulb. After an injection 
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into the NBM 6 days, mice were firstly acclimatized to situations in the experimental 
equipment. Mice were placed in the illuminated platform facing to the closed retractable 
door. The retractable door was raised 60 sec later, and mice were allowed to explore 
freely in the apparatus for 2 min, thereafter returned to home-cages. The training tests 
were performed after 24 h. Mice were placed in the illuminated compartment facing to 
the closed door and allowed to explore for 60 sec. The door was raised, and a latency 
defined as the time period since the door was opened until animals entered the dark 
compartment with all four paws (pre-shock latency) was recorded. After mice completely 
entered the dark compartment, the retractable door was closed, and a foot-shock (0.3 mA, 
2 sec) was delivered through the metal grid floor. After 30 sec mice were removed to 
home cages. Memory retention was performed after training 24 h. Each animal was 
placed in the illuminated compartment for 60 sec, after opening the door, a latency (post-
shock latency) to enter the dark compartment (as described in the training test) was 
recorded up to a maximum of 8 min.  
5.2.7 Statistical Analysis 
Neurotoxic effects of NMDA infusion and the efficacy of compound treatments in 
behavioral tests were calculated by using one-way ANOVA analysis of variance with 
comparison of post-hoc Tukey tests. A value of p < 0.05 (* p < 0.05, ** p < 0.01, *** p < 
0.001) was considered as statistical significance for the vaccine treatment. Data were 




5.3.1 NMDA-induced NBM Lesion Does not Alter the Short-term Memory in 
Both hu/mTNFR1-k/i and hu/mTNFR2-k/i Mice 
Through histopathological analyses, NMDA excitotoxicity indeed induced a significant 
reduction of cholinergic neurons in the NBM; however, cholinergic neuron loss was 
prevented by EHD2-scTNFR2 and ATROSAB, in both hu/mTNFR2-k/i mice and hu/mTNFR1-
k/i mice (unpublished data). To investigate whether the NBM lesion can lead to cognitive 
dysfunctions and to assess the potential therapeutic effects of EHD2-scTNFR2 and 
ATROSAB, all experimental mice were performed memory tests as shown by a time 
outline (Figure 5.1). After five days upon an infusion into the NBM, experimental mice 
were tested in a spontaneous alternation task to evaluate their short-term memory 
(Figure 5.2). Spontaneous alternation behaviour is generally regarded as a measure of 
short-term memory (working memory) (Dudchenko, 2004). We found that the NMDA-
induced NBM lesion and the compounds tested did not affect the short-term memory by 
shown the alternation rate and the frequency of entries in both mouse strains.  
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Figure 5.2. The NBM lesion does not trigger short-term memory impairment in both hu/mTNFR1-
k/i and hu/mTNFR2-k/i mice. NBM injection of NMDA and/or EHD2-scTNFR2 had no effect on short-
term memory, presented as (A) percentage of alternations and (B) number of total entries which 
were measured with spontaneous alternation in hu/mTNFR2-k/i mice. Moreover, NBM injection of 
NMDA and/or ATROSAB did not influence (C) percentage of alternations and (D) number of total 
entries in hu/mTNFR1-k/i mice. n = 7 - 9 mice/ group, bars indicate means ± SEM. All data were 
examined by one-way ANOVA analysis with post-hoc comparisons Tukey. 
5.3.2 NMDA-induced NBM Lesion Does not Influence Animal Anxiety in Both 
Transgenic Mouse Lines 
Subsequently, we examined experimental mice in an elevated plus maze to evaluate their 
anxiety-like behaviors. Our data showed no significant changes in the total number of 
entries  (Figure 5.3 A and D), entries into the open arms (Figure 5.3 B and E) and time 
spent in the dark and light arms, and center of the maze (Figure 5.3 C and F) among all of 
the tested groups. 
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Figure 5.3. NMDA-induced NBM lesion does not cause animal anxiety in both transgenic mouse 
lines. Evaluation of anxiety-like behaviours by elevated plus maze in hu/mTNFR2-k/i mice showed no 
significant differences between the groups in the (A) number of entries into the different arms, (B) 
entries into the open arms and (C) time spent in the different arms of the maze. Moreover, in 
hu/mTNFR1-k/i mice there were no significant differences between groups as well on (D) the 
number of total entries, (E) the entries into open arms and (F) the time spent in the different arms of 
the maze. n  Tukey tests. 
5.3.3 Both EHD2-scTNFR2 and ATROSAB Reverse Retention Memory Deficits 
Induced by the NBM Lesion 
Cholinergic innervations are considered to modulate directly neocortical memory and 
retention functions (Pearson et al., 1983). The passive avoidance paradigm is a memory 
and retention task, which depends, in part, on proper neocortical memory and retention 
functions. Here, we used this behavioral task to evaluate whether the NBM lesion could 
result in neocortical memory dysfunctions and the potential effects of EHD2-scTNFR2 and 
ATROSAB. Results from the passive avoidance paradigm showed that NMDA and 
application of EHD2-scTNFR2 or ATROSAB did not alter the pre-shock latency to enter the 
dark compartment in all mice tested (Figure 5.4 A and C). However, NMDA injected into 
the NBM caused a significant impairment in the post-shock latency in both transgenic 
mouse lines (Figure 5.4 B and D). Importantly, both EHD2-scTNFR2 and ATROSAB 
obliterated NMDA mediated memory impairments, respectively (Figure 5.4 B and D). 
EHD2-scTNFR2 and ATROSAB alone had no effects on post-shock latency (Figure 5.4 B and 
D).  
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Figure 5.4. Both ATROSAB and EHD2-scTNFR2 prevent the NBM lesion-induced memory deficits. 
Assessment of long term memory with a passive avoidance paradigm showed no significant 
differences pre-shock latency between the experimental groups of hu/mTNFR2-k/i and hu/mTNFR1-
k/i mice in (A and C). NBM injection of NMDA caused a significant impairment of long term memory, 
measured as post-shock latency, which was obliterated by co-treatment of EHD2-scTNFR2 in (B). (D) 
ATROSAB treatment preserved the post-shock latency. n = 7 - 9 mice/ group, all bars indicate means 
± SEM * p <0.05, ** p < 0.01, one-way ANOVA with post-hoc comparisons Tukey.  
 
5.4 DISCUSSION 
Post-mortem studies of AD patient brains have shown neurodegenerative devastation in 
cholinergic areas (Wilson et al., 2009). Since cholinergic innervations to cognitive areas of 
the brain are mainly contributed by the nucleus basalis of Meynert (NBM), investigation of 
the NBM role is paid more attention. Whitehouse et al. (1981) have demonstrated that 
neocortical cholinergic denervation is a hallmark of early-onset of AD. Furthermore, 
cholinergic neurons as well as the expression of choline acetyltransferase (ChAT) in the 
NBM are reduced in the elderly with mild cognitive impairment and early stage of AD 
(Gilmor et al., 1999). These studies suggest that NMDA lesion could lead to cognitive 
dysfunctions. Indeed, the NBM lesion has been shown to cause memory deficits in rats 
(Harkany et al., 2001). Here, we established the NBM lesion model by an injection of 
NMDA in humanized TNFR knock-in (hu/mTNFR1-k/i and hu/mTNFR2-k/i) mice, tested 
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cognitive functions related with cholinergic system, and evaluated the therapeutic effects 
of a human TNFR2 selective agonist EHD2-scTNFR2 and a human TNFR1 specific antagonist 
ATROSAB. Results of the present study showed a significant impairment on memory and 
retention performance in the NBM lesioned groups in both transgenic mouse strains 
(Figure 5.4 B and D), which is in line with previous studies in C57BL/6J mice and rats (Dolga 
et al., 2009; Harkany et al., 2001), while targeting TNFRs via EHD2-scTNFR2 and ATROSAB 
treatments reversed the retention performance deficits, respectively. Furthermore, our 
data showed that the NBM lesion did not alter short-term memory and animal anxiety in 
both transgenic mouse models.  
N-methyl-D-aspartate (NMDA) that stimulates the activation of NMDA receptors of 
postsynaptic neuron activates calcium channel and results in calcium overload (Que et al., 
2016). Much Ca2+ influx leads to acute oedema in the cell, and secondary cell toxicity 
ultimately triggers neuron apoptosis. NMDA injected into the NBM leads to apoptosis of 
cholinergic neurons, and thereby affects cholinergic system in the brain. The cholinergic 
system projected by cholinergic neurons in the NBM can influence and regulate various 
tissue functions such as cerebral cortex (Dolga et al., 2009), hippocampus (Rispoli et al., 
2008; Swarowsky et al., 2008), as well as amygdala (Nagai et al., 1982; Woolf and Butcher, 
1982). In order to assess whether the NBM lesion by NMDA injection could lead to 
cognitive dysfunctions and whether EHD2-scTNFR2 and ATROSAB could be able to 
counteract the cognitive deficits, all tested mice were performed in a spontaneous 
alternation task, an elevated plus maze and a passive avoidance paradigm. Since 
spontaneous alternation in a Y-maze is commonly associated with the functions of 
hippocampus and prefrontal-related short-term memory (Dudchenko, 2004; Senechal et 
al., 2008), here we used this task to evaluate the selectivity of the NBM lesion to 
hippocampus. Our data showed that the NBM lesion did not affect the short-term 
memory in transgenic mice, which is consistent with previous studies in which the NBM 
lesion unaffected the short-term memory of C57BL6/J mice and rats (Dolga et al., 2009; 
Gaykema et al., 1992), suggesting that hippocampus are not affected by NMDA-induced 
NBM lesion. Also, a recent study has shown that the loss of cholinergic NBM cells results in 
reduced cholinergic afferentiation to the neocortex rather than hippocampus (Ljubojevic 
et al., 2014). Furthermore, a few studies have reported mice with AD have no short-term 
memory deficits (Carroll et al., 2007; Zhang et al., 2010). 
Moreover, to elicit whether the NBM lesion could affect amygdala-related anxiety 
behaviours, the NBM-lesioned and EHD2-scTNFR2 and ATROSAB treated mice were tested 
in an elevated plus maze. This task is usually used to assessed the anxiety behaviours 
impacted by the amygdala (Pockros-Burgess et al., 2014). We observed that the NBM 
lesion did not alter animal anxiety-like behaviours, including the total number of entries, 
entries into the open arms and time spent in the dark and light arms, and center of the 
maze in all of the mice tested (Figure 5.3). The cholinergic innervations of human 
amygdala complex has been shown to be unaffected by AD whereas a significant 
reduction of cholinergic innervations was found in cerebral cortex (Emre et al., 1993). Our 
present study also showed that NMDA-mediated NBM lesion does not affect amygdala-
related behaviors in hu/mTNFR2-k/i and hu/mTNFR1-k/i mice, which is in line with Emre’s 
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research. In contrast, Harkany et al reported that NMDA-mediated NBM lesion led to rat 
anxiety behaviours (Harkany et al. 2000). The paradoxical results might be led to by 
different animal models.  
Additionally, we tested mice in a passive avoidance paradigm. This device is considered to 
be one of the test conditions of choice for behavioural assessment of the integrity of the 
neocortical system (Senechal et al., 2008). We found that NMDA excitotoxicity lesioned 
NBM led to a memory retention deficit by records of post-shock latency in both transgenic 
mice (Figure 5.4 B and D), in accordance to that in C57BL/J6 mice (Dolga et al., 2008) and 
in rats (Harkany et al., 2001; Harkany et al., 1995). However, the retention deficit was 
reversed by EHD2-scTNFR2 and ATROSAB. Our data showed that EHD2-scTNFR2 and 
ATROSAB indeed can prevent NMDA-induced damage to the NBM and improved 
neocortical memory dysfunctions. Similar to our findings, a number of studies have shown 
that the NBM lesion caused memory retention deficits was reversed by Lovastatin in 
C56BL/6J mice and rats ( Zhao et al., 2010; Dolga et al., 2009). Interestingly, the Lovastatin 
was shown to exert a neuroprotective effect via the activated TNFR2 signalling pathway 
(Dolga et al., 2008). Furthermore, our unpublished data showed that ATROSAB induced 
protection was dependent on TNFR2 signalling pathway. These suggest that TNFR2 is an 
essential role in improvements neocortical memory deficits induced by the NBM lesion. 
TNF-α, a pro-inflammatory cytokine, is involved in the physiopathology in 
neurodegenerative disorders, such as AD (Lourenco et al., 2013). TNF-α binding to TNFR1 
exerts exacerbation whereas its binding to TNFR2 is involved in neuroprotection (Fontaine 
et al., 2002). TNFR1 inhibition has been shown to prevent neurodegeneration and neuron 
cell death in vivo and in vitro (Liu et al., 2014; McAlpine et al., 2009; Williams et al., 2014). 
Fischer et al. (2011) illuminated that TNFR2 agonist rescues human neurons against 
oxidative stress. In the present study, we confirmed that functional consequences of 
NMDA induced-NBM lesions and the therapeutic activity of an activation of TNFR2 EHD2-
scTNFR2 and an inhibition of TNFR1 ATROSAB became phenotypically apparent in 
behavioural performance studies: Damage to the NBM selectively affected neocortical 
cholinergic denervation-related memory dysfunctions, while leaving particular 
hippocampal innervation and functions as well as amygdala innervations and its anxiety 
functions were unaffected. Treatment of such animals with either EHD2-scTNFR2 or 
ATROSAB fully restored the affected cortical cholinergic memory function. Our findings 
increase the possibility for EHD2-scTNFR2 and ATROSAB to apply to the treatment in AD.  
In a word, the therapeutic effects of activation of TNFR2 and inhibition of TNFR1 should be 
explored further to more fully understand the mechanisms of the NBM in mediating 
cognition. With a specific focus on targeting TNFRs in therapeutic strategies possibly 
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ABSTRACT 
Background: Soluble oligomeric (misfolded) species of amyloid-beta (Aβ) are the main 
mediators of toxicity in Alzheimer’s disease (AD). These oligomers subsequently form 
aggregates of insoluble fibrils that precipitate as extracellular and perivascular plaques in 
the brain. Active immunization against Aβ is a promising disease modifying strategy. 
However, eliciting an immune response against Aβ in general may interfere with its 
biological function and was shown to cause unwanted side-effects. Therefore, we have 
developed a novel experimental vaccine based on conformational neo-epitopes that are 
exposed in the misfolded oligomeric Aβ, inducing a specific antibody response. Objective: 
Here we investigate the protective effects of the experimental vaccine against oligomeric 
Aβ(1-42)-induced neuronal fibre loss in vivo. Methods:  C57BL/6 mice were immunized or 
mock-immunized. Antibody responses were measured by enzyme-linked immunosorbent 
assay. Next, mice received a stereotactic injection of oligomeric Aβ(1-42) into the nucleus 
basalis of Meynert (NBM) on one side of the brain (lesion side), and scrambled  Aβ(1-42) 
peptide in the contralateral NBM (control side). The densities of choline acetyltransferase-
stained cholinergic fibres origination from the NBM were measured in the parietal 
neocortex postmortem. The percentage of fibre loss in the lesion side was determined 
relative to the control side of the brain. Results: Immunized responders (79%) showed 23% 
less cholinergic fibre loss (p = 0.01) relative to mock-immunized mice. Moreover, fibre loss 
in immunized responders correlated negatively with the measured antibody responses (R2 
= 0.29, p = 0.02). Conclusion: These results may provide a lead towards a (prophylactic) 
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6.1. INTRODUCTION 
With worldwide progressing aging populations the burden and prevalence of Alzheimer’s 
disease (AD) is rapidly increasing. Over the next years AD may constitute an epidemic with 
high levels of individual suffering and staggering health care costs (Brookmeyer et al., 
2007). AD is characterized by its pathological features of extracellular amyloid β (Aβ) 
plaques and tau protein aggregates known as intracellular neurofibrillary tangles (NFTs). 
Although characteristic for AD, it is generally believed that both Aβ plaques and NFTs are 
relatively non-toxic. Indeed, Aβ plaque load does not directly correlate with clinical 
symptoms of patients (Nelson et al., 2012; Smith and Perry, 1997). Instead, soluble 
oligomeric forms of Aβ are believed to be the main mediators of toxicity in AD (Ashe and 
Aguzzi, 2013; Glabe, 2008; Haass and Selkoe, 2007; Klein et al., 2004; Wisniewski and Goñi, 
2015). These oligomeric species subsequently form aggregates of insoluble fibrils that 
precipitate as extracellular and perivascular plaques in the brain. In addition, intracellular 
aggregates of phosphorylated tau protein are formed at a later stage of the disease (Choi 
et al., 2014; Oddo et al., 2006). Based on this sequence of events it seems consequent to 
consider an immunization strategy directed against epitopes specific for the misfolded 
oligomeric forms of Aβ. Since 1999 (Schenk et al., 1999), there has been considerable 
interest in passive or active immunization with Aβ or Aβ-derived constructs against 
Alzheimer’s disease, although a breakthrough has not yet been reached (Agadjanyan et al., 
2015; Delrieu et al., 2014; Fettelschoss et al., 2014; Giacobini and Gold, 2013; Lemere, 
2013; Mandler et al., 2015; Panza et al., 2014). 
In a previous study, we showed that tetanus toxoid (TTd) conjugates of small cyclic 
peptides derived from amyloid Aβ, in particular cyclo[Aβ(22-28)-YNGK']-TTd, induced 
antibodies in Balb/c mice that cross-react in vitro with oligomeric and fibrillar Aβ(1-42) 
and amyloid plaques in mouse and human brain tissue. The antibodies did not recognize 
the homologous unmodified linear peptide or the amyloid precursor protein, indicating a 
high specificity for misfolded Aβ (Hoogerhout et al., 2011). 
Testing the neuroprotective effect of AD related vaccines or compounds in in vivo models 
is rather complicated and in most cases indirect. Mutant mice with phenotypes 
resembling AD pathology often do not show an overt neurotoxicity and the protective 
function of compounds or vaccines can only be evaluated by indirectly measuring the 
postmortem plaque load or by analyses in living mice such as electrophysiological changes 
and/or cognitive/behavioral changes. In the present study, we have investigated if 
immunization can induce protection against acute oligomeric Aβ(1-42)-induced 
neurodegeneration of the cholinergic nucleus basalis magnocellularis of Meynert (NBM) in 
C57BL/6 mice. This in vivo model combines several advantages for testing compounds in 
proof of concept studies and reflects some essential hallmarks of AD pathology.  The NBM 
is one of the early regions to be affected during AD and the overall neuropathology in this 
model, including cholinergic denervation and microglial activation, features much of the 
pathology found in AD patients (Granic et al., 2010a). The NBM lesion model provides the 
means to test directly the neuroprotective effect of the active immunization using cyclo-
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Aβ peptides. Cholinergic fibres emanating from the NBM innervate cortical and 
hippocampal brain areas. Loss of this innervation can be quantified by measuring fibre 
density and used to determine neuroprotective strategies in AD (Dolga et al., 2009; Granic 
et al., 2010a; Luiten et al., 1995). Injecting a validated amount of neurotoxic oligomeric 
Aβ(1-42) into the NBM creates an acute lesion with ~40% loss of cholinergic neurons 
(Granic et al., 2010a). Here we provide evidence that active immunization using a trivalent 
vaccine consisting of cyclo[Aβ(22-28)-YNGK'], cyclo[Aβ(23-29)-YNGK'], and cyclo[Aβ(22-
29)-YNGK'] peptide TTd conjugates provides significant protection in the Aβ(1-42)-induced 
NBM lesion model. 
 
6.2. MATERIALS AND METHODS 
 
6.2.1. Materials 
Lyophilized human Aβ(1-42)  
(DAEFRHDSGY10EVHHQKLVFF20AEDVGSNKGA30IIGLMVGGVV40IA) was purchased from 
AnaSpec (Freemont, CA, USA) or rPeptide (USA). Scrambled-sequence Aβ(1-42) was 
purchased from rPeptide (USA). Monophosphoryl lipid A (MPL) was purchased from 
Sigma-Aldrich (Lipid A, monophosphoryl from Salmonella enterica serotype minnesota Re 
595, Re mutant). An aqueous suspension of aluminum hydroxide (Alhydrogel 2%, 10.3 mg 
Al3+/ml) was purchased from Brenntag (Frederikssund, Denmark), and monoclonal 
antibody 6E10 against Aβ(1-17) from Covance Research Products, Dedham, MA, USA). 
Tetanus toxoid (TTd) was produced by the former Vaccine Division of the National 
Institute for Public Health and the Environment (Bilthoven, The Netherlands). 
6.2.2. Animals and Housing 
Experiments were performed using 33 male C57BL/6JRj mice (Janvier, Le Genest-St-Isle, 
France), 6-8 weeks old at arrival. All mice were housed individually in macrolon type II 
cages (length 35 cm, width 15 cm, height 13.5 cm, Bayer, Germany), with sawdust as 
bedding and shredded cardboard as nesting material. The mice were kept in a climate 
room with controlled temperature (22 ± 1°C) and humidity (55 ± 10%). A light/dark (LD) 
schedule (12h light - 12h dark; lights on at 07:00 h GMT + 1h; ± 50 lux) was maintained. 
Food (standard rodent chow: RMHB/ 2180, Arie Block BV, Woerden, NL) and normal tap 
water were available ad libitum. Cages were cleaned at least every two weeks. All mice 
were checked daily for food/water/health/activity/abnormal behavior. All procedures 
were in accordance with the regulation of the ethical committee for the use of 
experimental animals of the University of Groningen, The Netherlands (License number 
DEC 6579A). 
6.2.3. Experimental Outline 
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Mice were habituated to the climate room and housing conditions for seven days before 
receiving the first round of immunization. The mice were immunized by subcutaneous 
injection in the groin with either our trivalent vaccine (referred to as ‘immunized’ mice, n 
= 24) or mock vaccine (referred to as ‘mock-immunized’ or ‘mock’ mice, n = 9). Three, four 
or five immunizations were performed with three-weekly intervals. An overview of the 
experimental procedures is provided in Figure 6.1. Twelve days after all mice had received 
the third immunization, blood samples were collected from the tail vein and the derived 
serum samples were analyzed the next day (day 55) by enzyme-linked immunosorbent 
assay (ELISA). Based on the anti-oligomeric Aβ(1-42) endpoint titers obtained (ELISA 1), 8 
immunized and 3 mock-immunized mice were selected for stereotactic Aβ(1-42)-induced 
NBM lesion surgery which was performed the next day (group A, day 56, two weeks after 
the third immunization). Remaining mice received a fourth immunization (on day 63) and 
another tail puncture after 12 days (on day 75). Based on the titers obtained (ELISA 2), 8 
immunized and 4 mock-immunized mice were selected for Aβ(1-42)-induced NBM lesion 
surgery (group B, day 77, two weeks after the fourth immunization). Remaining mice 
(group C: eight immunized, two mock-immunized mice) received a fifth immunization (on 
day 84) and received Aβ(1-42)-induced NBM lesion surgery two weeks later (day 98). Mice 
from each group were transcardially perfused 10 days after NBM lesion surgery. Final 
blood samples were collected from the heart just before perfusion and derived serum 
samples were analyzed later (ELISA 3). Brains were isolated for further 
immunohistochemical analysis. 
6.2.4. Peptide Synthesis and Purification 
The synthesis and purification of the cyclic peptides cyclo[Aβ(22-28)-YNGK'], cyclo[Aβ(23-
29)-YNGK'], and cyclo[Aβ(22-29)-YNGK'], in which K' is N ε-(S-acetylmercaptoacetyl)lysyl 
for conjugation purposes, was performed as described earlier (Brugghe et al., 1994; 
Hoogerhout et al., 2011).  
6.2.5. Preparation of Conjugates and Vaccines 
The peptides were coupled to either bromoacetylated TTd (to obtain vaccine components) 
or maleimidyl-modified bovine serum albumin (BSA) (to obtain ELISA coating antigens) D. 
Bromoacetylated TTd was also capped with 2-aminoethanethiol, without prior incubation 
with peptide, to obtain the protein for the mock vaccine (capped  TTd). 
6.2.6. Vaccine Preparation 
Aliquots (300 or 120 µl) of a solution of MPL (1.0 mg/ml) in chloroform/methanol/water, 
74/23/3, were evaporated to dryness in round bottom polypropylene tubes. MPL films 
obtained from 300 µg samples were reconstituted with 0.60 ml of each cyclopeptide-TTd 
conjugate (0.50 mg/ml in physiological salt), followed by 0.58 ml Alhydrogel. MPL films 
obtained from 120 µg samples were reconstituted with 0.72 ml of capped TTd (0.50 
mg/ml in physiological salt), followed by 0.23 ml Alhydrogel. The tubes containing the 
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suspensions were left on a roller mixer for 1 h at room temperature and thereafter stored 
overnight at 4oC. Then, the concentrated vaccine was diluted with 6.62 ml of physiological 
salt and the concentrated mock vaccine with 2.65 ml physiological salt. One dose of 0.3 ml 
of vaccine contained 10 µg of each cyclopeptide-TTd conjugate, 10 µg MPL, and 0.2 mg 
Al3+. One dose of 0.3 ml of mock vaccine contained 30 µg capped TTd, 10 µg MPL, and 0.2 
mg Al3+. 
 
Figure 6.1. Experimental overview. Mice were randomly assigned to be mock-immunized (mock) or 
immunized. All mice received three rounds of subcutaneous injections in the groin with a 3-week 
interval. Mock mice received mock vaccine, immunized mice received our trivalent vaccine. Blood 
samples were collected from the tail vein and the serum was analyzed by ELISA. Based on the anti-
oligomeric Aβ(1-42) endpoint titers obtained (ELISA 1), 8 well responding immunized mice and 3 
mock mice were selected for oligomeric Aβ(1-42)-induced NBM lesion surgery (group A). Remaining 
mice received a fourth immunization and another tail puncture. Based on the titers obtained (ELISA 
2), 8 immunized- and 4 mock mice were selected for NBM lesion surgery (group B). Remaining mice 
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from each group were transcardially perfused 10 days after NBM lesion surgery. Final blood samples 
were collected from the heart just before perfusion and sera obtained were analyzed later (ELISA 3). 
Experimental days are indicated on the left. 
6.2.7. ELISA 
Wells of microtiter plates (Greiner 655092) were coated with oligomeric Aβ(1-42), 
peptide-BSA conjugates or TTd. Freshly prepared Aβ(1-42) oligomers were diluted to a 
final concentration of 2.5 µM (11.3 µg/ml) in 0.04 M sodium carbonate/bicarbonate 
buffer, pH 9.70. Peptide-BSA conjugates and TTd were diluted to a total concentration of 
0.5 µg/ml in the same carbonate/bicarbonate buffer. Aliquots (100 µl) of these solutions 
were transferred into wells of the plates. The plates were incubated for 90 min at 37oC, 
emptied and washed twice with tap water containing 0.05% Tween 80. The plates were 
incubated with threefold serial dilutions of the serum samples in phosphate buffered 
saline containing 0.1% Tween 80. Monoclonal antibody 6E10 was used as positive control 
on plates coated with oligomeric Aβ(1-42). The starting dilution for determination of anti-
oligomeric Aβ(1-42) titers and anti-linear[Aβ(1-15)-C] titers was 1/150. For determination 
of anti-cyclopeptide and anti-TTd titers, a starting dilution of 1/1500 was used. The plates 
were further processed as described earlier (Westdijk et al., 1997). Endpoint titers were 
defined as the dilution, which gave an optical density (OD) reading identical to the mean 
OD plus three times standard deviation of sera of mice immunized with mock vaccine 
(Frey et al., 1998). 
6.2.8. Preparation of Oligomeric Aβ(1-42) for Stereotactic NBM Lesions 
Oligomeric Aβ(1-42) was prepared as described before (Dahlgren et al., 2002; Granic et al., 
2010b; Stine et al., 2003). In short, lyophilized Aβ(1-42) peptide (rPeptide, USA) was 
dissolved in 1,1,1,3,3,3-hexafluoro-2-propanol (HFIP, Sigma-Aldrich, St. Louis, USA) at a 
concentration of 1 mM. The peptide solution was aliquoted and the HFIP removed by 
evaporation at room temperature in a flow cabinet for 3 h. The dry peptide films were 
stored at -20oC until further processing. Before use, Aβ(1-42) films were dissolved in 
anhydrous DMSO to 5 mM and subsequently diluted in neurobasal medium to a final 
concentration of 250 µM. The solution was incubated at 4oC for 24 h to enable Aβ(1-42) 
oligomerization. Scrambled Aβ(1-42)control peptide was processed using exactly the same 
procedure. 
6.2.9. Stereotactic Aβ(1-42)-induced NBM Lesions 
Mice were anaesthetized with an isoflurane/oxygen gas mixture and received 60 μl 
finadynes.c. (1 mg/ml, Schering-Plough NV/SA, Brussels, Belgium). Mice were then placed 
in a stereotact (Kopf instruments model 900, Tujunga, CA, USA) secured with cheek bars 
and a tooth-bar/nose clamp. The stereotact was equipped to support maintenance of the 
isoflurane/oxygen anesthesia. Eyes were protected against dehydration by applying Vita-
Pos® salve (Ursapharm) and the shaved skin was disinfected with 70% ethanol. A small 
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medial incision was made from bregma to lambda. The periost was gently scraped away 
with a scalpel and the scalp was cleaned using cotton swaps. A hole was drilled in the skull 
and the dura was punctured with  a needle. A 1-μl Hamilton syringe was slowly lowered 
into the brain (coordinates: 0.6 mm posterior to bregma; 2.1 mm lateral to the sagittal 
suture). 0.2 μl of 250 µM oligomeric Aβ(1-42) was slowly (0.1 μl/min) injected  at 4.6 and 
4.4 mm ventral to the dura (total unilateral injection amount: 0.4 μl, 100 pmol). The 
stereotactic coordinates had been confirmed by several pilot experiments in which trypan 
blue was injected into the NBM and traced (post-mortem) to the NBM. After injection, the 
syringe was kept in place for 2 min at each injection site to optimize diffusion into the 
brain and to limit spread of the solution during withdrawal of the needle. The same 
procedure was followed on the contralateral side of the brain, where scrambled Aβ(1-42) 
control peptide was injected. Left/right injections of the peptides were randomized 
between mice. After contralateral injection, mice were immediately removed from the 
stereotact. The head wound was sutured (Ethicon perma-hand N266 5-0), disinfected with 
Povidine-iodine (Betadine®) and mice received an i.p. injection of 0.5 ml warm (±25°C) 
saline/glucose (0.45% NaCl + 2.5% glucose). Mice were placed back in their homecage and 
kept under a IR heat lamp for 24 h. 
6.2.10. Transcardial Perfusion 
At postoperative day 10, under deep pentobarbital anaesthesia, mice were perfused 
transcardially for 1 min with 0.9% NaCl + 0.5% heparin (400 U) in H2O (15 ml/min), 
followed by 150 ml 4% paraformaldehyde (PFA) in 0.1 M phosphate buffer (PB) for fixation. 
Brains were collected, post fixated for 24 h in 4% PFA in 0.1 M PB, rinsed for one day in 
0.01 M phosphate buffered saline (PBS, pH = 7.40) and then kept overnight in 30% sucrose 
in PBS cryoprotectant at room temperature. Brains were frozen using liquid nitrogen and 
stored at -80oC. The brains were cut in 20 μm coronal sections using a cryotome, collected 
in PBS (0.01 M, pH = 7.40) containing 0.1% sodium azide and kept at 4oC until choline 
acetyltransferase (ChAT) immunostaining. 
6.2.11. Immunohistochemical ChAT Staining 
The free floating brain sections were rinsed three times (rinsing was always performed in 
0.01 M PBS, pH = 7.40, for 5 min on a shaker) before being incubated for 30 min in 0.3% 
H2O2 in PBS. Next, the brain slices were rinsed five times before pre-incubation for 1 h at 
room temperature in PBS containing 5% normal rabbit serum (NRS, Zymed, San Francisco, 
CA, USA) and 0.4% Triton X-100. Subsequently, sections were incubated for 3 days at 4oC 
in the primary antibody solution containing 1:333 diluted goat anti-ChATIgG (Millipore, 
Billerica, MA, USA), 1% NRS, 0.5% BSA and 0.4% Triton X-100 in PBS. Next, brain sections 
were rinsed five times and thereafter incubated at room temperature for 4h in the 
secondary antibody solution containing rabbit anti-goat IgG 1:500 (Sigma), 1% NRS, 0.2% 
Triton X-100 and 0.5% BSA in PBS. Afterwards, sections were rinsed five times before 
being incubated at RT for 2 h with Vectastain Elite ABC Kit (Vector Laboratories, CA, USA). 
Both the ‘A’ and ‘B’ solution were diluted to 1:500). The staining was completed with 
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nickel-enhanced (BDH Chemicals Ltd., UK) diaminobenzidine (DAB) reaction in the 
presence of H2O2. The next day, slices were mounted on glass from a 1% gelatin + 0.01% 
aluin solution, dried overnight and defatted/dehydrated through respectively 100% EtOH, 
100% EtOH, 70% EtOH + 30% Xylol,  30% EtOH + 70% Xylol, 100% Xylol, 100% Xylol, 100% 
Xylol. Glass preparations were cover slipped using DPX mountant, dried for two days and 
then cleaned.  
6.2.12. Quantitative Image Analysis 
The parietal neocortex is topographically the target of the afferent cholinergic pathway 
from the NBM sites where the Aβ(1-42) oligomers were injected. The quantification 
procedure was established in our laboratory and described in detail in a series of previous 
publications (Dolga et al., 2009; Granic et al., 2010a; Harkany et al., 1998, 2001; Horvath et 
al., 2000). Briefly, exact measurement took place in the superficial sublayer of the layer V 
cortical area representing the densest zone of cortical cholinergic innervation (coordinates: 
0.6 mm posterior to bregma; Paxinos and Franklin, 2001). After background subtraction 
and gray-scale threshold determination, the surface area of ChAT-positive fibres 
(percentage of the area covered by ChAT-positive cholinergic fibres relative to the total 
sampling area) was measured on both contralateral sides of 8 coronal sections per animal 
using a Quantimet 600 HR Image Analysis System (Leica, Rijswijk, the Netherlands). The 
percentage of fibre loss relative to the control side was calculated within each of the slices 
and these values were averaged as an indicator of cholinergic degeneration per animal. 
One immunized mouse showed over 40% fibre loss and was excluded as an outlier from all 
analyses. 
6.2.13. Statistics 
Statistical analyses were performed using GraphPad Prism 5.01 (GraphPad software, Inc.) 
and SigmaPlot 12.5 (Systat software, inc.). Fibre densities in control- and lesion sides of 
the brains of mock and immunized mice were analyzed using a 2-way repeated measures 
(RM) analysis of variance (ANOVA). Differences between groups were tested by two-tailed 
unpaired t-tests. Pre-post differences between groups were tested by two-tailed paired t-





6.3.1. ELISA: Results before Aβ(1-42)-induced Nucleus Basalis Lesions 
Mice were immunized with either trivalent vaccine (immunized, n = 24) or mock vaccine 
(mock, n = 9). Three, four or five (mock-) immunizations were performed with three-
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weekly intervals while intermediate blood samples were taken from the tail vain (Figure 
6.1). The derived serum samples were analyzed by enzyme-linked immunosorbent assay 
(ELISA) using oligomeric Aβ(1-42) as coating antigen. Figure 6.2 shows the 10log[Aβ(1-42) 
endpoint titers] obtained. Vertical axis categories are numbered between square brackets 
for easy reference. 
After three immunizations (ELISA 1 in Figure 6.1), a significant difference was found 
between all mock and immunized mice (Figure 6.2 [1]: two-tailed unpaired t-test: p < 
0.001). 
 
Figure 6.2. Average of the 10log value of anti-oligomeric Aβ(1-42) ELISA endpoint titers of 
immunized and mock mice before- and after Aβ(1-42)-induced NBM lesions. After all mice had 
received three (mock-) immunizations, mice with high titers (ELISA 1) and randomly selected mock 
mice were selected as the first group to receive NBM lesion surgery (group A). Remaining mice 
received a fourth (mock-) immunization. Again, mice with high titers (ELISA 2) and randomly selected 
mock mice were selected as the second group to receive NBM lesion surgery (group B). Remaining 
mice (group C) received a fifth (mock-) immunization before lesion surgery. Measurements before 
NBM lesions (ELISA 1 and 2) were performed on sera from blood samples collected from the tail vein. 
Measurements after NBM lesions (ELISA 3) were performed on sera from blood samples taken from 
the heart, just before transcardial perfusion. The results show that three rounds of immunizations 
are highly effective, while a fourth and fifth round of immunizations have only minor added effect. 
Vertical axis categories are numbered between square brackets for easy reference. Error bars 
represent SEM. Statistical indicators: * p < 0.05, *** p < 0.001, ns indicates p > 0.05. 
Mice (n = 8) with high titers were selected for the first round of Aβ(1-42)-induced NBM 
lesion surgery, forming ‘group A’ together with randomly selected mock animals (n = 3) 
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(Figure 6.2 [2]: two-tailed unpaired t-test mock vs. immunized mice: p < 0.001). Remaining 
animals still showed a significant difference between mock and immunized mice (Figure 
6.2 [3]: two-tailed unpaired t-test: p < 0.05), but received a fourth (mock-) immunization 
followed by a second tail vein puncture. Aβ titers (ELISA 2) showed that the difference 
between mock and immunized mice was maintained (Figure 6.2 [4]: two-tailed unpaired t-
test: p < 0.05), but that the fourth immunization did not significantly increase Aβ titers 
(Figure 6.2 [4] vs. [3]: two-tailed paired t-test before vs. after fourth immunization: mock: 
p = 0.98, immunized: p = 0.81). Again, immunized mice with high titers (n = 8) and 
randomly selected mock mice (n = 4) were selected for the second round of Aβ(1-42)-
induced NBM lesion surgery, forming group B (Figure 6.2 [5]: two-tailed unpaired t-test 
mock vs. immunized mice:  p < 0.05). The remaining mock (n = 2) and immunized (n = 8) 
mice formed group C. As measured from the serum samples after the fourth immunization 
(ELISA 2), no significant difference between mock and immunized animals was present in 
group C mice (Figure 6.2 [6]: two-tailed unpaired t-test: p = 0.46). These mice received a 
fifth round of (mock-) immunization before Aβ(1-42)-induced NBM lesion surgery. 
6.3.2. ELISA: Results after Aβ(1-42)-induced Nucleus Basalis Lesions 
After the Aβ(1-42)-induced NBM lesions, blood samples from all mice were obtained by a 
heart puncture just after the mice were sacrificed, before transcardial perfusion. ELISA 
analysis (ELISA 3) showed that considering all animals, a significant difference was again 
found between mock and immunized mice (Figure 2 [7]: two-tailed unpaired t-test: p < 
0.001). Similarly, a significant difference was again found between mock and immunized 
mice of group A and B, but not of group C (Figure 6.2 [8], [9], [10]: two-tailed unpaired t-
test: group A: p < 0.001; group B: p < 0.05; group C: p = 0.46). These results confirm the 
earlier intermediate titers before the Aβ(1-42)-induced NBM lesions (ELISA 1 and 2). 
No significant differences were found between the titers before vs. after the Aβ(1-42)-
induced NBM lesions of mock and immunized mice (statistical comparisons not indicated 
in Figure 6.2: two-tailed paired t-test, before vs. after NBM lesion: group A mock mice: p = 
0.42; group A immunized mice: p = 0.33; group B mock mice: p = 0.94; group B immunized 
mice: p = 0.30; group C mock mice: p = 0.67; group C immunized mice: p = 0.96). These 
results indicate that injecting oligomeric Aβ(1-42) in the NBM, did not significantly affect 
antibody responses. Moreover, these results indicate that the fifth round of (mock-) 
immunizations, as performed on the group C animals, did not significantly increase their 
average antibody response. Together, the results show that three rounds of 
immunizations are very much effective, while a fourth and fifth round of immunizations 
have only minor added effect. 
6.3.3. ELISA: Responders and Non-responders 
The ELISA results revealed a degree of variation in the measured antibody responses. 
Although most mice responded well to the immunizations, others showed a lesser 
response. Supplementary Table I shows the 10log[Aβ(1-42) endpoint titers] obtained for 
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individual mice. We used a rigorous criterion to identify responders and non-responders. 
‘Responders’ were defined as mice which showed higher titers than the average of the 
mock animals plus three standard deviations. After three immunizations, 14 out of 24 
mice (56%) were identified as responders (ELISA 1). Measurements on serum samples 
after the fourth immunization (ELISA 2) revealed both increases- and decreases in titers. 
Measurements from serum samples obtained after the heart puncture before transcardial 
perfusion (ELISA 3) showed 16 out of 24 responders (67%). Overall, 79% of the mice were 
identified as a responder in at least one measurement, leaving five mice (21%) identified 
as consistent non-responders. 
6.3.4. ELISA: Investigating Vaccine Specificity 
The sera obtained by heart puncture were analyzed more extensively (ELISA 3). In addition 
to oligomericAβ(1-42), BSA conjugates of cyclo[Aβ(22-28)-YNGK'] and its 23-29 and 22-29 
analogues and linear [Aβ(1-15)-C], as well as plain TTd, were used as coating antigens. As 
expected, all serum samples obtained after the heart puncture had high anti-TTd antibody 
titers (all mice showed a 10log[endpoint titer] > 5.52 on a TTd ELISA coating, data not 
shown). The serum samples of immunized mice showed high antibody titers against each 
of the three amyloid cyclopeptides, but not to linear Aβ(1-15) which contains the 
immunodominant epitope of Aβ(1-42) (data not shown). 
6.3.5. Immunohistochemistry: Aβ(1-42)-induced Nucleus Basalis Lesions 
An excitotoxic damage model was used to assess whether immunized mice were more 
protected against oligomeric Aβ(1-42) insult to the brain compared to mock mice. The 
nucleus basalis magnocellularis (NBM) is the origin of many cholinergic projections to the 
cortex. Oligomeric Aβ(1-42) was unilaterally injected in the NBM and the neurotoxic 
impact assessed by determining cholinergic fibre loss in the parietal neocortex relatively 
to the control hemisphere which was injected with scrambled Aβ(1-42) peptide (Aβ-scr) 
(Figure 6.3). 
In the mock mice, average fibre density on the control- and lesion side was 10.30 ± 0.36 
SEM and 7.95 ± 0.28 SEM respectively. In the immunized mice, average fibre density on 
the control- and lesion side was 9.91 ± 0.35 SEM and 8.17 ± 0.33 SEM respectively. A 2-
way RM ANOVA with independent variables ‘treatment’ (mock-immunized or immunized) 
and ‘brain side’ (oligomeric Aβ(1-42)-injected or scrambled Aβ(1-42)-injected), revealed a 
significant difference between brain sides. The side of the brain injected with oligomeric 
Aβ(1-42) consistently showed less fibre density than the scrambled-Aβ injected sides of 
the brains (F(1,30) = 398.83, p < 0.001) (Figure 6.4A). An ‘All Pairwise Multiple Comparison’ 
posthoc test (Holm-Sidak method) revealed that this difference was present within both 
the mock- (t = 13.54, p < 0.001) and immunized mice (t = 16.02, p < 0.001).These results 
indicate that the oligomeric Aβ(1-42)-induced NBM lesion model was highly effective. A 
significant interaction effect was found between treatment and brain side (F(1,30) = 8.88, 
p = 0.006), but no significant effect of treatment was detected (F(1,30) = 0.02, p = 0.88) 
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within either the oligomeric Aβ(1-42)-injected- (t = 0.38, p = 0.71), or scrambled Aβ(1-42)-
injected (t = 0.67, p = 0.51) brain sides. 
 
Figure 6.3. Active immunization prevents the loss of cholinergic innervations induced by 
oligomeric Aβ(1-42) injected into the NBM. Shown are representative images of ChAT-positive 
fibres in the parietal neocortex of mock (A and B) and immunized mice (C and D). Images on the left 
(A and C) show the side of the brain injected with scrambled Aβ(1-42) control peptide (Aβ-scr). 
Images on the right (B and D) show the contralateral lesion-sides of the brain injected with 
oligomeric Aβ(1-42) (Aβ-oligo). Note that in practice the compounds were randomly injected in the 
left- or right side of the brain. Comparing control- and lesion sides of the brain, immunized mice 
show reduced fibre loss compared to mock mice. In each image the area between the parallel bars 
indicates the quantified area (layer V of the somatosensory cortex). The horizontal scale bar shown 
in (D) applies to all images and represents 100 µm. 
However, differences between mock and immunized mice became apparent when 
comparing lesion sides with control sides within each of the brain slices and calculating 
the average percentage of fibre loss (Figure 6.4B). On average, immunized mice showed 
significantly less loss of cholinergic fibres in the parietal neocortex than mock mice 
(immunized: 16.77 % ± 0.99 SEM vs. mock: 21.05 % ± 1.43 SEM, two-tailed unpaired t-test: 
p = 0.02, effect size: Cohen’s d = 0.95). As expected, these statistics slightly improve when 
excluding the five identified non-responders from the immunized group (immunized 
responders: 16.22 % ± 1.09 SEM vs. mock: 21.05 % ± 1.43 SEM, two-tailed unpaired t-test: 
p = 0.01, effect size: Cohen’s d = 1.08). Immunized mice showed 20.3% reduced fibre loss 
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relative to the mock mice, or 22.9% when excluding the five non-responders from the 
immunized mice.  
 
Figure 6.4. Effectiveness of the oligomeric Aβ(1-42)-induced NBM lesion model and effects in mock 
and immunized mice. All mice consistently showed less cortical cholinergic fibre density on the Aβ 
injected side of the brain, as compared to the scrambled-Aβ (Aβscr) injected control side of the brain 
(A). Compared to mock mice, immunized mice showed significantly reduced cholinergic fibre loss in 
the cortex, as measured by optical fibre density after ChAT immunostaining (B). In both panels the 
error bars represent SEM. 
6.3.6. Correlation between Cholinergic Fibre Loss and Antibody Response 
We investigated whether the loss of cholinergic fibre density in the cortex correlated 
negatively with the measured antibody responses. When using the Aβ(1-42) endpoint 
titers based on the serum samples obtained after the heart puncture (ELISA 3), a 
significant negative correlation was found between the titers and the percentage of fibre 
loss when considering all mice (Pearson r = -0.38, R2 = 0.15, p = 0.03). However, this 
correlation was not significant when considering only the immunized mice, with or 
without the five non-responders (p = 0.49 and p = 0.91 respectively).  The titers obtained 
from the tail vain puncture before Aβ(1-42)-induced NBM lesions, after all mice had 
equally received three immunizations (ELISA 1), showed similar results with a better 
correlation. Using these titers a significant negative correlation was found between fibre 
loss and antibody response (considering all mice: Pearson r = -0.49, R2 = 0.24, p = 0.004; 
considering only the immunized mice: Pearson r = -0.44, R2 = 0.20, p = 0.03; considering 
immunized mice without the non-responders: Pearson r = -0.54, R2 = 0.29, p = 0.02). 
Results are shown in Figure 6.5. 
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Figure 6.5. Correlation of the 10log value of anti-oligomeric Aβ(1-42) endpoint titers (x-axis) vs. 
cholinergic fibre loss (y-axis). Titers were obtained by ELISA of sera obtained from blood samples 
taken from the tail vein on day 54 (ELISA 1), after which all mice had received three immunization 
injections. Percentage of fibre loss was calculated for each animal based on ChAT-stained cholinergic 
fibre density in the bilateral parietal neocortex, which is the target of afferent cholinergic pathways 
from the bilateral NBM sites. The Aβ(1-42) injected lesion side of the brain was compared to the 
scrambled-Aβ(1-42) injected control side of the brain to determine the percentage of cholinergic 
fibre loss. The linear regression line and Pearson correlation is based on the immunized mice 
(indicated by black circles) including the non-responders (separately indicated by open triangles), 
but not including the mock mice (indicated by grey circles). The R-squared- and two-tailed p-value is 
indicated in the figure. 
 
6.4. DISCUSSION 
In recent years it became more and more apparent that amyloid plaques do not primarily 
correlate with AD pathology. This seems rather be true for the amount of tangles 
consisting of hyperphosphorylated tau proteins (Alafuzoff et al., 1987; Arriagada et al., 
1992; Gómez-Isla et al., 1997; Herrup, 2015; Musiek and Holtzman, 2015; Wilcock and Esiri, 
1982). A possible explanation for that may lie in the fact that Aβ plaques per se are not 
neurotoxic and that tangles in contrast represent dead neuronal cell bodies and therefore 
neuronal cell loss. In fact the most neurotoxic molecules in AD pathology turned out to be 
soluble oligomeric forms of misfolded Aβ (Haass and Selkoe, 2007; Lue et al., 1999; 
McLean et al., 1999; Näslund et al., 2000; Wang et al., 1999). As even under normal 
physiological conditions Aβ is produced (Moghekar et al., 2011), a vaccination against non-
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oligomeric or non-fibrillary Aβ might result in unwanted side effects (Tabira, 2010). Indeed, 
non-aggregated Aβ peptide at low doses have been found to exhibit neurotrophic effects 
including enhancement of neuronal survival, neurite-promoting and neural stem cell 
differentiation effects (Heo et al., 2007; Pike et al., 1993; Whitson et al., 1989, 1990; 
Yankner et al., 1990). Using cyclic peptides mimicking conformational neo-epitopes of 
oligomeric Aβ forms could circumvent the problems that would arise if peptides would be 
used which represent epitopes related to Aβ in general. 
In a previous study, we have shown that tetanus toxoid (TTd) conjugates of small cyclic 
peptides derived from Aβ, in particular cyclo[Aβ(22-28)-YNGK']-TTd can be used for active 
immunization in mice. Two immunizations effectively produced antibodies in Balb/c mice 
that cross-react in vitro with oligomeric and fibrillar Aβ(1-42) and amyloid plaques in 
mouse and human brain tissue. Importantly, the antibodies did not recognize the 
homologous linear peptide or the amyloid precursor protein, indicating a high specificity 
for misfolded Aβ (Hoogerhout et al., 2011). In preliminary experiments it was found that 
C57BL/6 mice responded rather poorly to the original vaccine formulation, that is, 
cyclo[Aβ(22-28)-YNGK']-TTd conjugate with aluminum phosphate as adjuvant. The 
response in C57BL/6 was improved by immunization with the trivalent vaccine as used in 
the current study (a mixture of TTd conjugates of three cyclopeptides, cyclo[Aβ(22-28)-
YNGK'] and its 23-29 and 22-29 analogues, with aluminum hydroxide gel and 
monophosphoryl lipid A (MPL) as adjuvant). In addition, a third immunization significantly 
improved the antibody response (data not shown). Our current data confirm these earlier 
results and show that subsequent fourth and fifth round of immunizations have little 
added effect on the antibody response. It is noteworthy that in the course of our 
investigation it was reported that the MPL adjuvant by itself may have beneficial effects 
on AD pathology, as measured in APPswe/PS1 transgenic mice (Michaud et al., 2013; 
Wang, 2013). In the current study both immunized and mock-immunized mice received 
the same amounts and dosages of MPL adjuvant. Therefore, the mock mice might have 
had some level of protection, induced by the MPL they received, indicating that the effect 
of immunization might be underestimated in the current study. Future studies may lead to 
further optimization of the vaccine formula, dosage, and administration scheme to 
enhance its efficacy. 
We used the established NBM lesion model in C57Bl/6J mice (Dolga et al., 2009; Granic et 
al., 2010a), to test directly whether the specific antibodies produced by the active 
immunization have a protective potential against the cytotoxic effects of oligomeric Aβ(1-
42). We found that immunized mice showed 20% less cholinergic fibre loss in the parietal 
neocortex relative to mock-immunized mice (or 23% when excluding five non-responders).  
These results are very promising. Injecting substantial amounts of neurotoxic oligomeric 
Aβ(1-42) into the NBM creates an acute lesion. It was not certain whether the used Aβ 
concentration and incubation time (10 days) were optimal to show an effect at all. 
Similarly, it was uncertain if there would be enough neutralizing antibodies produced by 
the immune system and if these antibodies would reach the lesion site effectively enough. 
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Although we did not attempt to detect (in brain slices) the specific anti-Aβ antibodies 
produced by the immune system, it has been shown that peripheral antibodies are able to 
cross the blood brain barrier (Sas et al., 2008). Additionally, due to the administration of 
Aβ(1-42) via stereotactic injection, a local microglial response may have led to a local 
leakage of the blood brain barrier, allowing anti-Aβ antibodies to enter the brain 
parenchyma from blood vessels. 
A main source of variation was the observed difference in antibody response of the mice. 
This variation allowed us to correlate the antibody responses of individual mice to the 
measured fibre loss. As expected, fibre loss significantly correlated negatively with the 
antibody titers induced by immunization. When considering only the immunized mice, this 
was however only true when using the titers obtained after all mice had received three 
rounds of immunizations (ELISA 1, before Aβ(1-42)-induced NBM lesions), but not when 
using the titers obtained from the serum samples after the NBM lesions (ELISA 3). Note 
that the blood samples taken after three rounds of immunizations (ELISA 1) were collected 
from all mice at the same time, while the heart punctures (ELISA 3) were acquired and 
processed at different days for the three groups (see supplemental table I). The serum 
samples obtained after three rounds of immunizations (ELISA 1) are therefore comparable 
measures and this initial assessment of the antibody response showed to correlate 
significantly with the measured fibre loss, even within the immunized group only and 
excluding consistent non-responders. These results are promising given that titers are not 
an accurate measure for effective antibody passage over the blood brain barrier and for 
the effectiveness of the immune system to neutralize Aβ.  
Taken together, the tested trivalent vaccine has now been demonstrated to effectively 
induce a specific antibody response against misfolded Aβ in Balb/c as well as C57BL/6 mice 
without noticeable side effects. Furthermore, in the present study we show that this 
active immunization protects against acute oligomeric Aβ(1-42) insult to the brain in vivo. 
A clear next step is to immunize transgenic Alzheimer disease model mice and investigate 
the effect of immunization on cognition and amyloid plaque load with aging. Together, 
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7.1 TNF-ALPHA SIGNALLING IN NEURODEGENERATION 
Neurodegeneration is a detrimental process associated with neuronal damage and 
ultimately neuronal death in the central nervous system (CNS) involved in many diseases 
such as Alzheimer’s disease (AD), multiple sclerosis (MS), Parkinson’s disease (PD), stroke, 
as well as trauma and brain ischemia. In particular, AD is the major common chronic 
disease with progressive neuronal death. The main pathological findings in AD include 
molecular changes, such as amyloid-β peptide plaque generation and tau protein 
hyperphosphorylation forming neurofibrillary tangles. Besides those changes, 
neuroinflammation is another major pathological feature of AD and notably characterized 
by activated microglia. Activated microglia are generally considered as immune cells in the 
brain, which can secrete a variety of cytokines that can be either trophic or toxic for 
neurons, dependent on the environmental conditions. One of the most important 
cytokines secreted by microglia is the pro-inflammatory cytokine TNF-α, which has been 
implicated to be involved in huge numbers of diseases, such as AD, excitotoxic injury, and 
MS (Gregory et al., 2012; Zheng et al., 2016). 
TNF-α is synthesized as a transmembrane protein (mTNF-α) that can be processed by 
proteolytic cleavage via TNF alpha converting enzyme (TACE/ ADAM17) to a soluble homo-
trimeric molecule (sTNF-α). TNF-α induces various cellular responses through its 
interaction with two distinct transmembrane receptors, TNFR1 and TNFR2. Under normal 
physiological conditions, TNFR1 is ubiquitously expressed in various cell types and tissues, 
whereas TNFR2 is predominantly expressed at low levels in immune cells and endothelial 
cells (Loetscher et al., 1990; Schall et al., 1990; Smith et al., 1990; Cabal-Hierro and Lazo, 
2012). TNFR1 activation can be induced by either sTNF-α or mTNF-α, and TNFR2 activation 
is predominantly initiated by mTNF-α (Grell et al., 1995). TNFR1 activation can trigger 
fibroblast growth, endothelial cell adhesion, neuroinflammation, and cell death while 
TNFR2 promotes proliferation of thymocytes and peripheral T cells and inhibition of early 
hematopoiesis (MacEwan, 2002). 
Expression of TNF-α and TNFR1 is significantly up-regulated in the affected brain regions 
of AD patients and related with the pathopysiology of AD (Yamamoto et al., 2007; Zhao et 
al., 2003; He et al., 2007; Scalzo et al., 2009). Fiore et al. (2000) also showed that TNF-α 
over-expression in mice induced detrimental effects for synaptic plasticity led to memory 
and learning damages. Recently, TNF-α signalling pathways has been reported to associate 
with APP processing and Aβ production in vitro (Yamamoto et al., 2007). These studies 
indicate that anti-TNF-α reagents seem to be able to prevent or treat neurodegenerative 
disorders. In preliminary trials in rheumatoid patients anti-TNF appears to have an 
impressive effect on indices of disease activity including serum amyloid A production 
(Maini et al., 1993). Some anti-TNF-α agents, such as Lenercept, were applied to treat 
patients with rheumatoid arthritis and indeed effectively attenuates this inflammatory 
disease (Meyer, 2000). Anti-TNF-α therapeutics, however, failed in the CNS diseases 
(Arnason, 2011). This failure could be caused by TNF-α pleiotropic functions through its 
interaction with two distinct receptors: TNF-α binding to TNFR2 mediates neuroprotection 
in neurodegenerative diseases (Masuch et al., 2016; Sullivan et al., 1999;Barger et al., 
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1995; Cheng et al., 1994; Fontaine etal. 2002; Marchetti et al., 2004; Dolga et al., 2008; 
Dong et al., 2015), whereas its interaction with TNFR1 triggers severe inflammation and 
thereby leads to cell death (Kaczmarek et al., 2013). Complete blockade of TNF-α 
therefore prevents not only TNFR1 mediated neuroinflammatory and degenerative but 
also TNF-α/TNFR2-mediated neuroprotective effects. 
Expression of soluble TNFR levels (sTNFR1 and sTNFR2) are significantly elevated in 
cerebrospinal fluid and serum during preclinical stages of AD (Jiang et al., 2011). 
Production of sTNFRs correlate positive with TACE1 activity and Aβ40 levels and 
expression of tau protein (Buchhave et al., 2010). This seems that sTNFRs could be one of 
hallmarks of AD. However, sTNFRs circulate during inflammation and can neutralize TNF-
α-induced cytotoxicity and immunoreactivity in vivo and in vitro (Van Zee et al., 1992). The 
role of sTNFRs has been detailed in Chapter 2 of this thesis. Whether sTNFRs could be 
applied to modulate inflammation-induced exacerbation in neurodegenerative disorders 
could be subject of further investigation. Nevertheless, sTNFRs could be considered as 
independent inflammatory markers, since the expression of TNFRs and their conversion 
into soluble forms is a complex process that not solely depends on TNF-α activity but also 
on other inflammatory effectors such as interferon-γ (Diez-Ruiz et al., 1995). 
In Chapter 2, we mainly reviewed the complex TNF-α signalling pathways and their 
involvement in neurodegenerative disorders as well as the potential therapeutic 
properties resulting from the antithetic effects of TNFR1 and TNFR2 signalling. We 
discussed that selective targeting TNFRs could be the basis of a novel and effective 
therapeutic strategy against neurodegenerative disorders. This addressed our next 
investigations concerning on the therapeutic functions of targeting TNFRs reagents in 
neurodegenerative mouse models. Due to TNFR1-induced neurodegeneration and TNFR2-
mediated neuroprotection, one specific manipulation of TNF-α downstream pathways is 
to use pharmacological agents that only block TNFR1 signalling without altering the 
activation of TNFR2 signalling pathway or that activate TNFR2 signalling, for instance, a 
TNFR1 antagonist and a TNFR2 specific agonist. 
 
7.2 TARGETING TNFRS AS A THERAPEUTIC STRATEGY AGAINST 
ALZHEIMER’S DISEASE 
Up-regulated TNFR1 increases aggregation of Aβ peptides and Aβ formation in AD mouse 
models (He et al., 2007; Scalzo et al., 2009), and its activation triggers severe inflammation 
and thereby leads to neuronal cell death (Kaczmarek et al., 2013). Additionally, it has been 
suggested that TNF-α mediates Aβ oligomer-induced memory impairments by interaction 
with its receptor one (Lourenco et al., 2013). He et al. (2007) found that deletion of TNFR1 
diminishes Aβ plaque formation, inhibits Aβ generation and prevents learning and 
memory deficits in APP23 transgenic mice, indicating that inhibiting TNFR1 pathway could 
be a possible therapeutic approach in AD. Selective inhibitors of soluble TNF-α have been 
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demonstrated to efficiently prevent acceleration of amyloid plaques in transgenic mice by 
inactivation of TNF-α/TNFR1 signalling pathway (McAlpine et al., 2009). In contrast, TNFR2 
activation has been implicated to mediate neuroprotection through PKB/Akt-mediated 
NF-κB pathway (Marchetti et al., 2004). TNFR2 null mice show sensitized response to 
cholesterol-bearing pullulan nanogel-induced resorption compared to wild type mice, 
suggesting also a protective role of TNFR2 (Nagano et al., 2011). Furthermore, Fontaine et 
al. (2002) reported that TNFR2 activation can protect against ischemic reperfusion-
induced retinal neuronal death, which is in contrast with the role of TNFR1 signalling in 
this injury model. Recently, more evidence came up for the potentially protective effects 
of TNFR2 pathways. For instance, Fischer et al. (2011) demonstrated that agonistic TNFR2 
activation significantly prevents neuronal cell death induced by oxidative stress; Aoki’s 
group (2007) designed a loop peptide mimetic of TNFR1 that can inactivate TNFR1 
signalling pathway and found that administration of this molecule strongly ameliorates 
collagen-induced arthritis. Williams and colleagues (Williams et al., 2014) have 
demonstrated that a TNFR1 antagonist attenuates MS-related pathological features in EAE 
mouse model; Furthermore, a novel TNFR1 antagonist effectively suppressed arterial 
inflammation and intimal hyperplasia in mice (Kitagaki et al., 2012). Therefore, these 
studies suggest that targeting TNFRs by activation of TNFR2 and/or inhibition of TNFR1 
could become a therapeutic strategy against neurodegeneration, such as AD. 
To investigate the therapeutic potential of humanized TNFR1 selective antagonists or 
humanized TNFR2 specific agonists in vivo, we generated knock-in mice that carry the 
human extracellular domains of TNFR1 and TNFR2. In Chapter 3, we demonstrated the 
generation and identification and characterization of knock-in mice with chimeric 
humanized TNFRs. 
In Chapter 4, the therapeutic potential of both the human TNFR2 selective agonists, EHD2-
scTNFR2 and TNC-scTNFR2, as well as the human specific TNFR1 antagonist ATROSAB were 
analyzed in the nucleus basalis lesion model. In this lesion model, NMDA was injected into 
the nucleus basalis magnocellularis (NBM) and thereby led to excitotoxic cell death of 
cholinergic neurons. This leads not only to a strong lesion in the NBM but also to a decline 
in cholinergic innervations in the parietal cortex of the brain. We found that EHD2-scTNFR2 
and TNC-scTNFR2 as well as ATROSAB significantly reduced microglial activation at the site 
of the lesion and protected cholinergic neurons and the neocortical innervations against 
NMDA induced excitotoxic damage. Because the NBM lesion-mediated neocortical 
cholinergic denervation results in memory dysfunctions such as learning and memory 
deficits and retention dysfunctions (Coyle et al., 1983), we here evaluated the behavioral 
functions, associated with hippocampus, amygdala and cerebral cortex, affected by NBM-
induced cholinergic denervation. The functional outcome after NMDA induced 
neurodegeneration as shown in Chapter 5 is in the line with tissue damage: impairment to 
the NBM selectively affected neocortical cholinergic innervation and its related retention 
memory deficits, while leaving in particular hippocampal and amygdala innervation and 
functions unaffected. These results confirmed that selective activation of TNFR2 and 
inhibition of TNFR1 as a therapeutic target could be highly useful to treat 
neurodegenerative conditions and diseases.  
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Importantly, we found that ATROSAB neuroprotection against NMDA-mediated 
excitotoxicity was dependent on a concurrent activation of TNFR2 signalling. This finding 
supports previous studies (Dolga et al., 2008a; Dolga et al., 2008b; Fontaine et al., 2002;  
Marchetti et al., 2004), which indicated the important protective signalling pathway of PI3 
Kinase induced PKB/Akt phosphorylation and subsequent NF-κB activation through TNFR2 
both in vitro and in vivo. 
So far, our investigation thoroughly explained TNF-α duality on neuroprotection and 
aggravation in the CNS diseases, mainly due to its two distinct receptors. With TNFR2 
being neuroprotective, whereas TNFR1 promotes neuronal degeneration and is involved 
in the pathology of AD by promoting Aβ generation. Furthermore, our results also provide 
the rational for the previous failure of clinical studies using anti-TNF-α drugs in 
neurodegenerative diseases and highlight the essential protective role of TNFR2. Our 
studies were also supported by recent studies using the biological compound XPro-1595 
as a selective blocker of soluble TNF-α (Brambilla et al., 2011; Taoufik et al., 2011). 
 
7.3 MODULATION OF AMYLOID-BETA 
According to ‘amyloid hypothesis’, Aβ peptide accumulation is a pivotal pathological 
characteristic in the brain of AD patients. Various strategies therefore have been 
developed to minimize or reverse the negative effects of Aβ, for instance reducing Aβ load, 
inhibiting Aβ misfolding and aggregation, enhancing Aβ clearance (Scalzo et al., 2009; 
Schenk et al., 1999; Sigurdsson et al., 2000). Approaches diminishing Aβ level by inhibition 
of Aβ generation using β- and γ-secretase inhibitors, have experienced a drawback since 
these proteases are not only involved in the generation of Aβ but are as well involved in 
important cellular processes like axonal myelination, synapse maintenance and Notch 
signalling (Bittner et al., 2009; Lleó et al., 2003; Willem et al., 2006). Also, β-secretase 
inhibitors just reduce Aβ levels in the periphery but not in the brain (Georgievska et al., 
2015), indicating that this strategy using β- or γ-secretase inhibitor is not sufficient. Thus, 
the challenge is to develop selective inhibitors that effectively target only the 
amyloidogenic cascade without affecting other cell processes. 
Another approach for targeting Aβ-peptides is raising neutralizing antibodies by either 
passive or active immunization. Aβ vaccination has been shown already some time ago to 
lead to amyloid plaque clearance in a mouse model of AD (Schenk et al., 1999). 
Furthermore, immunization has also been demonstrated to reverse memory deficits in 
APP transgenic mice (Dodart et al., 2002). Vaccination against Aβ was considered to be the 
most promising therapeutic strategy until immunized patients showed a strong brain 
inflammatory response and a few eventually died (Imbimbo, 2002; Münch and Robinson, 
2002). Potential safety concerns of anti-Aβ vaccines, lead to the development of 
alternative strategies to reduce Aβ burden in AD. Soluble oligomeric forms of Aβ are 
thought to be the chief mediator of cytotoxicity in AD (Wisniewski and Goñi, 2015). 
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Naturally secreted oligomeric assembly of Aβ potently alters hippocampal synaptic 
plasticity by inhibiting long-term potentiation which is associated with memory 
impairments (Walsh et al., 2002). Also, the number of dendritic spines was dramatically 
decreased when neurons were incubated with Aβ oligomers, but not with monomers 
(Walsh et al., 2002).  
Therefore, immunotherapy could be achieved by the inhibition of Aβ aggregation using 
small peptides, which specifically recognize and interact with Aβ pathological forms to 
reduce its aggregation and toxicity. Vaccination by anti-oligomeric monoclonal antibodies 
shows improvements of cognitive functions by reducing Aβ deposition and tau pathology 
in 3xTg-AD mice (Rasool et al., 2013). A recent study showed that the Aβ-derived peptide 
prevents Aβ oligomers and protects against Aβ toxicity in transgenic C. elegans (Diomede 
et al., 2016). Of note, immunization with recombinant 6Aβ15-T antigen robust anti-Aβ 
serum, strongly recognize Aβ1-42 markedly reduced Aβ burden, and improved behavioral 
performance in different mice (Wang et al., 2016). 
A previous study of Hoogerhout and colleagues showed that tetanus toxoid (TTd) 
conjugates of small cyclic peptides derived from Aβ, specifically cyclo[Aβ(22-28)-YNGK']-
TTd, induced antibodies in Balb/c mice that cross-react in vitro with oligomeric and fibrillar 
Aβ1-42 and amyloid plaques in mouse and human brain tissue. The antibodies did not 
recognize the homologous unmodified linear peptide or the amyloid precursor protein, 
indicating a high specificity for misfolded Aβ (Hoogerhout et al., 2011). However, a poor 
response with this vaccine formulation was shown in C57BL/6 mice in preliminary 
experiments. They next developed a new vaccine that consisted of cyclo[Aβ(22-28)-YNGK'], 
cyclo[Aβ(23-29)-YNGK'], and cyclo[Aβ(22-29)-YNGK'] peptide with aluminum hydroxide gel 
and monophosphoryl lipid A (MPL) as adjuvant, assessed its potential immunization. Our 
research group tested the immunotherapeutic properties  of this vaccine in C57BL/6 mice 
shown in Chapter 6 of the thesis. In the study, we established NBM lesion with oligomeric 
Aβ1-42 or scrambled Aβ1-42 in immunized and mock-immunized mice that both received 
the same amount of and dosages of MPL adjuvant. We found that C57BL/6 mice 
responded to this trivalent vaccine and there was a negative correlation between the 
antibody response and the cortical innervation loss. The MPL adjuvant by itself, therefore, 
may have beneficial effects on AD pathology, as measured in  APP(swe)/PS1 transgenic 
mice (Michaud et al., 2013). In fact we could give supporting evidence for the protective 
function of an active vaccination against epitopes of oligomeric Aβ1-42 peptides (Mulder 
et al., 2016). 
 
7.4 FUTURE PERSPECTIVES OF AD THERAPEUTICS 
The challenge to investigate therapeutic strategies in neurodegeneration is the exact 
understanding of their neuropathological mechanisms. Cytokine expression is drastically 
altered in various neurodegenerative disorders (Bhaskar et al., 2014; Fillit et al., 1991). For 
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instance, up-regulated expression of TNF-α, TNFR1 and TRADD can be observed in AD  
(Fillit et al., 1991; Zhao et al., 2003). Neuroscientists have studied whether anti-TNF-α 
agents could be able to therapy neurodegenerative disorders, such as AD. However, anti-
TNF-α reagents induced some side-effects in patients with multiple sclerosis (Sicotte and 
Voskuhl, 2001). Studies have shown that TNF-α interacting with two distinct receptors can 
perform the two opposite functions: TNF-α linking to TNFR1 induces neurodegeneration 
whereas TNF-α linking to TNFR2 rescues neurons from neurodegeneration (He et al., 2007, 
Williams et al., 2014). We thought that selective targeting TNFRs, inhibiting TNFR1 
signalling and activating TNFR2 signalling, could effectively prevent neurodegenerative 
disorders. We indeed found that both TNFR2 agonist and TNFR1 antagonist prevent the 
neocortical denervation and improve the related memory deficits (Dong et al., 2016), as 
described in this thesis. This therapeutic strategy could improve the therapeutic deficits of 
anti-TNF-α agents because selective inhibiting TNFR1 and/or activating TNFR2 changed the 
rate of TNFR1/TNFR2 towards neuroprotective signalling and inhibiting TNFR1 rather than 
suppressed all TNF-α signalling. These suggest that TNFR1 targets or TNFR2 targets are 
worth to be considered to develop the therapeutic agents against AD. Apparently, the 
proof that TNFR1 antagonists and TNFR2 agonists prevented neurodegenerative disorders 
in an acute AD mouse model could be further provided from the chronic AD mouse model 
and the clinical trials with AD. The follow-up experiment derived from the thesis could 
focus on the therapeutic effecacy in chronic AD animal models. Before we test both 
compounds in chronic AD mouse models, a burning question should be resolved that both 
coumpounds must be redesigned to develop pharmacological drugs which can penetrate 
the blood-brain-barrier to respond the lesion regions in the brain of AD. 
Furthermore, dependent on TNFR1-mediated signalling pathway, targeting a certain core 
mediator in apoptotic processes could provide a novel approach to treat AD. TNFR1 
mediated cell death is mainly due to the core adaptor TNFR-associated death domain 
(TRADD) and Fas-associated death domain (FADD) activation. Therefore, that prevention 
of TREDD activation or FADD activation depresses TNFR1 death signalling could be an 
effective treatment for AD. An advantage of this strategy might be that just prevention of 
TREDD and FADD inhibits TNFR1-mediated death signalling but not interfere TNFR1-
mediated other signalling pathways such as TNFR1-activated NF-κB signalling or TNFR2 
neuroprotective effects. In future, some novel therapeutic strategies based on cytokine 
signalling pathways could be prevalent against neurodegenerative disorders.  
In addition, accumulation of Aβ plaque peptides is responsible for the onset of AD. 
Although Aβ plaques are involved in the pathology of AD, Aβ plaques also seems to occur 
in non-diseased aging people (Dugger et al., 2014; Elobeid et al., 2016; Kovacs et al., 2013). 
This could result in the failure of anti-Aβ vaccines for AD.  As we know, it seems that Aβ 
oligomers are mainly responsible for toxic stress in the brains in AD patients. 
Immunization against oligomeric Aβ might appear to be promising strategy. We indeed 
found that an anti-oligomeric Aβ vaccine prevent AD-related lesion (Chapter 6). However, 
immunization is a complicated approach that involves vaccine optimization and the 
possibility of side-effects. Consequently, immunization  to treat AD could need more time 
and experiments to verify vaccine safty and effecacy. 
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Neurodegeneratieve ziektes zijn gedefinieerd als genetische en sporadische 
condities, gekenmerkt door voortschrijdende degeneratie van het 
zenuwstelsel. Voorbeelden van neurodegeneratieve condities zijn de ziekte 
van Alzheimer, Parkinson, multiple sclerose (MS), amyotrofische laterale 
sclerose (ALS) en de ziekte van Huntington,maar ook bij een herseninfarct, 
hersenbloeding en traumatisch hersenletsel kan neurodegeneratie 
plaatsvinden, in het centrale of perifere zenuwstelsel. In deze thesis 
hebben we potentiele therapeutische strategieën tegen neurodegeneratie 
onderzocht, in het Nucleus Basalis Magnocellularis (NBM) lesie model. 
NBM lesies resulteren in het verlies van cholinerge neuronale projecties in 
de cerebrale cortex, en kunnen dienen als een acuut model voor de ziekte 
van Alzheimer.  
Tumor necrosis factor alfa (TNF-α) is voorgesteld als een belangrijke speler 
in neurodegeneratie, zoals in de ziekte van Alzheimer, MS en herseninfarct. 
Terwijl TNF-α via het activeren van TNF receptor 1 voornamelijk schadelijke 
effecten op hersencellen heeft, induceert TNF-α via TNFR receptor 2 juist 
neuro-protectieve effecten. Gebaseerd op de tegenovergestelde effecten 
van TNF-α via TNF receptor 1 en TNF receptor 2, hebben we de effecten 
van een humaan-specifieke antagonist van TNF receptor 1 (ATROSAB) en 
specifieke agonisten van TNF receptor 2 (TNC-scTNF en EHD2-scTNF) 
onderzocht in het NBM lesie muismodel. Omdat deze stoffen niet werken 
op muis TNF receptoren, hebben we gehumaniseerde TNF receptor knock-
in muizen ontwikkeld, waarin de extracellulaire domeinen van de 
endogene muis TNF receptoren zijn vervangen door hun humane 
tegenhangers. In deze muizen vonden we dat beide TNF receptor-
modulatoren in staat waren neuronale schade en ontstekingen als gevolg 
van de NBM lesie significant te verminderen, en cognitieve achteruitgang 
tegen te gaan. Een belangrijke bevinding hierbij was dat activatie van TNF 
receptor 2 essentieel is voor neuroprotectie. In een andere studie vonden 
we dat immunisatie van muizen met cyclopeptide-conjugaten, afgeleid van 
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oligomeer Aβ, beschermend werkte tegen oligomeer Aβ-geïnduceerde 
NBM lesies in muizen. In conclusie hebben we in deze thesis twee 
potentiele therapeutische interventies onderzocht voor de behandeling 
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